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ABSTRACT 
Ovarian tumors involve a wide range of neoplasms, from innocuous benign tumors 
to aggressive cancers. Not seldom are they found by chance, without any notable 
symptoms, and, as cancers, they may already have metastasized at that point. The 
diagnostic golden standard includes vaginal ultrasound (US) along with serum 
biomarkers, traditionally CA125, to assess tumor characteristics. The correct 
preoperative diagnosis of cancer is essential, as it allows a prompt referral to a center, 
where the operations are performed by gynecologic oncologists. In ovarian cancer 
(OC), effective and correct primary surgery is the most important prognostic factor. 
On the other hand, conservative follow-up may be sufficient for benign tumors. 
Against this background, the aim of this thesis was to study advanced US 
modalities and to discover new possible biomarkers or methods to distinguish 
ovarian pathology preoperatively. First, we examined 100 at least 50-year-old women 
scheduled for surgery with an unclear ovarian tumor using traditional US and 
comparing it to various US scoring methods and three-dimensional ultrasound (3D 
US) with power Doppler (PD). The findings were compared with the results of 
examinations made by another experienced US examiner and also with 
histopathological diagnoses. None of the advanced US methods exceeded the 
accuracy of the subjective opinion of an expert. In addition, the 3D US with PD 
added no significant value to traditional methods. However, the results produced by 
two examiners were in good agreement. 
To extend our investigation, we collected urine samples from 71 women with 
indefinite adnexal masses and from 22 controls, and analyzed urinary polyamines 
using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Polyamines 
are naturally occurring components of all mammalian cells and have many functions, 
including cell growth. They are linked to carcinogenesis, and especially their 
diacetylated forms are found to be elevated in many cancers, although not previously 
in OC. In Study II, we showed that diacetylated spermine (DiAcSpm) was 
significantly elevated in urine from OC patients. While the levels of DiAcSpm 
differed even between low-stage OCs and benign ovarian tumors, the highest levels 
were found in high-grade OCs. Urinary DiAcSpm was even more sensitive than 
serum CA125 with its commonly used cutoff value (35 U/mL): their respective 
sensitivities were 86.5% and 75.7%. 
Based on previous experiments on the ability of dogs to detect the odor of cancer, 
urine samples (60 from women with adnexal tumors and 18 from controls) were also 
examined using field asymmetric waveform ion mobility spectrometry (FAIMS), a 
novel artificial olfactory technology. In our proof-of-concept Study III, we used 
FAIMS to differentiate between ovarian malignancy and benign tumors or controls 
with respective accuracies of 77.3% and 81.3%. When only high-grade cancers were 
taken into account, the accuracy in distinguishing them from low-grade cancers was 
88.7%. Even low-grade cancers were differentiated from benign tumors with an 
accuracy of 83.9%.  
Metabolic alterations, including lipid changes, in blood and tissues are associated 
with OC. However, it is unclear which specific lipids or lipid species are altered. A 
previous study showed decreases in levels of nearly all lipid species in blood samples 
from high-grade serous ovarian carcinoma patients, compared with women with 
benign gynecological disorders. In Study IV, our aim was to validate those previous 
results in a larger population, including also low-grade and early-stage cancers and 
histological pathology other than only serous. Lipidomic analysis was performed on 
354 blood samples from women with OCs or benign gynecological pathologies; the 
women were from Finland or Germany. The results were compared with the 
previous results from 250 women. A total of 39 lipids were altered consistently and 
significantly in both early and late stages in all three cohorts (Finnish, German and 
previous study), 23 of them in all histological subtypes. Results showed lower levels 
of most of the lipids; there were higher levels of only one ceramide (Cer[d18:1/18:0]) 
and triacylglycerol (TAG[18:1/18:1/20:4]) in all stages and histologies. 
Combinations of some lipids and lipid ratios with CA125 improved the diagnostic 
value of serum CA125.  
In conclusion, the subjective evaluation of two-dimensional US by an expert 
remains the most reliable preoperative diagnostic tool of adnexal masses. Emerging 
objective biochemical and biophysical methods include urinary polyamine analysis, 
FAIMS technology, and serum lipidomic profile.  
TIIVISTELMÄ 
Munasarjakasvaimet ovat ryhmä hyvin erilaisia kasvaimia viattomasta 
hyvänlaatuisesta kasvaimesta aggressiiviseen syöpään. Ne ovat usein 
sattumalöydöksiä oireettomilla naisilla, jopa levinneessä syövässä. Diagnostiikan 
kulmakivi on emättimen kautta tehtävä ultraäänitutkimus yhdistettynä verestä 
mitattaviin merkkiaineisiin, joista perinteisesti käytetyin on CA125-merkkiaine. 
Oikea ja mahdollisimman varhainen diagnoosi vaikuttaa kasvaimen hoitolinjoihin ja 
ennusteeseen, joka heikkenee merkittävästi levinneessä syövässä verrattuna 
alkuvaiheen munasarjasyöpään. Riittävän laaja leikkaushoito on merkittävin 
munasarjasyövän ennusteeseen vaikuttava tekijä. Toisaalta hyvänlaatuisten 
kasvaimien kohdalla konservatiivinen seurantalinja voi olla riittävä hoito, jolloin 
voidaan välttää turhia leikkausriskejä. 
Väitöskirjan tavoitteena oli tutkia kehittyneempiä ultraäänitutkimusmenetelmiä ja 
-luokitteluja verrattuna perinteiseen kaksiulotteiseen ultraäänitutkimukseen, sekä 
etsiä uusia menetelmiä ja mahdollisia merkkiaineita munasarjakasvaimien 
erotusdiagnostiikkaan. Ensimmäisessä osatyössä tutkittiin 100 vähintään 50-
vuotiasta naista, jotka odottivat munasarjakasvaimen vuoksi tehtävää leikkausta. 
Naiset tutkittiin ennen leikkausta kolmiulotteisella ultraäänitutkimuksella sekä 
moderneilla kaksiulotteiseen ultraäänitutkimukseen perustuvilla luokitteluilla, ja 
löydöksiä verrattiin keskenään. Mikään menetelmä ei ollut parempi kuin kokeneen 
ultraäänitutkijan oma arvio (ns. expert opinion) kaksiulotteisesta 
ultraäänitutkimuksesta. Kolmiulotteinen ultraäänitutkimus ei tuonut merkittävää 
lisäarvoa perinteisiin menetelmiin verrattuna. Jälkikäteen toinen kokenut 
ultraäänitutkija arvioi samat potilaat tallennettujen ultraäänikuvien perusteella, ja 
löydösten arviointi oli hyvin yhteneväistä tutkijoiden kesken. 
Tutkimuksia laajennettiin keräämällä ennen leikkausta 71 munasarjakasvain- ja 22 
kontrollipotilailta virtsanäytteitä, joista analysoitiin ja mitattiin nestekromatografia-
massaspektrometrialla polyamiineja. Polyamiinit ovat nisäkässoluissa esiintyviä mm. 
solujen kasvulle välttämättömiä molekyylejä, joiden on todettu liittyvän myös 
karsinogeneesiin. Erityisesti asetyloituneiden polyamiinien kohonneita pitoisuuksia 
elimistön nesteissä on todettu useissa syövissä. Toisessa osatyössä osoitettiin 
ensimmäistä kertaa diasetyloituneen spermiinin (DiAcSpm) pitoisuuden olevan 
kohonneen myös munasarjasyöpäpotilaiden virtsassa verrattuna kontrolleihin ja 
naisiin, joilla on hyvänlaatuinen munasarjakasvain. Korkeimmat virtsan DiAcSpm-
pitoisuudet mitattiin potilailla, joilla oli huonosti erilaistunut ja levinnyt 
munasarjasyöpä (high-grade syöpä). Virtsan DiAcSpm oli tutkimuksessa jopa 
herkempi merkkiaine kuin yleisesti käytetty seerumin CA125 raja-arvolla 35 U/ml 
(86.5% vs. 75.7%). 
Koirakokeissa on todettu, että koulutettu koira tunnistaa hajuaistin avulla 
syöpäkudoksen ja syöpäpotilaan eritteet. Nykyteknologia mahdollistaa analytiikan, 
jolla näytteen sisältämien orgaanisten yhdisteiden muodostama hajuspektri 
analysoidaan mm. koneellisen nenän (elektroninen nenä, eNose) avulla. 
Kolmannessa osatyössä virtsanäytteet (51 munasarjakasvain- ja 18 kontrollipotilailta) 
tutkittiin FAIMS (field asymmetric waveform ion mobility spectrometry)-
teknologialla, joka on ionimobiliteettispektrometrian muunnelma sijoittuen 
massaspektrometrian ja elektronisen nenän välimaastoon. FAIMS-teknologian avulla 
munasarjasyöpäpotilaiden virtsa erotettiin kontrollien sekä hyvänlaatuisten 
kasvainpotilaiden virtsasta 81.3%:n ja 77.3%:n tarkkuuksilla. High-grade 
munasarjasyöpää sairastavien potilaiden virtsa oli erotettavissa varhaisvaiheen (low-
grade) munasarjasyöpää sairastavien naisten virtsasta, joka puolestaan erosi 
hyvänlaatuisten kasvainpotilaiden virtsasta.  
Munasarjasyövän metaboliatutkimuksissa on todettu muutoksia myös rasva-
aineiden (lipidi) aineenvaihdunnassa syöpäpotilailla. On kuitenkin ollut epäselvää, 
mitkä lipidiryhmät muuttuvat erityisesti. Aiemmassa suomalais-saksalaisessa 
tutkimuksessa todettiin lähes kaikkien lipidien pitoisuuden laskevan high-grade 
seröösiä munasarjasyöpää sairastavien potilaiden veressä verrattuna naisiin, joilla oli 
hyvänlaatuinen gynekologinen sairaus. Neljännessä osatyössä 
lipidiaineenvaihdunnan muutoksia tutkittiin 354 verinäytteestä, jotka oli otettu 
varhais- ja levinneen vaiheen sekä erilaisia syöpäkasvaintyyppejä (muitakin kuin 
seröösi) sairastavilta munasarjasyöpäpotilailta ja hyvänlaatuista gynekologista 
sairautta sairastavilta naisilta. Yhteensä 39 lipidiä oli samansuuntaisesti ja pääosin 
tilastollisesti merkitsevästi muuttunut sekä varhais- että myöhäisasteen syövissä, ja 23 
näistä lipideistä oli muuttunut myös kaikissa kasvaintyypeissä. Pääosin 
lipidipitoisuudet olivat vähentyneet syöpäpotilaiden veressä verrattuna ei-
syöpäpotilaiden verinäytteisiin. Vain yksi keramidi (Cer[d18:1/18:0]) ja 
triasyyliglyseroli (TAG[18:1/18:1/20:4]) olivat kohonneet kaikissa 
levinneisyysasteissa ja kudostyypeissä. Lipidiyhdistelmät yhdessä seerumin CA125-
pitoisuuden kanssa paransivat diagnostista osuvuutta yksittäiseen CA125-arvoon 
verrattuna.  
Kokeneen tutkijan oma arvio kasvaimen laadusta perinteisessä kaksiulotteisessa 
ultraäänitutkimuksessa on edelleen luotettavin ultraäänitutkimusmenetelmä 
munasarjakasvaimien laatua arvioitaessa. Virtsan polyamiinien mittaaminen, FAIMS- 
teknologia ja seerumin lipidiprofiilin tutkiminen ovat lupaavia uusia objektiivisia 
tutkimusmenetelmiä munasarjakasvainten arvioinnissa.  
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1 INTRODUCTION 
Approximately 239,000 new ovarian cancer (OC) cases are found annually 
worldwide, and the peak incidence rate is among postmenopausal women (Ferlay et 
al. 2015). At the same time, OC is the most lethal gynecological cancer and the fifth 
leading cause of cancer deaths in the U.S.. The five-year relative survival rate has 
improved significantly in the U.S., from 36% to 46% in 1975-2011, a rate that is still 
quite poor compared to the localized OC survival rate of 92% (Siegel et al. 2016). In 
Finland, the published overall five-year survival for OC patients was 43% in 2013-
2015 (Finnish Cancer Registry 2018). Because the prognosis improves remarkably 
when OC is diagnosed at an early-stage, better diagnostic methods are urgently 
needed. 
Accurate preoperative classification of ovarian tumors is necessary for the 
appropriate treatment of tumors, especially classification into benign and malignant 
tumors. Women with suspected OC should be operated on and treated in specialized 
centers because optimal cytoreductive surgery is one of the main prognostic factors 
in the treatment (Bristow et al. 2002). On the other hand, a majority of ovarian 
neoplasms are benign, and an accurate diagnosis is needed to avoid unnecessary or 
overly radical surgery in order to reduce the risk of surgical procedures.  
The symptoms of OC are non-specific and can mimic other conditions such as 
upper-abdominal disease. At early stages of the disease, most women are 
asymptomatic. Large ovarian tumors can be palpable in a clinical examination, but 
often a further evaluation of the pelvis using vaginal ultrasound (US) is performed 
to diagnose and classify the ovarian mass as either benign or malignant. Previous 
studies have determined sonographic morphological and vascular features of adnexal 
masses that specify their nature. The gold standard of ovarian tumor markers is 
CA125, which – together with US findings – is typically used in predicting the 
malignancy of an adnexal tumor. The disadvantage of CA125 is that increased serum 
levels are associated more with advanced and serous OCs than with low-stage 
cancers or other histological subtypes. Also, serum CA125 has a quite poor 
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specificity for OC because it can also be elevated in some non-ovarian cancers and 
in benign gynecological conditions (Jacobs & Bast 1989). 
Several predictive models have been created to optimize the diagnostic 
performance of sonography, including different scoring systems, logistic regression 
analysis and neural networks. The risk of malignancy index (RMI) is the first score 
criterion that takes into consideration US findings, serum CA125 level, and patient 
age and menopausal status (Jacobs et al. 1990). In 2008, the International Ovarian 
Tumor Analysis (IOTA) group published simple US-based rules which can be used 
to correctly classify most ovarian tumors (Timmerman et al. 2008). 
Polyamines are molecules necessary for eukaryotes and essential for cellular 
proliferation, also in carcinogenesis. Increased polyamine concentrations have been 
found in many cancers (Gerner & Meyskens 2004). New technology has permitted 
the simultaneous large-pattern analysis of both acetylated and unacetylated 
polyamines from urine (Häkkinen et al. 2013). 
Some cancers have distinct odors caused by volatile organic compounds (VOCs) 
which can be detected in urine, blood and breath by a canine’s olfactory sense (Lippi 
& Cervellin 2012). In addition to canine studies, various new technical methods have 
been studied, e.g. the so-called electronic nose (eNose) and lately more modern 
variants such as field asymmetric waveform ion mobility spectrometry (or FAIMS) 
(Covington et al. 2015). 
Several metabolic alterations occur in cancer cells due to the increased demand 
for energy. Metabolomic profiling is a new diagnostic tool in understanding these 
metabolic changes. In OC, altered serum metabolites have been shown to include 
ketone bodies, carbohydrates, amino acids, lipids and fatty acids (Hilvo et al. 2016). 
Especially alterations in the phospho- and sphingolipid metabolism are associated 
with malignancies, and changes in those lipids have also been found in OC (Furuya 
et al. 2011; Tania et al. 2010). To date, there are no validation studies of the most-
altered lipids in OC (Ke et al. 2015).  
In this thesis, new preoperative diagnostic methods are demonstrated to 
distinguish between benign and malignant ovarian processes. First, women with 
unclear ovarian masses were examined using various sonographic predictive 
methods, including three-dimensional power Doppler (3D-PD) US before surgery. 
Preoperatively collected urine samples were investigated, employing liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) to explore the polyamine 
concentrations in women with and without ovarian neoplasms. The urine samples 
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were also tested using FAIMS to determine the ability of the system to detect volatile 
compounds in the urine of OC patients. Finally, lipidomic analysis of blood samples 
from women with ovarian tumors and benign gynecological diseases was performed 
to identify possible alterations in lipidomic profiling.  
  
  
22 
 
2  REVIEW OF THE LITERATURE 
2.1 Ovarian neoplasms 
Primary ovarian tumors can be categorized into three main types: surface epithelial-
stromal, sex cord-stromal and germ cell. Each category contains many subgroups, 
and some tumors are mixed tumors consisting of different types of cells (V. W. Chen 
et al. 2003).  
Figure 1.  Origin of the main types of ovarian tumors (modified from V. W. Chen et al. 2003). 
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In recent years, molecular, genetic and epigenetic studies have improved 
knowledge about the pathology of ovarian tumors, so the World Health 
Organization (WHO) revised the classification of cancers of the ovaries, fallopian 
tubes and peritoneum in 2014 (Kurman et al. 2014; see Table 1). It is based mainly 
on histopathological findings and takes into account the pathogenesis and prognosis 
of the OC subtypes (Meinhold-Heerlein et al. 2015; Meinhold-Heerlein et al. 2016). 
In parallel with WHO reclassification, the International Federation of Gynecology 
and Obstetrics (FIGO) introduced a new surgical staging classification for cancers 
of the ovary, fallopian tubes and peritoneum. It recognizes that OCs are a 
heterogenous group of malignant tumors with different characteristics and outcomes 
(Zeppernick & Meinhold-Heerlein 2014). 
Table 1.  The current (2014) WHO classification of epithelial ovarian tumors (Kurman et al. 2014). 
Serous tumors Benign type 
 
Cystadenoma 
Adenofibroma 
Surface papilloma 
Borderline (SBOT) 
   
SBOT/atypical proliferating 
tumor 
SBOT, micropapillary type/ 
non-invasive, serous low-grade  
carcinoma 
Malignant type 
   
Serous low-grade carcinoma 
Serous high-grade carcinoma 
Mucinous tumors Benign type 
 
Cystadenoma 
Adenofibroma 
Borderline (MBOT) 
 
MBOT/atypical proliferating 
mucinous tumor 
Malignant type 
 
Mucinous carcinoma 
Endometrioid tumors Benign type 
 
Endometriosis cyst 
Endometrioid cystadenoma 
Endometrioid cystadenofibroma 
Borderline (EBOT) 
 
EBOT/atypical proliferating 
endometrioid tumor 
Malignant type 
 
Endometrioid carcinoma 
Clear cell tumors Benign type 
 
Cystadenoma 
Borderline (CBOT) 
 
CBOT/atypical proliferating clear  
cell tumor 
Malignant type 
   
Clear cell carcinoma 
Brenner tumors Benign type 
 
Brenner tumor 
Borderline 
 
Borderline Brenner tumor/atypical 
proliferating Brenner tumor 
Malignant type 
 
Malignant Brenner tumor 
Seromucinous tumors Benign type 
 
Seromucinous cystadenoma 
Seromucinous adenofibroma 
Borderline 
 
Seromucinous borderline 
tumor/atypical proliferating 
seromucinous tumor 
Malignant type 
 
Seromucinous carcinoma 
 
Undifferentiated 
carcinoma 
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2.1.1 Benign ovarian tumors 
While epithelial tumors form the majority of ovarian malignancies, germ cell tumors, 
or mature cystic teratomas (dermoid cysts), represent the most common benign 
ovarian neoplasms, appearing mainly among youth and younger women of 
reproductive age (Koonings et al. 1989; Park et al. 2015). They are assumed to 
originate from primordial germ cells of yolk sac migrated along the coelomic cavity 
to the ovary (Koonings et al. 1989).  
The most common benign ovarian tumor among women over 50 years old is 
serous cystadenoma (Koonings et al. 1989). Mucinous cystadenomas often occur as 
large cystic masses and represent approximately 10-15% of benign ovarian 
neoplasms. Epithelial cystadenomas are believed to be formed from coelomic 
inclusion cysts that undergo metaplasia (Brown & Frumovitz 2014; Koonings et al. 
1989). 
2.1.2 Borderline ovarian tumors 
Borderline ovarian tumors (BOTs) are neoplasms classified between the benign and 
malignant categories. They are low-malignancy potential tumors that have an 
elevated mitotic activity and slight nuclear atypia without marked stromal invasion. 
Most of them are serous and mucinous subtypes (Silverberg et al. 2004). BOTs occur 
also in younger women, when correct diagnosis and treatment options must also take 
into account fertility preservation issues. Serous BOTs share molecular and genetic 
similarities with low-grade serous carcinomas (LGSCs), and they can exist at 
advanced stages with peritoneal implants and/or lymph node involvement. Non-
serous BOTs occur mainly at Stage I. The new WHO classification reformed the 
terminology of microinvasion: microinvasive foci have dimensions of maximum 5 
mm, but if they have solid nests or cribriform glands histologically reminiscent of 
LGSCs, they are classified as LGSCs despite the size of the microinvasion 
(Hauptmann et al. 2017). 
The recent classification of WHO also mentioned micropapillary serous BOT as 
a distinct variant of BOT. It is also determined as a non-invasive LGSC. 
Micropapillary pattern of serous BOT is not an independent prognostic factor, but 
it is more often associated with poor clinicopathological factors e.g. found at 
advanced stages (Hauptmann et al. 2017). Previously the peritoneal implants of 
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serous BOT were divided into invasive and non-invasive while the new WHO 
classification considers the invasive foci as peritoneal LGSC (Meinhold-Heerlein et 
al. 2016).  
2.1.3 Ovarian cancer 
One in 75 women develops OC during her lifetime. The risk is higher in the U.S. 
and Europe than in Asia (Reid et al. 2017).  
At least 90% of ovarian malignancies are of epithelial origin, and the main subtype 
is high-grade serous (HGSC; 70%), followed by endometrioid (10%), clear cell 
(10%), mucinous (3%), and LGSC (<5%) (Zeppernick & Meinhold-Heerlein 2014). 
Malignant sex cord-stromal (mainly granulosa cell tumors) and germ cell tumors 
(dysgerminomas, yolk sac tumors and immature teratomas) represent respectively 1-
2% and 3% of OCs (Prat & FIGO Committee on Gynecologic Oncology 2014).  
Nowadays epithelial OC is roughly divided into two groups: type I and type II 
(Koshiyama et al. 2017; Kurman & Shih 2016; Labidi-Galy et al. 2017).  
Table 2.  The characteristics of type I and II epithelial ovarian carcinoma. 
 Type I ovarian cancer Type II ovarian cancer 
Behavior Slow-growing Aggressive 
Origin → 
Histological 
subtype   
Endometriosis → Endometrioid carcinoma, Clear cell  
carcinoma, Seromucinous carcinoma 
Fallopian tube → LGSC 
Germ cell (via mature teratoma) → Mucinous 
carcinoma? 
Transitional cell → Mucinous carcinoma?, Malignant 
Brenner tumor 
Fallopian tube → HGSC, Carcinosarcoma, 
Undifferentiated carcinoma 
Stage Frequently early stage Mostly advanced stage 
Precursor 
 
A benign precursor cyst or atypical proliferative 
(borderline) tumor 
Mostly STICs (de novo starting) 
 
Proliferative 
activity 
Usually low Always high 
BRCA1 / BRCA2 
mutation 
Low High 
TP53 mutation Low  High 
Chromosomal 
instability 
Low High 
Homologous 
recombination 
repair 
Rarely defective Often defective 
Clinical outcome Usually good Often poor 
LGSC: low-grade serous carcinoma; HGSC: high-grade serous carcinoma; STIC: serous tubal intraepithelial carcinoma. 
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2.1.4 Treatment 
2.1.4.1 Benign ovarian tumors 
Examination by an experienced sonographist is essential for the accurate diagnosis 
of ovarian tumors and making decisions regarding their treatment. Asymptomatic 
adnexal tumors can be managed conservatively by appropriate follow-up, which 
diminishes surgical risks by minimizing unnecessary surgery. The effect of a tumor 
or surgery on hormonal status should also be considered. On the other hand, ovarian 
tumors with a suspicion of malignancy must be referred to a gynecologic oncologist.  
An international panel of experts has drafted consensus recommendations for 
the clinical assessment and management of asymptomatic ovarian tumors (Glanc et 
al. 2017). Based on this and other publications, treatment of simple cysts (Greenlee 
et al. 2010; Modesitt et al. 2003) or cysts with solid components, septated tumors 
(Saunders et al. 2010), solid tumors (Alcazar et al. 2017; Timmerman et al. 2008; S. 
Wang & Johnson 2012), dermoid cysts (Park et al. 2015) and endometrioid cysts (He 
et al. 2017) are summarized in Table 3 below.  
Table 3.  Treatment recommendations for asymptomatic sonographically benign ovarian tumors.  
Ultrasound finding Risk of malignancy Recommended treatment 
Simple cyst <10 cm Minimal Conservative follow-up 
Thin (<3 mm) septas of 
a cyst 
Minimal Conservative follow-up 
Cysts with a few solid 
(<3 mm) components 
Minimal 
More or larger components increase risk of 
malignancy 
Conservative follow-up 
Solid tumor Tumors with acoustic shadows, non-
detectable or minimal blood flow in color 
Doppler without ascites bear minimal risk 
(2% in postmenopausal women) 
Conservative follow-up  
Dermoid cyst Older age, elevated CA125 levels, 
postmenopausal status, or large tumors 
increase the risk 
Surgery for large tumors or for 
those with changes in follow-up 
Endometrioid cyst Postmenopausal status and size of  
>8 cm increase the risk 
OR for clear cell cancer =3.05 
OR for endometrioid cancer =2.04 
OR for low-grade serous cancer =2.11 
 
No evidence that early surgical 
treatment reduces the risk for 
cancer; surgery or careful follow-up 
for women with risk factors 
OR: Odds ratio. 
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2.1.4.2 Borderline ovarian tumors 
Borderline ovarian tumors occur in younger women than epithelial OC, and 
therefore more conservative surgery is often discussed in order to retain fertility. The 
prognosis for BOTs is generally excellent because they are mainly diagnosed at a 
non-advanced stage. The five-year survival for Stage I patients is 95-97%; because 
recurrences can appear late, the ten-year survival is 70-95%. In turn, the five-year 
survival for women with Stage II or III BOT is 65-87% (Fischerova et al. 2012).  
Recurrences are associated more often with conservative treatment than with 
radical surgery. In the study of Suh-Burgmann (2006), 193 women with BOTs, 
mainly Stage I disease, were treated conservatively. The patients who underwent 
cystectomy relapsed more often than the patients who underwent oophorectomy 
(23% vs. 7% respectively). Two women (1%) saw a recurrence with malignant OC 
in the three years after their first surgery. 
The standard surgery for BOTs remains bilateral salpingo-oophorectomy with or 
without hysterectomy, including FIGO staging procedures, and it is recommended 
for women without wish to remain fertile. In these cases, preoperative counselling 
before conservative surgery is important. Routine lymphadenectomy is not 
recommended (Fischerova et al. 2012; Gershenson 2017). Adequate staging includes 
appendicectomy in the case of mucinous BOTs (Morice et al. 2012).  
To date, there is no data evidencing the benefits of adjuvant chemotherapy, even 
at advanced stages of BOTs (Fischerova et al. 2012). Still, for women with serous 
BOTs and invasive peritoneal implants, platinum-based chemotherapy is 
recommended. Increasingly, these BOTs are called low-grade carcinomas 
(Gershenson 2017).  
2.1.4.3 Epithelial ovarian cancer 
The histopathological evaluation of tissue samples is needed to confirm the diagnosis 
of OC; surgery is often required to obtain such samples. The main targets of the 
surgery are to verify the diagnosis, determine the stage of the cancer and achieve 
maximal removal of the tumor. Both the histopathological type of tumor (WHO 
classification) and the surgical stage of tumor (FIGO classification) are important in 
therapeutic decisions regarding OC. The FIGO staging classification from 2014 is 
shown in Table 4 (Prat & FIGO Committee on Gynecologic Oncology 2014). 
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Table 4.  The FIGO staging classification (2014) of ovarian cancer. 
Stage Description 
I Tumor confined to the ovaries 
IA Tumor restricted to one ovary (capsule is intact); no tumor on ovarian surface; 
no malignant cells in the ascites or peritoneal washings 
IB Tumor is restricted to both ovaries (capsule is intact), no tumor on ovarian 
surface, no malignant cells in the ascites or peritoneal washings 
IC Tumor is restricted to one or both ovaries with one of the following: 
IC1 x capsule rupture intraoperatively 
IC2 x capsule rupture preoperatively or tumor on ovarian surface 
IC3 x malignant cells in the ascites or peritoneal washings 
II Tumor involves one or both ovaries with pelvic involvement 
IIA Extension and/or implants on uterus and/or fallopian tubes and/or ovaries 
IIB Extension to other pelvic intraperitoneal tissue 
III Tumor involves one or both ovaries with cytologically or histologically verified 
peritoneal metastases outside the pelvis and/or in retroperitoneal lymph nodes 
 
IIIA1 (Cytologically or histologically verified) metastases in retroperitoneal lymph 
nodes 
(i) maximum diameter 10 mm 
(ii) maximum diameter >10 mm 
 
IIIA2 Microscopic peritoneal metastases outside the pelvis with or without 
metastases in retroperitoneal lymph nodes 
 
IIIB Macroscopic peritoneal metastases ≤2 cm outside the pelvis with or without 
metastases in retroperitoneal lymph nodes 
 
IIIC Macroscopic peritoneal metastases >2 cm outside the pelvis with or without 
metastases in retroperitoneal lymph nodes (including capsule of the 
liver/spleen but excluding parenchymatous metastases) 
IV Distant metastasis without peritoneal metastases 
IVA Pleural effusion with positive cytology 
IVB Parenchymal metastases and metastases in extra-abdominal organs (including 
inguinal and extra-abdominal lymph node metastases) 
 
The cornerstones of epithelial OC treatment are surgery and postoperative 
chemotherapy. The surgery consists of staging laparotomy (longitudinal incision), 
including a total hysterectomy with bilateral salpingo-oophorectomy, peritoneal 
cytology, biopsies from the peritoneum and/or resection of suspicious lesions of the 
peritoneum, omentectomy, and pelvic and para-aortal lymphadenectomies. The aim 
of the surgery is an optimal debulking removing all the visible tumor manifestations, 
which is the main prognostic factor in patient survival (Meinhold-Heerlein et al. 
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2015). Neoadjuvant chemotherapy may decrease postoperative morbidity in patients 
in poor condition or with co-morbidities and may improve the likelihood of optimal 
surgery, but it cannot improve the prognosis of a patient (Hacker & Rao 2017). 
A review of Chiva et al. (2016) collected information from 12,000 patients with 
Stage III-IV OC. The patients with completely resected disease had a median overall 
survival of 70 months compared with patients with a minimal macroscopic residual 
disease of 0.1-0.5 cm or suboptimal debulking (residual disease >0.5-1 cm), who 
survived 53 and 30-40 months respectively. Melamed et al. (2017) established that 
optimal cytoreductive surgery was an important prognostic factor in Stage IIIC-IV 
OC of the serous, clear cell and mucinous histological subtypes. To achieve complete 
primary cytoreduction, extensive ultra-radical surgery is performed in the 
management of advanced OCs. This aggressive surgery may include procedures such 
as diaphragm peritonectomy, splenectomy, bowel resection and liver resection 
(Chang et al. 2015).  
Platinum- and taxane-based chemotherapy is the standard first-line treatment for 
early- and advanced-stage epithelial OC after primary surgery. Adjuvant 
chemotherapy is not recommended for patients whose disease is restricted to the 
ovary (Stage IA or IB) and of a low histological grade, because they have a five-year 
survival of >90% after successful surgery (Young et al. 1990). The chemotherapy is 
received in six cycles every three weeks, although shorter courses of chemotherapy 
may be sufficient for patients with a non-serous histology (Webber & Friedlander 
2017). The addition of bevacizumab to standard chemotherapy has improved the 
overall survival of OC patients with a high risk of cancer progression (Oza et al. 
2015). 
2.1.4.4 Non-epithelial malignant ovarian tumors 
Malignant germ cell ovarian tumors are mainly unilateral and restricted only to the 
ovary, which enables fertility-sparing surgery such as unilateral salpingo-
oophorectomy. The extent of surgical staging depends, for example, on the age of 
the patient. A careful evaluation of the abdominal cavity is performed with 
cytological samples, peritoneal biopsies, palpation of the omentum or omentectomy, 
and lymph node biopsies or lymphadenectomies are performed as in epithelial OC 
staging (Brown et al. 2014; Gershenson 2007). Cisplatin-based adjuvant 
chemotherapy, bleomycin-etoposide-cisplatin (BEP), has been a postoperative 
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standard (Brown et al. 2014). However, women with Stage IA dysgerminomas and 
highly differentiated Stage IA immature teratomas can be treated with surgery alone 
(Colombo et al. 2012).  
The surgical treatment of malignant sex cord-stromal ovarian tumors is similar to 
that of epithelial OCs, but systematic lymphadenectomies are not recommended. 
Young women with localized tumors (Stage IA) can have conservative surgery that 
spares the contralateral adnex. According to the recommendations, postoperative 
chemotherapy (e.g. BEP) is utilized only in advanced stages: granulosa cell tumors 
Stages IIA-IV and Sertoli-Leydig cell tumors with poor differentiation (Colombo et 
al. 2012). 
2.1.5 Ovarian cancer screening 
Screening for OC has thus far turned out to be quite ineffective. The results of the 
UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) were published 
recently. In that randomized controlled trial, they recruited 200,000 postmenopausal 
women and divided them in a ratio of 1:1:2 into three groups: one with annual 
multimodal screening with CA125 measuring with a transvaginal US as a secondary 
test for women with increased CA125 levels, one with annual transvaginal US 
screening and one without any screening. The primary analysis of UKCTOCS did 
not reveal any significant reduction in OC mortality in the screening groups, 
although a subgroup analysis excluding prevalent OCs did (Jacobs et al. 2016).  
MicroRNAs are small, non-coding RNA molecules found circulating in 
peripheral blood and shown to be deregulated in cancer, also in OC. Therefore, they 
have been studied as potential early biomarkers of OC, but large population studies 
are still lacking (Prahm et al. 2016). Liquid-based Pap smear specimens, which can 
reveal previously identified DNA mutations indicating OC, have also been tested for 
OC diagnostics. These tests will have to be improved before they can be used in 
routine screening (Kinde et al. 2013). 
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2.2 Preoperative assessment of ovarian tumors with biomarkers 
2.2.1 Cancer antigen 125 
Cancer antigen 125 (CA125) is the most studied OC biomarker; it was described as 
elevated in epithelial OC patients in 1983 by Bast et al. (Jacobs & Bast 1989). CA125 
is an antigen on a high-molecular-weight membrane glycoprotein recognized by the 
corresponding monoclonal antibody OC125, which was discovered when mice were 
immunized with an ovarian cancer cell line. It is expressed in Müllerian and coelomic 
epithelia, but originally it was not found on normal adult and fetal ovarian surfaces. 
Later studies showed immunohistochemical CA125 expression also in normal 
ovarian epithelium tissue (Jacobs & Bast 1989). In turn, CA125 promotes ovarian 
cancer cell proliferation and suppresses an anti-cancer immune response, and is 
therefore overexpressed in epithelial cancers (Bast & Spriggs 2011). It has been 
detected in, for example, normal seminal fluid, fallopian tubes and the endometrium, 
but also in the lungs and conjunctiva, although its physiological function remains 
unclear (Bast & Spriggs 2011). The original CA125 test reacts only to OC125, and 
serum levels of CA125 are considered to be normal if ≤35 U/mL (van Nagell & 
Miller 2016).  
The serum CA125 marker is used to distinguish OC from benign ovarian tumors, 
to check therapeutic response and to detect recurrence of OC (Bast et al. 2005). It is 
elevated in over 80% of epithelial OC patients, but mucinous or early-stage (FIGO 
Stage I) cancers are associated with lower CA125 values (Duffy et al. 2005). CA125 
detects epithelial OC in postmenopausal women at an early- and advanced-stage with 
a specificity of 90% and a respective sensitivity of 50-60% and 80-90% (Muinao et 
al. 2018). In a study by Chen et al., women with type II OC were shown to have 
higher CA125 levels than women with type I OC: the respective median CA125 
levels were 937 U/mL and 171 U/mL (X. Chen et al. 2013).  
CA125 levels may be elevated due to many benign or extraovarian malignant 
causes, which attenuates its usefulness as a diagnostic biomarker (Duffy et al. 2005; 
Jacobs & Bast 1989; Sevinc et al. 2007; see Table 5). The predictive value of CA125 
is better for postmenopausal than premenopausal women, who can be healthy and 
still have higher CA125 levels. Pregnancy increases CA125 levels, which also 
fluctuate during the menstrual cycle (Duffy et al. 2005; Jacobs & Bast 1989). In a 
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pooled analysis of 13 studies, it was concluded that a higher body mass index and 
non-white race may be factors in higher CA125 values (Babic et al. 2017). Monitoring 
CA125 values over time may give a more reliable view of the disease: benign or non-
gynecological causes may result in fluctuating or stable values, whereas, with OC, 
CA125 values tend to increase (Bast et al. 2005). 
Table 5.  Benign and malignant conditions other than ovarian cancer affecting elevated CA125 
concentrations. 
Benign  
gynecological  
disorders  
Benign non-
gynecological  
disorders 
Malignant 
gynecological  
disorders 
Malignant non-
gynecological 
disorders* 
Endometriosis Pancreatitis Advanced uterine cancer Breast cancer 
Uterine myomas Renal failure  Lung cancer 
Adenomyosis Liver cirrhosis  Pancreatic cancer 
Pelvic inflammatory disease Some lung and pleural 
diseases 
 Gastro-intestinal cancer 
Ovarian hyperstimulation 
syndrome 
Other conditions associated 
with ascites 
 Hepato-biliary cancer 
Meig`s syndrome   Bladder cancer 
(Pregnancy)   Lymphoma with peritoneal 
involvement 
* Especially with peritoneal metastasis. 
2.2.2 Human epididymis protein 4  
Human epididymis protein 4 (HE4) is encoded by the WFDC2 gene, which was 
originally found in epithelial cells of the human epididymis (Hellstrom et al. 2003). 
HE4 is expressed in normal reproductive and respiratory tracts and in salivary gland 
secretions, but minimal expression is found in normal ovarian tissues. The 
overexpression of HE4 is seen in epithelial OCs, especially in serous and 
endometrioid adenocarcinomas. Benign and borderline ovarian tumors have lower 
levels of HE4 (N. S. Karlsen et al. 2014). 
The first experiment showing that serum HE4 could act as an OC biomarker was 
published in 2003. In that study, HE4 was shown to be comparable with CA125 in 
distinguishing localized and advanced OC (Hellstrom et al. 2003). Later studies have 
reported HE4 to be as good as CA125 or even better in detecting OC. Moore et al. 
compared multiple ovarian biomarkers for detecting OC. HE4 had the highest 
sensitivity (72.9%) in finding OC, with a specificity of 95%, but the combination of 
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CA125 and HE4 improved the sensitivity to 76.4%. HE4 was found to be also the 
best biomarker to differentiate Stage I OC from benign tumors, although the 
sensitivity of HE4 was quite low, 45.9%, with a specificity of 95%, and a combination 
with CA125 did not improve the results (Moore et al. 2008). In a study by Holcomb 
et al. (2011), serum HE4 performed better (sensitivity 88.9% and specificity 91.8%) 
compared with CA125 (83.3% and 59.5% respectively) in distinguishing between 
benign and malignant adnexal masses in premenopausal women  
In 2008, the Food and Drug Administration (FDA) in the U.S. approved serum 
HE4 as a diagnostic tool for OC (N. S. Karlsen et al. 2014). Urinary HE4 has also 
been proven to be a feasible non-invasive diagnostic biomarker for OC. One meta-
analysis of seven studies estimated a sensitivity of 76% and specificity of 92% for 
urine HE4 in detecting OC (Jia et al. 2017). 
The advantage of HE4 over CA125 is its very low production in normal ovarian 
tissue. Consequently, while CA125 levels are often elevated in premenopausal 
women with endometriomas or other benign ovarian tumors, serum levels of HE4 
remain normal (Huhtinen et al. 2009; Moore et al. 2008). The commonly used cutoff 
value for serum HE4 concentration is 70 pmol/L (Moore et al. 2008). Serum levels 
of HE4 increase along age and smoking (Bolstad et al. 2012). Pregnant women in 
every trimester have lower levels of HE4 than other premenopausal women (Moore 
et al. 2012). In contrast with HE4, serum levels of CA125 in postmenopausal women 
are significantly lower than in premenopausal women (Bon et al. 1996), which means 
it is more useful than HE4 with postmenopausal women. The guidelines of the Royal 
College of Obstetricians and Gynaecologists do not recommend the routine use of 
serum HE4 instead of CA125 in the diagnosis of postmenopausal ovarian neoplasms 
due to insufficient data (Royal College of Obstetricians and Gynaecologists 2016). 
Higher HE4 levels can be associated with some non-malignant diseases, of which 
renal failure is the most significant, featuring HE4 levels that increase with the serum 
creatine concentration (Escudero et al. 2011). Serum HE4 levels are elevated in acute 
and chronic heart failure correlating with severity of the disease and renal function 
(de Boer et al. 2013; Piek et al. 2017). Significantly elevated HE4 levels are also found 
in malignancies, not only in epithelial OC but also in endometrial cancer, lung 
adenocarcinoma and transitional cell carcinoma. Patients with liver metastases from 
any cancer origin have been found to have elevated HE4 levels (Escudero et al. 2011; 
N. S. Karlsen et al. 2014). 
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2.2.3 The risk of malignancy algorithm  
The serum HE4 biomarker has been studied and used mostly as a complementary 
biomarker for CA125. Moore et al. evaluated the risk of malignancy algorithm 
(ROMA) as a diagnostic marker for the prediction of ovarian tumors and combined 
serum CA125 and HE4 into two logistic regression algorithms depending on 
patients’ menopausal status. The ROMA algorithm classified tumors as a low or high 
risk in post- and premenopausal groups with sensitivities of 92% and 77% 
respectively and specificities of 75% in both groups (Moore et al. 2009). FDA 
approved ROMA as a preoperative test in evaluating ovarian tumors in 2011 (Miller 
& Ueland 2012).  
Meta-analyses of 11 (F. Li et al. 2012) and 32 studies (J. Wang et al. 2014) 
evaluated the diagnostic performance of ROMA, single HE4 and CA125 parameters 
in predicting OC (Table 6). 
Table 6.  Summary of pooled/mean estimates for prediction of ovarian cancer. 
Reference  CA125 HE4 ROMA 
Li et al. 2012 Overall 
  Sensitivity (95% CI) 
  Specificity (95% CI) 
 
Epithelial ovarian cancer 
  Sensitivity (95% CI) 
  Specificity (95% CI) 
     
  Premenopausal women 
      Sensitivity (95% CI) 
      Specificity (95% CI) 
    
  Postmenopausal women 
      Sensitivity (95% CI) 
      Specificity (95% CI) 
 
0.73 (0.63-0.81) 
0.86 (0.81-0.90) 
 
 
0.77 (0.58-0.89) 
0.84 (0.76-0.90) 
 
 
0.88 (0.59-0.99) 
0.59 (0.47-0.71) 
 
 
0.95 (0.83-0.99) 
0.86 (0.73-0.96) 
 
0.77 (0.72- 0.81) 
0.88 (0.82-0.93) 
 
 
0.79 (0.74-0.84) 
0.93 (0.87-0.96) 
 
 
0.87 (0.65-0.99) 
0.93 (0.86-0.98) 
 
 
0.82 (0.68-0.94) 
0.95 (0.81-1.00) 
 
0.86 (0.82-0.89) 
0.78 (0.75-0.81) 
 
 
0.89 (0.84-0.93) 
0.83 (0.77-0.88) 
 
 
0.82 (0.67-0.91) 
0.82 (0.74-0.88) 
 
 
0.93 (0.89-0.96) 
0.79 (0.73-0.83) 
 
Wang et al. 2014 Overall 
  Sensitivity (95% CI) 
  Specificity (95% CI) 
 
  Premenopausal women 
      Sensitivity (95% CI) 
      Specificity (95% CI) 
 
  Postmenopausal women 
      Sensitivity (95% CI) 
      Specificity (95% CI) 
 
Epithelial ovarian cancer 
  Sensitivity (95% CI) 
  Specificity (95% CI) 
 
0.79 (0.74-0.84) 
0.82 (0.77-0.87) 
 
 
0.80 (0.70-0.88) 
0.76 (0.63-0.86) 
 
 
0.86 (0.79-0.91) 
0.85 (0.79-0.90) 
 
 
0.81 (0.74-0.87) 
0.81 (0.73-0.87) 
 
0.76 (0.72-0.80) 
0.94 (0.90-0.96) 
 
 
0.71 (0.64-0.78) 
0.94 (0.88-0.97) 
 
 
0.78 (0.71-0.85) 
0.90 (0.78-0.97) 
 
 
0.77 (0.71-0.82) 
0.94 (0.90-0.96) 
 
0.85 (0.81-0.89) 
0.82 (0.77-0.87) 
 
 
0.76 (0.70-0.81) 
0.85 (0.80-0.89) 
 
 
0.91 (0.87-0.93) 
0.79 (0.74-0.84) 
 
 
0.90 (0.86-0.93) 
0.77 (0.69-0.84) 
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In a prospective study of 1,218 patients with an adnexal tumor, HE4 and CA125 
were measured and combined in a ROMA index. All three biomarkers were 
compared with the RMI, which considers CA125 value, menopausal status and US 
findings. Both ROMA and RMI indices improved the specificities of single CA125 
and HE4 markers with a similar sensitivity. The areas under the curve (AUCs) of 
ROMA and the RMI were equivalent in distinguishing between OC and benign 
tumors but did not differ considerably from AUCs of CA125 or HE4 alone, whereas 
RMI was slightly more sensitive and specific than ROMA among premenopausal 
women (M. A. Karlsen et al. 2012).  
2.2.4 Other biomarkers 
CA125 lacks specificity in premenopausal ovarian tumors and sensitivity in the 
diagnosis of early-stage and mucinous OC, which is why many ovarian tumor 
markers have been tested together with CA125 to complement it (Duffy et al. 2005). 
In 2009, the FDA approved a multivariate index assay, OVA1, to help in the 
clinical decision of whether to refer patients with undetermined ovarian tumors to a 
gynecologic oncologist. The OVA1 test includes five biomarkers: two upregulated 
(CA125 and β-2 microglobulin) and three downregulated proteins (transferrin, 
prealbumin and apolipoprotein A1). An appropriate software program, OvaCalc, 
combines the values of each protein and uses a multivariate index assay logarithm to 
form an ovarian malignancy risk index. The numeric results vary from 0.0 to 10.0, 
indicating a high probability of OC in premenopausal and postmenopausal women 
with respective values ≥5.0 and 4.4 (Miller & Ueland 2012).  
In a study of Ueland et al. (2011), the sensitivity of OVA1 in identifying epithelial 
OC was 99%, compared to 83% with CA125. Even in premenopausal early-stage 
OCs (FIGO Stage I or II), the sensitivity was 93%, compared to 36% with CA125. 
It has been emphasized that the OVA1 test should be used only for decision-making 
regarding where ovarian tumor surgery should be performed. The cost of the test 
limits its availabity (Muller 2010).  
Subsequently, a second-generation multivariate index assay has been developed 
that includes three OVA1 markers (CA125, transferrin and apolipoprotein A1) and 
two other markers (follicle-stimulating hormone and HE4). It achieved better 
specificity and positive predictive values than the previous OVA1 test, although the 
sensitivity and negative predictive value did not change (Coleman et al. 2016). 
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There are no good serum biomarkers for mucinous ovarian tumors. However, 
carcinoembryonic antigen (CEA) is considered to be the most applicable tumor 
marker (Brown & Frumovitz 2014), and tumor-associated trypsin inhibitor (TATI) 
combined with CA125 have achieved better accuracy than CA125 or TATI alone 
(Medl et al. 1995; Mogensen et al. 1990).  
The most common malignant sex cord-stromal tumors are adult-type granulosa 
cell tumors that produce estrogen, which causes their most typical symptoms. In 
turn, Sertoli-Leydig cell tumors (androblastomas) are usually associated with 
virilization and elevated serum androgen levels. The most-used biomarkers for 
preoperative diagnosis and follow-up, also for malignant germ cell tumors, are 
presented in Table 7 (Al-Hussaini et al. 2017; Färkkilä et al. 2015; Goyal et al. 2014; 
Haltia et al. 2017).  
Table 7.  Most commonly used serum biomarkers for non-epithelial ovarian tumors. 
 Sex cord-stromal tumors Germ cell tumors 
 Adult-type granulosa 
cell tumor 
Sertoli-Leydig cell 
tumor 
Dysgerminoma 
Yolk sac tumor 
Immature teratoma 
Biomarker Inhibin B 
AMH 
Androgens 
AFP 
hCG 
LDH 
AFP  
AMH: anti-Müllerian hormone; AFP: alpha-fetoprotein; hCG: human chorionic gonadotrophin; LDH: lactate  
dehydrogenase. 
2.3 Preoperative assessment of ovarian tumors with imaging 
2.3.1 Two-dimensional sonography with Doppler 
Transvaginal US alone or combined with serum biomarkers is considered to 
represent the best method to detect an ovarian tumor and determine its benign or 
malignant nature. Ovarian tumors are classified by US into benign, malignant or 
indeterminate, depending on their morphological findings. The entire tumor must 
be visualized, also by transabdominal US if the tumor is too large for the transvaginal 
scan. The presence of cystic or solid lesions, as well as septations, cystic wall 
abnormalities and possible ascites in the abdominal cavity, must be recognized. To 
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optimize the diagnostic performance of transvaginal US, many scoring and 
predicting models have been developed. In order to standardize the morphological 
terms, definitions and the US measurement and examination techniques, an 
international IOTA group of, currently, approximately 50 contributing clinical 
centers was founded in 1999 (Abramowicz & Timmerman 2017), and a consensus 
paper was published (Timmerman et al. 2000). 
The assessment of the vascularity of ovarian tumors by color or power Doppler 
is combined with gray-scale morphologic sonography in the differential diagnosis of 
ovarian tumors. It is based on the increased neovascularization of malignant tumors, 
leading to low-impedance blood flow due to anatomical differences between normal 
blood vessels and those developed by tumor angiogenesis, which lack smooth 
muscle in their walls, resulting in a reduced resistance to flow (Miller & Ueland 2012). 
The impedance of the vascularity can be measured by using pulsatility (PI) and 
resistance indices (RI).  
There have been attempts to determine cutoff levels for PI and RI, but the levels 
of benign and malignant tumors have been overlapping (Fleischer et al. 1991; Salem 
et al. 1994; Tekay & Jouppila 1992). While the entire tumor should be examined with 
color Doppler, PIs and RIs can be measured only from the areas selected. 
Additionally, the measurements are angle-dependent, which means decreased intra- 
and interobserver reproducibility. 
Vascularization of ovarian tumors can be detected also from benign tumors, and 
then it more often occurs in the peripherical areas of the tumor, whereas 
vascularization in the central or solid areas of a tumor is more indicative of malignant 
processes. Nevertheless, most non-vascularized tumors are benign (Guerriero et al. 
2002; Schelling et al. 2000). The higher the color content of the tumor assessed by 
color Doppler, the greater the risk of malignancy. The subjective evaluation of the 
color content of the tumor is used to determine the nature of the ovarian tumor 
(Valentin 1997). In the IOTA consensus paper, the vascularity of ovarian tumors is 
divided into four scores: a score of 1 is for tumors with no found blood flow, 2 for 
tumors with minimal flow, 3 for tumors with moderate flow and 4 for highly 
vascularized tumors (Timmerman et al. 2000). The intra- and interobserver 
agreement of the assessment of the color content of adnexal masses was, 
respectively, good to very good and moderate to good in a study with 100 tumors 
and seven US examiners with different degrees of experience (Zannoni et al. 2013).  
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Figure 2.  Vascularization of an ovarian tumor examined using color Doppler. 
 
2.3.1.1 Risk of malignancy index  
Jacobs et al. developed a scoring system in 1990, the RMI, as a tool for differentiating 
between different types of adnexal masses in less specialized centers to help 
treatment decisions. The RMI was the first prediction model combining menopausal 
status, US findings and CA125 measurement in order to characterize ovarian tumors 
(Jacobs et al. 1990). Subsequent modifications of RMI include RMI 2 and 3 
(Tingulstad et al. 1996; Tingulstad et al. 1999), and RMI 4 (Yamamoto et al. 2009). 
The formulas for RMI 1-4 are presented in Table 8 below.  
Table 8.  Variants of risk of malignancy index (RMI). 
Variant Ultrasound score (U)* Menopausal score (M) Tumor size (S), mm 
(single greatest diameter) 
RMI 1 (U x M x CA125) U = 0 (0 parameter) 
U = 1 (1 parameter) 
U = 2 (≥2 parameters) 
 
M = 1 (premenopausal) 
M = 3 (postmenopausal) 
Not applicable 
RMI 2 (U x M x CA125) U = 1 (0-1 parameter) 
U = 4 (≥2 parameters) 
 
M = 1 (premenopausal) 
M = 4 (postmenopausal) 
Not applicable 
RMI 3 (U x M x CA125) U = 1 (0–1 parameter) 
U = 3 (≥2 parameters) 
 
M = 1 (premenopausal) 
M = 3 (postmenopausal) 
Not applicable 
RMI 4 (U x M x S x CA125) U = 1 (0-1 parameter) 
U = 4 (≥2 parameters) 
M = 1 (premenopausal)  
M = 4 (postmenopausal) 
S = 1 (<70 mm) 
S = 2 (≥70 mm) 
*Parameters: presence of a multilocular cystic lesion, solid areas, bilateral lesions, ascites, intra-abdominal metastases. 
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RMI 1 and RMI 2 have been assessed in 16 and seven clinical studies respectively. 
With a cutoff value of 200, their pooled sensitivity was 78% and specificity 87% 
(Geomini et al. 2009). The RMI may be above the threshold of 200 in many benign 
conditions and, on the other hand, may not in early malignancies. Therefore a cutoff 
level of 250 for the RMI is sometimes utilized, with a poorer sensitivity, 70%, but a 
better specificity, i.e. 90% (Royal College of Obstetricians and Gynaecologists 2016). 
Three variants of RMI (RMI 1-3) were validated in a retrospective study of 152 
women with pelvic masses. There were no significant differences between those 
three variants in identifying OC (Manjunath et al. 2001). RMI 4 proved to be the 
most accurate of all RMI variants in differentiating OC (Yamamoto et al. 2009), but 
later no significant differences were found in the performances of RMI 1-4 in 
another study (Campos et al. 2016). The original, RMI 1, is the most validated, and 
the other RMIs have not been found to be clinically more beneficial than RMI 1; 
therefore it is recommended as the scoring system for triaging ovarian tumors (Royal 
College of Obstetricians and Gynaecologists 2016). 
2.3.1.2 IOTA Logistic regression models 1 and 2  
After the standardization of the US terms and examination protocols (Timmerman 
et al. 2000), the IOTA group developed and internally validated, in 1999-2002, 
various risk prediction models from their database of 1,066 women for the 
preoperative evaluation of ovarian tumors. Subsequently, the most workable models 
were temporally and later externally validated in a new patient data set and compared 
with the other existing scoring models such as the RMI between 2002 and 2007 
(Kaijser et al. 2013). A total of 11 mathematical prediction models developed by 
IOTA were validated using different statistical models and compared with various 
previously developed scoring and mathematical models. In an external validation 
study, the IOTA models performed similarly to and better than non-IOTA models 
(Van Holsbeke et al. 2012). However, the more complex statistical techniques did 
not improve the diagnostic performances of two more simple logistic regression 
models designed by IOTA called LR1 and LR2 (see Table 9; Kaijser et al. 2013). 
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Table 9.  The LR1 model features 12 and the LR2 model six variables. 
LR1 
 
LR2 
Personal history of ovarian cancer (yes/no)  
Current hormonal therapy (yes/no)  
Age of the patient (in years) Age of the patient (in years) 
Presence of pain during the examination (yes/no)  
Maximum diameter of the ovarian tumor (mm)  
Appearance of a solely solid tumor (yes/no)  
Maximum diameter of the solid lesion of tumor  
(in millimeters) 
Maximum diameter of the solid lesion of tumor (in 
millimeters) 
Appearance of blood flow in the solid or papillary lesion 
of the tumor (yes/no) 
Appearance of blood flow in the solid or papillary 
lesion of the tumor (yes/no) 
Color content of the tumor (score 1-4)  
Irregular internal cyst walls (yes/no)  Irregular internal cyst walls (yes/no) 
Appearance of acoustic shadows (yes/no) Appearance of acoustic shadows (yes/no) 
Appearance of ascites (yes/no) Appearance of ascites (yes/no) 
 
The risk of malignancy is derived by using specific logistic regression analysis. 
The results from development and test data from IOTA studies achieved the 
sensitivity and specificity for LR1 of 93% and 76-77%, by choosing a 10% risk of 
malignancy (Timmerman et al. 2005), which has subsequently been the most usable 
cutoff level. 
The following IOTA temporal and external validation studies showed an equal 
reliability of LR1 and LR2. As a simpler and more user-friendly method, LR2 may 
be recommended as the main mathematical prediction model in the future 
(Timmerman et al. 2010b). The IOTA studies, which comprised 5,191 women, 
improved the usability of LR models in differentiating between benign and malignant 
ovarian lesions preoperatively. The sensitivities and specificities of LR2, using the 
cutoff risk level of 10%, varied between 88-95% and 74-90% (Kaijser 2015).  
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2.3.1.3 IOTA Simple rules  
Besides the mathematical scoring systems, the IOTA group established simple, 
clinically useful US-based rules for the preoperative discrimination of ovarian tumors 
which were based on the fact that many benign and malignant adnexal masses have 
typical US features. The rules provide no risk estimate for malignancy but categorize 
the mass as benign, malignant or inconclusive without any need for a computer. 
Numerous combinations of US variables and their ability to predict a tumor’s 
malignant or benign nature were tested in a development study. Finally, a 
combination of five rules for malignancy (M-rules) and five for predicting benign 
tumors (B-rules) were presented in Table 10. 
Table 10.  Ten simple ultrasound-based rules for classifying ovarian tumors. 
Appearances that indicate benign tumors (B-rules) 
 
Appearances that indicate malignant tumors (M-rules) 
B1: Unilocular cyst M1: Irregular solid tumor 
B2: Presence of solid components with a maximum 
diameter of <7 mm 
M2: Presence of ascites 
B3: Presence of acoustic shadows M3: At least four papillary structures 
B4: Smooth multilocular tumor with a maximum diameter of 
<100 mm 
M4: Irregular multilocular solid tumor with a maximum 
diameter of ≥100 mm 
B5: No blood flow (color score: 1) M5: Very strong blood flow (color score: 4) 
 
If only B-rules and no M-rules apply, the tumor is categorized as benign. In turn, 
if M-rules and no B-rules apply, the tumor is categorized as malignant. In the case 
of both or neither of these rules applying, the tumor is unclassifiable, i.e. the results 
are considered inconclusive (Timmerman et al. 2008). 
Development, temporal and external validation studies by IOTA accomplished 
similar results: the simple rules were usable in 76-77% of masses with sensitivities of 
92-93% and specificities of 90-96% (Timmerman et al. 2008; Timmerman et al. 
2010a). Expert opinion was recommended as a secondary test (the so-called two-
step strategy) with tumors to which the simple rules provided inconclusive results 
achieving a sensitivity of 91% (95% CI 88-93) and specificity of 93% (95% CI 91-
94). An alternative for inconclusive tumors is to classify them as malignant tumors 
(Timmerman et al. 2010a). Results from various studies using these two alternatives 
as a secondary test for inconclusive tumors are seen in Table 11. 
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Initially, the IOTA models (LR1, LR2 and simple rules) were validated by US 
experts, although the original idea was to utilize them as predictive tools for 
inexperienced clinicians for referrals to tertiary centers. Sayasneh et al. (2013) 
validated the LR models and simple rules in examiners with variable US experience 
and training. Their findings were in accordance with previous results from IOTA 
external studies showing IOTA predicting models working well also among non-
experts. In fact, IOTA models demonstrated a better test performance than the RMI 
among examiners.  
2.3.1.4 The Assessment of different neoplasias in the adnexa (ADNEX) model 
The IOTA group also developed a mathematical polytomous risk-scoring model in 
order to distinguish between not only benign and malignant ovarian tumors but also 
to differentiate between benign, borderline, Stage I invasive, Stage II-IV, and 
secondary metastatic adnexal masses from each other. The need to categorize into 
four different types of malignancy arises from the desire to provide the optimal 
treatment and surgery and to plan it better preoperatively. The data from the first 
prospective diagnostic study originated in 5,909 nonpregnant women with adnexal 
tumors waiting for the surgery. The prediction model was designed to contain nine 
variables. The predictors included three clinical findings (age, serum CA125 level and 
the type of treatment center, i.e. tertiary oncological hospitals vs. other hospital 
types) and six US findings (maximum diameter of lesion, proportion of solid tissue, 
more than ten cystic locules, existence of acoustic shadows or/and ascites, and the 
number of papillary projections): the CA125 value and the solid portion of the tumor 
were the strongest ones. The ADNEX model calculates a total risk of malignancy 
and probabilities of the four types of malignancy. The developed risk scoring model 
is available for use on the website of the IOTA group and in mobile applications. 
When the 10% prediction level for malignancy was used, it yielded a sensitivity of 
96.5% and a specificity of 71.3%. The AUCs classifying the four subtypes of 
malignancies varied from 0.71 to 0.95 (Van Calster et al. 2014). The cutoff level for 
malignancy can be modified depending on the local protocols in order to choose 
either a higher sensitivity, i.e. lower than 10% as the cutoff level, or a higher 
specificity, i.e. higher than 10% as the cutoff level (Van Calster et al. 2015).  
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A recent validation study compared the subjective assessment of an expert US 
examiner and four malignancy prediction models in differentiating the nature of an 
ovarian tumor preoperatively (Meys et al. 2017). The results are shown in Table 11.  
2.3.1.5 Subjective assessment by an expert ultrasound examiner and comparison of 
various predictive methods 
One of the best methods for preoperative analysis of ovarian tumors is subjective 
assessment (also called pattern recognition) of US findings after an accurate 
transvaginal examination by an experienced US examiner using two-dimensional 
(2D) sonography with Doppler (Valentin et al. 2001). However, in the hands of an 
expert, about 7% of the adnexal masses examined could not be distinguished as 
benign or malignant tumors, and the RMI or LR did not improve the classification. 
Tumors difficult to classify were multilocular cystic tumors with solid components, 
and histopathological diagnoses were borderline tumors, cystadeno(fibro)mas and 
fibromas (Valentin et al. 2011).  
The IOTA methods and other scoring systems have been compared with 
subjective assessment, although they were developed more as diagnostic tools to 
help relatively inexperienced clinicians using US in primary and secondary centers. 
Table 11 shows the sensitivities and specificities of different scoring methods from 
three publications, or the IOTA Phase III study (Testa et al. 2014), the meta-analysis 
of 47 articles (Meys et al. 2016) and the external validation study of the ADNEX 
model (Meys et al. 2017). 
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Table 11.  Summary of results from various scoring methods (LR2 and ADNEX at cutoff point 10% 
and RMI 200). 
Author Patients Method Sensitivity, % 
(95% CI) 
Specificity, % 
(95% CI) 
Testa et al. 2014 2,403 RMI 1 67.1 (61.4-72.4) 90.6 (87.3-93.1) 
  LR2 90.2 (86.9-92.8) 78.9 (73.2-83.7) 
  SA 92.5 (89.4-94.8) 87.7 (83.2-91.2) 
  SR(mal) 95.3 (93.1-96.9) 74.1 (67.7-79.7) 
  SR+SA (two-step 
strategy) 
 
91.8 (89.1-93.9) 89.0 (85.2-92.0) 
Meys et al. 2016 6,970 RMI 1 75 (72-79)* 92 (88-94)* 
 1,544 LR2 93 (89-95)* 84 (78-89)* 
 12,294 SA 93 (92-95)* 89 (86-92)* 
 3,073 SR(mal) 93 (91-95)* 80 (77-82)* 
 2,231 SR+SA 91 (89-93)* 91 (87-94)* 
 
Meys et al. 2017 326 RMI 1 71 (62-79) 79 (72-84) 
  LR2 93 (86-97) 79 (73-84) 
  SA 90 (83-95) 91 (86-94) 
  SR(mal) 93 (86-97) 68 (61-70) 
  SR+SA 89 (81-94) 90 (85-94) 
  ADNEX 98 (93-100) 62 (55-68) 
RMI 1: risk of malignancy index 1; LR2: logistic regression model 2; SA: subjective assessment; SR(mal): simple rules, and when 
the result is inconclusive, the tumor is classified as malignant; SR+SA: simple rules, and when results are inconclusive, the tumor 
is classified by subjective assessment; ADNEX: assessment of different neoplasias in the adnexa model. 
* Pooled sensitivity and specificity. 
 
The approaches to assessment of an adnexal tumor by ultrasonography according 
to the IOTA studies are presented in Figure 3 (Kaijser et al. 2013; Kaijser 2015). 
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Figure 3.  The flowchart for the use of ultrasonographic assessment methods for ovarian tumors.  
 
 
 
Mobile applications of IOTA models (LR1, LR2, simple rules and ADNEX) have 
been developed to facilitate their use in a clinical setting (Kaijser 2015). 
2.3.2 Three-dimensional sonography 
At the beginning of the century, 3D US for the characterization of ovarian lesions 
was introduced, a new tool that allowed visualization of the assessed lesion in three 
planes (coronal, sagittal and frontal) and permitted data on its volume to be acquired, 
stored and later analyzed. The internal structure of the lesion can be examined 
thoroughly. For volume calculation, an application named Virtual Organ Computer-
Aided Analysis (VOCAL) can be used (Alcazar & Jurado 2011).  
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In addition to its morphology, the vascularization and flow pattern of the entire 
adnexal mass can be visualized using 3D-PD and VOCAL software. The term 
“Doppler imaging” usually refers to normal or color Doppler, which is based on 
Doppler frequency shifts relative to the velocity of blood flow. In turn, PD is based 
on the amplitude shift proportional to the number of blood cells detected. Compared 
to normal color Doppler, PD has some benefits like its sensitivity in noticing blood 
flow and characterizing vascular patterns (Alcazar & Castillo 2005). With the aid of 
3D-PD, the architecture and density of the vascularity of the target can be described. 
Using the clinically popular 4D View software (GE Medical Systems, Zipf, Austria) 
and its histogram facility, the PD signal can be quantitatively measured. First, the 
examiner specifies the volume of interest whose PD signal intensities are 
demonstrated by histogram using VOCAL. Secondly, three vascular indices, 
vascularization index (VI), flow index (FI) and vascularization-flow index (VFI) are 
calculated with the aid of histogram utility. VI reflects the proportion of blood 
vessels within the assessed volume and is reported as a percentage. FI represents the 
mean PD intensity during the 3D sweep and is presented as a value of 0-100, as is 
the VFI, which is a combination of VI and FI. These indices are influenced by 
various internal and external factors: the local erythrocyte concentration, flow rate 
and number of vessels in the examined lesion, including its distance from the 
transducer, can affect them. Nevertheless, VI and VFI seemed to have a linear 
relationship with the changes in confounding factors in a phantom study (Raine-
Fenning et al. 2008a). Many Doppler settings – especially gain, signal power and 
pulse repetition frequency – seem to have significant effects on the 3D-PD indices. 
Therefore, it is important to perform examinations using similar settings when 
comparing indices between persons and for the same patient (Raine-Fenning et al. 
2008b). 
2.3.2.1 Three-dimensional gray-scale morphologic ultrasound 
Several studies comparing 3D US with traditional 2D US in determining malignant 
ovarian tumors have been published. These reports used 3D rendering or a 
multiplanar view to determine benign or malignant morphological characteristics 
such as irregular inner wall surface, papillary projection or thick septa, mostly solid 
tumor and echogenity of the tumor (Alcazar et al. 2003; Alcazar et al. 2007; Bonilla-
Musoles et al. 1995; Chan et al. 1997; Hata et al. 1999; Kurjak et al. 2001).  
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The results are conflicting. Some studies found 3D US to provide positive 
additional value compared with 2D US (Bonilla-Musoles et al. 1995; Hata et al. 1999; 
Kurjak et al. 2001); other studies failed to demonstrate significant benefits over 2D 
US in classifying adnexal lesions (Alcazar et al. 2003; Alcazar et al. 2007). An 
explanation for this discrepancy may be that both the 2D US and 3D gray scale US 
methods are based on the subjective opinion of the examiner (Hata et al. 2011). 
2.3.2.2 Three-dimensional power Doppler angiography 
There are two approaches to the use of 3D-PD in evaluating adnexal tumors. One 
is evaluating the morphological changes in vessels suspected of malignancy, and the 
other is using an objective quantification of vascularity by the VOCAL program or 
some other software. The characteristics in vessels that can change with malignancy 
are density, caliber, tortuosity, irregular branching, and bridges between vessels 
(Sladkevicius et al. 2007).  
The sensitivities and specificities of 3D-PD vs. 2D US varied between 77-100% 
vs. 94-100% and 50-99% vs. 50-97% in a review of seven studies involving the use 
of 3D-PD vascular tree assessment in detecting OC (Alcazar & Jurado 2011). Only 
one of seven studies showed a significant difference (p <0.05) between the detection 
ability of 3D-PD and 2D US, but it indicated that 2D US had an advantage (Dai et 
al. 2008). Nor did the review by Hata et al. (2011) find any significant or reported 
differences in the accuracies of 2D US and 3D-PD. 
Alcazar et al. reported their results regarding quantification of 3D-PD vascular 
indices. They used a focused sampling from the most vascularized and suspected 
areas, and the indices were calculated automatically from that area using the VOCAL 
program. All PD indices differed significantly in ovarian malignancies compared with 
benign tumors (Alcazar et al. 2005), but the VIs and VFIs from ovarian tumors were 
significantly higher in advanced or metastasized OC than in early-stage cancers 
(Alcazar 2006). In a subsequent study of Geomini et al. (2007), only FI – and not VI 
or VFI – showed significantly higher levels in malignant tumors than in benign 
tumors when assessed from the whole tumor.  
Modified approaches to vascular sampling have been developed based on 
automatically calculated 1-5 cm3 spherical samples from the most vascularized areas. 
The 3D-PD indices significantly separated benign and malignant tumors (Jokubkiene 
et al. 2007; Kudla & Alcazar 2010). Vascular sampling can also take place by manually 
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outlining the highly vascularized areas. Both methods can be used, but spherical 
sampling is not possible in all small tumors (Alcazar & Prka 2009). 
Repeatability in assessments of 3D-PD indices in offline analyses from the stored 
3D volumes has proved to be good, as is the intra- and interobserver agreement, 
regardless of the method used for vascular sampling (Alcazar et al. 2008; Alcazar & 
Prka 2009; Jokubkiene et al. 2007). The agreement of offline analysis with the real-
time US results in the diagnosis of benign or malignant tumor was good, with a 
similar diagnostic performance (Alcazar et al. 2012). The IOTA US rules, color score 
system (scores 1-4), simple rules, LR1 and LR2 models, and expert opinion were 
analyzed later by other US examiners using stored 3D data. The intra- and 
interobserver agreement, also between examiners with different experience, varied 
mainly between moderate and good (Guerriero et al. 2013; Pineda et al. 2014; Ruiz 
de Gauna et al. 2014; Sladkevicius & Valentin 2013). However, it has been stated 
that offline analyses are not comparable with real-time US because they lack the 
interactive nature of examinations (Sladkevicius & Valentin 2013). In general, the 
use of 3D-PD indices and their importance in practical work is restricted by a lack 
of standardization and complete understanding of their significance (Guerriero et al. 
2015).  
2.3.3 Ultrasound contrast agents 
Neovascularization, i.e. increased intratumoral microvascularization, is characteristic 
of malignancies, and color and power Doppler sonography is used to describe it. 
However, these techniques cannot detect vessels with a diameter of less than 0.1 
mm. Intratumoral Doppler signals can be enhanced with the aid of intravascular 
sonographic contrast agents, which may promote earlier detection of OC (Testa et 
al. 2005).  
Ultrasound contrast agents used intravenously contain microbubbles that are 
smaller than erythrocytes and can flow into capillaries, allowing the depiction of low 
volume blood flow. Pulse-inversion techniques with related software enable the 
description of contrast agent microbubbles in normal and neovascularized tumor 
tissues (Fleischer et al. 2010). 
With the aid of modern software, second-generation contrast agents such as 
Definity® (perflutren, Lantheus Medical Imaging, North Billerica, MA), available in 
the U.S., and SonoVue® (sulfur hexafluoride, Bracco Imaging S.p.A, Milan, Italy) 
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can be detected by the harmonic response of microbubbles to US signals at a low 
acoustic pressure (Fleischer et al. 2010). The major advantage of SonoVue® is that 
microbubbles insonated by US persist in the blood for a few minutes (Testa et al. 
2005). 
The preliminary study by Testa et al. (2005) showed that SonoVue®, together 
with contrast-tuned imaging technology, allows for a higher number of intratumoral 
vessels in ovarian tumors to be detectable in a PD examination than without contrast 
media. Studies evaluating the kinetic parameters of second-generation contrast 
agents in US examinations have shown significantly different results in malignant 
and benign tumors (Fleischer et al. 2008; Testa et al. 2009; J. Wang et al. 2011), 
although the AUC of the best contrast variable was smaller than that of an expert 
opinion (Testa et al. 2009). The benefit of contrast-enhanced US appears to be 
uncertain because there is overlapping in the parameters of benign, borderline and 
malignant ovarian tumors; contrast agents are also rather expensive (Testa et al. 
2009).  
The ability of SonoVue®-enhanced US in discriminating ovarian tumors has also 
been studied in 3D sonography in small study series, also compared with 2D-
enhanced US (Hu et al. 2014; Xiang et al. 2013). 3D-enhanced US may help especially 
in classifying early diagnoses of small ovarian malignancies, but larger validation 
studies are warranted to evaluate the possible advantages of combining 3D US 
technology and contrast-enhanced US. 
2.3.4 Magnetic resonance imaging 
The advantage of magnetic resonance imaging (MRI) is its high-contrast resolution, 
especially soft tissue contrast, without an exposure to ionizing radiation (Foti et al. 
2016). The European Society of Urogenital Radiology has published guidelines that 
recommend the use of MRI together with an algorithm approach as an additional 
tool in identifying indeterminate ovarian masses. This protocol divides the unclear 
tumors into three categories based on the findings in T1- and T2- weighted 
sequences. The categories include additional imaging sequences – for example, fat-
saturated T1-weighted or oblique sequences – or the assessment of intravenous 
gadolium-contrast enhancement (Spencer et al. 2010). 
A meta-analysis of various preoperative methods determined the optimal method 
in presurgical identification of ovarian masses. The pooled sensitivity and specificity 
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from 24 datasets for conventional MRI techniques was 91.9% and 88.4% 
respectively and was similar to transvaginal 2D and 3D US (Dodge et al. 2012). In 
turn, earlier meta-analysis demonstrated that contrast-enhanced MRI appears to be 
more sensitive and specific than unenhanced MRI but increases only specificity as 
compared with 2D Doppler US (sensitivities 81% vs. 76% vs. 84%, and specificities 
98% vs. 97% vs. 82% respectively) (Kinkel et al. 2005). 
The addition of functional imaging via diffusion-weighted imaging (DWI) has 
provided controversial results in the literature. DWI measures randomly moving 
water molecules in tissues affected by hypercellularity and changes in cellular 
membrane integrity. The apparent diffusion coefficient (ADC) values derived from 
DWI provide information on the diffusivity of the imaged tissue (Sharma et al. 2016). 
A meta-analysis of 21 studies revealed no significant difference between the ADC 
values of benign and malignant ovarian tumors, although subgroup analysis of 
benign tumors produced higher ADC values than malignant ones. However, 
overlapping of ADC values was seen, as especially endometriomas and teratomas 
produced the very low ADCs typical of malignant tumors (Kim et al. 2016).  
The use of dynamic contrast-enhanced MRI (DCE MRI) produces information 
on the vascularity and permeability of tumor as time-intensity curves after the 
injection of contrast agent (Sharma et al. 2016). The use of DWI and DCE MRI 
enables a morphologic and vascular assessment of tumors and improves the 
differentiation of complex ovarian lesions as well as peritoneal dissemination (Fujii 
et al. 2008; Sala et al. 2010; Thomassin-Naggara et al. 2008; Thomassin-Naggara et 
al. 2009; Thomassin-Naggara et al. 2011). The use of functional sequences, DWI and 
DCE MRI provided new criteria for ovarian tumor imaging and resulted in the 
development of an MRI scoring system for adnexal tumors (ADNEX MR scoring) 
(Thomassin-Naggara et al. 2013). 
By virtue of these additional tools for ovarian tumor imaging, the guidelines by 
the European Society of Urogenital Radiology were reconsidered in 2016. The new 
guidelines recommend the use of DWI and DCE MRI especially in the cases of solid 
and complex cystic adnexal tumors (Forstner et al. 2016).  
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2.3.5 Computed tomography 
Contrast-enhanced computed tomography (CT) is preferred for a preoperative 
evaluation of the extent of suspected OC and the likelihood of successful 
cytoreductive surgery, and for postoperative assessment of residual tumor tissue 
after surgery. The advantages of CT are its easy availability, shorter duration of 
examinations, and lower cost compared with MRI. In turn, the use of iodine-based 
contrast agent may be contraindicated, and exposure to radiation restricts its use 
(Fischerova & Burgetova 2014).  
CT has a lower soft-tissue contrast than MRI, and will only miss small early-stage 
adnexal lesions (Bharwani et al. 2011). Contrast-enhanced MRI and CT are equally 
accurate modalities in the preoperative staging of OC. Their accuracy in detecting 
metastasized lymph nodes and peritoneal implants depends on their size, location 
and possible ascites. In one series, MRI was superior to CT in detecting pathological 
lymph nodes (p <0.04) while being equivalent for peritoneal implants (p <0.91) 
(Tempany et al. 2000). 
2.3.6 Positron emission tomography/Computed tomography 
Positron emission tomography (PET) uses a positron-emitting radiolabeled tracer, 
commonly 18F-2-fluoro-2-deoxy-D-glucose, which accumulates in the tissues and 
cells whose glucose metabolism is high, such as cancer cells. If PET is combined 
with CT (PET-CT), this enhanced glucose uptake can be anatomically localized to 
specific areas (Fischerova & Burgetova 2014). 
PET-CT is not recommended for the primary diagnosis of OC due to a reported 
sensitivity of only 58% and a specificity of 76%. Elevated metabolic activity has been 
reported in inflammatory processes, endometriomas and premenopausal ovaries, 
depending on the phase of the menstrual cycle, resulting in false-positive results. In 
turn, false-negative results have been reported in borderline tumors and early-stage 
OCs (Fenchel et al. 2002). 
PET-CT may, however, be of some use in the preoperative staging of OC. PET-
CT is accurate in detecting regional lymph node and distant metastasis. There are 
studies showing better sensitivity for PET-CT in diagnosing pathological lymph 
nodes, especially retroperitoneal or supradiaphragmatic, than CT or MRI 
(Fischerova & Burgetova 2014; Khiewvan et al. 2017).  
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A summary of various imaging modalities and their main roles in imaging ovarian 
tumors is seen Table 12 (Fischerova et al. 2012; Fleischer et al. 2010; Guerriero et al. 
2015; Khiewvan et al. 2017; Tempany et al. 2000). 
Table 12.  Summary of imaging modalities in ovarian cancer. 
Imaging 
modality 
2D ultrasound 3D ultrasound Contrast-
enhanced 
ultrasound 
CT Dynamic 
contrast-
enhanced MRI 
PET-CT 
 First line 
evaluation of 
adnexal 
masses 
Potential aid in 
preoperative 
discrimination 
of 
indeterminate 
tumors  
 
Potential aid in 
preoperative 
discrimination 
of 
indeterminate 
tumors  
 
Preoperative 
staging in 
advanced 
cancer 
(especially 
evaluation of 
peritoneal 
implants, sub-
diaphragmatic 
space and 
hepatic 
surface)  
 
Potential aid in 
preoperative 
discrimination 
of 
indeterminate 
tumors  
Preoperative 
staging in 
advanced 
cancer? 
(especially 
evaluation of 
supra-
diaphragmatic 
and 
retroperitoneal 
space) 
 
 Preoperative 
staging in 
advanced 
cancer as a 
supplement for 
CT or MRI 
(especially 
evaluation of 
liver and lymph 
nodes) 
   Preoperative 
staging in 
advanced 
cancer 
(especially 
evaluation of 
peritoneal 
implants, sub-
diaphragmatic 
space, and 
hepatic 
surface) 
In recurrent 
cancer 
 
2.4 Polyamines 
2.4.1 Overview of polyamine metabolism 
Polyamines are low-molecular-weight polycations derived from amino acids, 
predominantly ornithine and methionine (Miller-Fleming et al. 2015). They are 
found in most living organisms, and nearly all cells can produce them. In addition to 
biosynthesis, polyamines are acquired from dietary sources and produced by the 
intestinal bacteria (Hussain et al. 2017). The most common polyamines in mammals 
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are putrescine, spermidine and spermine with respectively two, three and four amino 
groups in a hydrocarbon chain, followed by cadaverine and 1,3-diaminopropane 
(Miller-Fleming et al. 2015).  
Ornithine, produced from arginine in the urea cycle, is converted to putrescine, 
which is the precursor for spermidine and spermine. Intracellular polyamine quantity 
is regulated by the monoacetylation of spermidine and the mono- and diacetylation 
of spermine. These acetylated polyamines can be either excreted to the urine or 
converted back to putrescine. Putrescine, spermidine and spermine can also be 
transported into the intracellular space (Gerner & Meyskens 2004). Synopsis of 
polyamine metabolism and key enzymes are presented in Figure 4. 
Figure 4.  Polyamine metabolism (modified from Gerner & Meyskens 2004; Seiler 2004; Soda 2011). 
 
ODC: ornithine decarboxylase; N8SAT: spermidine-N8-acetyltransferase; SRM: spermidine synthase; SMS: spermine synthase;  
SSAT: spermidine/spermine N1-acetyltransferase; SMO: spermine oxidase; APAO: acetylpolyamine oxidase; DAX: diamine 
exporter. 
 
Polyamines are involved in many body functions affecting cellular proliferation, 
tissue growth and development, including gene transcription, posttranscriptional 
regulation, cell apoptosis, the control of ion channel activity, and the modulation of 
cell cycles, cell membrane structure and cell function. Polyamines also have anti-
inflammatory properties and effects on protein synthesis (Hussain et al. 2017; 
Igarashi & Kashiwagi 2010; Pegg & Casero 2011). 
  
54 
 
2.4.1.1 Polyamines in cancer 
An overactivation of polyamine synthesis is associated with carcinogenesis. It leads 
to elevated polyamine concentrations and the overexpression of genes and enzymes 
involved in polyamine biosynthesis in cancer cells (Thomas & Thomas 2003). Levels 
of the enzyme ornithine decarboxylase are increased in cancer tissues, and it is not 
only a target for Myc- and Ras-oncogenes, but also a potential oncogene itself 
because its overexpression can alter cell lines alone or together with other oncogenes 
(Casero et al. 2018; Gerner & Meyskens 2004; Miller-Fleming et al. 2015). Increased 
polyamine levels stimulate cell proliferation and decrease apoptosis, both of which 
are characteristic of cancer. Polyamines are also needed for angiogenesis in 
tumorigenesis (Gerner & Meyskens 2004). 
In a hypoxic situation, cancer cells advance metastasizing and invasion by 
decreasing cell adhesion. Also, polyamine uptake from extracellular space is elevated 
due to hypoxia. The expression of the adhesion molecules CD44 and E-cadherin is 
reportedly diminished in malignancies, which promotes invasion and metastatic 
potential. Increased spermine levels in cells are shown to be involved in decreased 
CD44 expression (Tsujinaka et al. 2011), and they may also prevent normal 
antitumor immune cell function by decreasing the chemokine and cytokine 
production of immune cells and enabling tumor progression (Kano et al. 2007). 
Arising from the association between cancer and polyamine metabolism, many 
therapeutical cancer treatments have been developed, albeit without great clinical 
success thus far. The most studied one is DL-α-difluoromethylornithine (DFMO), 
an irreversible binding inhibitor of ornithine decarboxylase (Bae et al. 2018; Murray-
Stewart et al. 2016). DFMO has been found to reduce tumor growth in animal 
experiments and to have chemopreventive properties, also in clinical trials and 
mainly combined with other chemotherapeutic medications, e.g. in gliomas (Alexiou 
et al. 2017; Casero et al. 2018). 
Elevated polyamine concentrations in the urine of cancer patients were first 
reported by Russell et al. over 45 years ago (Russell et al. 1971). They analyzed 24-
hour urine samples using liquid chromatography-mass spectrometry (LC-MS), but, 
interestingly, the highest concentrations of putrescine, spermine and spermidine 
were found in a patient with a large solid benign ovarian teratoma. Polyamine levels 
dropped after tumor removal. Increased polyamine levels in the blood of cancer 
patients have also been found (Russell 1983; Uehara et al. 1980). Serum polyamine 
concentrations are correlated with urinary levels (Durie et al. 1977), demonstrating 
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that polyamines produced by malignancies are delivered to the circulation and 
excreted via the kidneys to urine (Soda 2011). 
Polyamines are also produced in non-cancerous tissues and transferred to various 
organs such as the intestinal mucosa, where they can also be produced by the 
intestinal microbiota (Soda 2011; Timmons et al. 2012). In one study, an elevated 
polyamine nutritional intake over two months increased serum polyamine levels in 
mice and in humans (Soda et al. 2009). Thus, these factors must be taken into 
account in analyzing the polyamine levels in cancer patients. In addition, the 
individual variation in polyamine concentrations in healthy people is high, which 
makes it difficult to determine whether values are abnormal (Hiramatsu et al. 1995; 
Soda 2011). Furthermore, benign diseases such as polymyositis, hemolytic anemia 
and inflammatory bowel diseases can increase polyamine levels (Hiramatsu et al. 
2005; Suh et al. 1997). Urinary polyamine concentrations are highest in the morning 
and higher in men than in women (Pöyhönen et al. 1990). In women, estrogen may 
affect at least some polyamine levels: premenopausal women with breast cancer have 
been found to have higher polyamine concentrations in serum, in contrast to 
postmenopausal patients and healthy controls (Byun et al. 2009). 
2.4.2 Analysis of polyamines 
Polyamines are found in cells in free and conjugated forms, and, in physiological 
fluids, mainly in acetylated forms. In healthy people, monoacetylated polyamines 
form the major component of polyamines in urine. Levels of N1, N12-
diacetylspermine (DiAcSpm) and N1, N8-diacetylspermidine (DiAcSpd) in normal 
urine are 0.46% and 1.4% of total polyamines (Hiramatsu et al. 1995).  
Several analytical methods used for polyamine analysis are based on LC and gas 
chromatography (GC). Most of these methods require pre- or post-column 
derivatization, and these different derivates can be detected with selective detectors, 
e.g. by measuring ultraviolet absorbance or fluorescence, or using mass spectrometry 
(MS). However, diacetylated polyamines without a free amino group cannot be 
derivatized and detected using conventional methods (Häkkinen et al. 2013; 
Jeevanandam & Petersen 2001).  
For a long time, the polyamine field lacked a method of analyzing free, mono- 
and diacetylated amines simultaneously. Byun et al. (2008) reported a LC/MS 
method using an extractive carbamoylation to analyze ten polyamines simultaneously 
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from serum and urine of healthy women and patients with breast cancer. However, 
these polyamines did not include diacetylated forms. Häkkinen et al. (2013) 
published a LC-MS/MS method for the concurrent analysis of 14 urinary polyamines 
(free, mono- and diacetylated forms) without any derivatization.  
DiAcSpd and DiAcSpm were first identified in normal human urine using high-
performance liquid chromatography (HPLC) combined with an enzyme reactor 
(Hiramatsu et al. 1995). Because these diacetylated polyamines are studied as 
diagnostic and prognostic biomarkers, there was a demand for convenient and less-
time-consuming analytics. Highly specific antibodies for DiAcSpd and DiAcSpm 
have been produced and enzyme-linked immunosorbent assays (ELISA) developed 
for urinary detection as alternatives to HPLC analysis (Hiramatsu et al. 1997; 
Hiramatsu et al. 1998). Concentrations of DiAcSpm and DiAcSpd measured by 
these ELISA-based methods have been shown to be comparable to concentrations 
obtained with HPLC. However, minimal cross-reaction with monoacetylated 
spermine and spermidine should be taken account in the analysis (Hamaoki et al. 
2002). Subsequently, a kit for urinary DiAcSpm detection based on colloidal gold 
aggregation with automatic analyzers was developed for commercial use (Kawakita 
et al. 2011). 
2.4.3 Polyamines as tumor markers 
As a consequence of the first finding of elevated polyamine concentrations in the 
urine of cancer patients (Russell et al. 1971), the potential of polyamines to act as 
tumor markers for cancer was evaluated. Levels of monoacetylated polyamines, or 
the amount of N1-acetylspermidine and the ratio of N1-acetylspermidine to N8-
acetylspermidine, were higher in the urine of patients with lymphoma (Abdel-
Monem et al. 1982). However, their clinical use was proven to be limited due to their 
elevated concentrations also in benign disorders and a wide normal variation in the 
population (Kawakita & Hiramatsu 2006). Sugimoto et al. (1995) showed that the 
total amount of urinary polyamines and N1-acetylspermidine did not differ 
significantly in patients with and without cancer, and N1-acetylspermidine levels were 
often elevated in patients with benign diseases. However, the concentrations of 
DiAcSpd and DiAcSpm in cancer patients were significantly higher than in controls 
or people with benign disorders. This strongly promoted further research into 
DiAcSpd and DiAcSpm as tumor markers. 
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The metabolism of DiAcSpm and DiAcSpd is not totally clear: several 
mechanisms may lead to increased excretion. The source of DiAcSpm in cancer 
patients may be spermine produced either by cancerous or non-cancerous tissues 
(Takahashi, Sakaguchi et al. 2015). Levels of DiAcSpm are elevated in colorectal 
cancer tissues and even in precancerous lesions, which could be a sign that cancer 
cells produce DiAcSpm (Kuwata et al. 2013). The increased activity of the SSAT 
enzyme may also stimulate cancer cells to increase the excretion of acetylated 
polyamines as a feedback mechanism for elevated intracellular polyamine levels to 
control the polyamine homeostasis (Kawakita & Hiramatsu 2006). Despite the 
secretion of DiAcSpm into the circulation, its content in urine remains quite stable 
without any relevant decrease because it is not reabsorbed from the kidneys (Miki et 
al. 2005). Therefore, the glomerular clearance of DiAcSpm is analogous with that of 
creatinine, and the DiAcSpm concentrations are usually normalized in relation to 
creatinine concentrations (Takahashi, Horio et al. 2015). Provided this normalization 
with creatinine has been undertaken, single urine samples taken at any time of day, 
can be considered to reflect the general urinary concentration level of DiAcSpm of 
a given individual. However, the gender, age and menstrual cycle of the patient have 
effect on the concentrations (Hiramatsu et al. 2014). 
The molecular character of the enzyme responsible for DiAcSpd is not identified, 
which may explain why studies of DiAcSpd as a tumor marker have waned 
(Kawakita & Hiramatsu 2006). On the other hand, DiAcSpm has been widely studied 
as a tumor and prognostic factor in malignancies including leukemias and urogenital, 
hepatocellular, colorectal, breast, pancreaticobiliary and non-small cell lung cancers 
(see Table 13). It is notable that, in studies of colorectal cancer, urinary DiAcSpm 
seems to be a more reliable tumor marker than CEA (Hiramatsu et al. 2005; 
Nakayama et al. 2012; Umemori et al. 2010).  
Although increased concentrations of free and monoacetylated polyamines have 
previously been found in the urine of OC patients (Lawton et al. 1989; Suh et al. 
1997), to the best of my knowledge, no previous literature on diacetylated 
polyamines involving OC is available. 
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2.5 Detection of volatile organic compounds 
2.5.1 Overview 
Historically dogs are known to have a superior olfactory apparatus. A letter to the 
editor of The Lancet in 1989 laid the foundation for medical research on “sniffer 
dogs” to detect malignancy by its odor. The letter was about a dog who was 
desperately interested in its owner’s mole, which proved to be malignant (Williams 
& Pembroke 1989). Consequently, studies on whether dogs could be trained to 
detect the odor of cancers were initiated. The first published studies of trained canine 
experiments were the detection of bladder cancer from urine and melanoma from 
tissue samples (Pickel et al. 2004; Willis et al. 2004). Subsequently, canines were 
taught to differentiate breath samples from breast and lung cancer patients 
(McCulloch et al. 2006) and urine samples from breast and prostatic cancer patients 
(Gordon et al. 2008). Horvath et al. began to examine whether OC also has a typical 
odor that dogs can detect. The first study showed that one trained dog could make 
the distinction between 31 OC tissue samples representing different histopathologies 
and stages, and healthy control tissues in a double-blind test with a sensitivity of 
100% and specificity of 97.5%. For the discrimination between OC and other 
gynecological cancers the sensitivity was also 100%, while the specificity was 91% 
(G. Horvath et al. 2008). Later, two trained dogs discriminated between the blood 
samples of OC patients and those from healthy controls with a sensitivity of 100% 
and specificity of 95% (G. Horvath et al. 2010). In the following study, dogs detected 
distinct features of OC from blood samples during chemotherapy. Three and six 
months after the chemotherapy, dogs were able to detect from patient blood samples 
which patients had relapsed (G. Horvath et al. 2013). 
These studies have proved that various cancers may produce some cancer-
specific molecules and volatile organic compounds (VOCs) which are released into 
the urine, stool and blood and into the surrounding air by breath and sweat (Lippi 
& Cervellin 2012; Sonoda et al. 2011). Arasaradnam et al. (2011) proposed that 
colonic fermentation products such as volatile gases and their alterations could be 
changed, at least in colonic and metabolic diseases. These gases would exist as VOCs 
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and be detected in the urine of patients with colorectal inflammatory disease and 
diabetes.  
Clinical use of the excellent canine sense of olfaction is challenging, because the 
dogs require highly specified and intensive training and, even then, their ability to 
detect odors differs from individual to individual, even in the case of the same dog. 
Therefore, artificial methods to replace the canine olfactory system have been 
developed.  
2.5.2 Technical analytical methods 
The gold standard for the analysis of VOCs is GC-MS. Analyzing volatile molecules 
by MS is a quantitative method; however, it has limitations in clinical settings, e.g. 
large and expensive equipment which requires well-trained operators and time-
consuming procedures. Due to these restrictions, there has been an interest in 
developing new non-invasive, simple and rapid methods of detecting VOCs. The 
utilization of the eNose in the medical field began in the nineties; a range of 
applications have subsequently been developed (D'Amico et al. 2012). An eNose 
consists of an array of non-selective sensors which recognize not simply one VOC 
but, rather, respond to all the volatile information from the sample by creating a 
qualitative spectrum reflecting it (Bernabei et al. 2008; Z. Zhang & Li 2010). The 
principles for all techniques that mimic human olfactory system are similar (Wilson 
& Baietto 2011).  
Figure 5.  The process of VOC analytics. 
 
 
First, the sample is processed by a sampling technique responsible for introducing 
odors to the analyzer. The aim of such a technique is to collect an optimal and 
homogenous sample by enriching and cleaning the sample, and then amplifying it. 
Static headspace extraction is one of the most common ways of delivering the sample 
to the sensor. The sample is stored in a hermetic container from which accumulated 
volatile gases can be extracted when an equilibrium has been reached between the 
  
62 
 
matrix and the gas phase in the headspace. In the dynamic headspace technique, the 
VOCs of the sample are removed by the continuous gas flow that conveys the 
molecules to the sensor. Solid-phase microextraction employs a fiber-coated solid 
material in the headspace of the sample in which volatile compounds are adsorbed. 
The volatile molecules are extracted from the headspace and released from the 
material via heating (S. Chen et al. 2013). 
The first eNose sensor arrays were metal oxide semiconductor sensors, and more 
advanced technologies for gas sensing have since been established (S. Chen et al. 
2013). Information generated from sensor arrays is analyzed by data computing 
systems using pattern recognition methods. The analysis begins when signals from 
sensors are obtained and stored in the computer. Signal preprocessing is conducted 
to remove noise, optimize signal quality and select the descriptive patterns of the 
arrays and create a vector from them for further processing. Pattern recognition 
methods are unsupervised and supervised learning procedures. In unsupervised 
learning, different algorithms learn to extract features from the vectors that might 
classify these odor vectors without any knowledge of the status of the samples. 
Principal component analysis is the technique most often used to accomplish this. 
In supervised learning, the unknown odor is classified according to the previously 
existing knowledge about the feature. Typically, this pattern recognition method 
requires several samples in order to form this knowledge basis. With supervised 
learning, the classifier is given the information regarding the status of the sample (eg. 
healthy or diseased). The classifier then attempts to find the features that distinguish 
the two groups from each other with maximum accuracy. Linear discriminant 
analysis (LDA) is an example of supervised learning methods. When the classifier of 
the odor data has been found, it must be cross-validated to avoid overfitting, a 
phenomenon in which samples are discriminated according to unique features of the 
dataset that do not generalize to another population. Thus, all eNose results should 
be cross-validated by an independent sample population or in smaller datasets by 
leave-one-out cross-validation (S. Chen et al. 2013). 
2.5.2.1 Field asymmetric waveform ion mobility spectrometry  
ENose technology suffers from poor repeatability and sensitivity due to 
indiscriminate chemical interactions between the sample and the sensors. Ion 
mobility spectrometry is a variant of eNose technology between MS and traditional 
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eNose. It measures the ion mobility in an atmospheric pressure using air as a carrier 
gas, compared to MS, which needs vacuum (Covington et al. 2015). The gas with the 
sample is first ionized and then passed through an orthogonal electric field in which 
ions collide with the air molecules, discriminating ions by their mobility. The time 
that an ion spends in an electric channel is the parameter measured by ion mobility 
spectrometry and detected by an electrometer at the end of the channel. FAIMS is a 
variant of ion mobility spectrometry (see Figure 6 below). It applies an alternating 
voltage between the plates and thus can select only certain ions to pass through the 
alternating electric field to the sensor, which improves its discrimination ability 
(Covington et al. 2015; Kolakowski & Mester 2007). 
Figure 6.  Schema of the FAIMS procedure (adapted from Kolakowski & Mester 2007). 
 
2.5.3 Detection of cancer 
Some VOCs associated with cancer have been identified by GC-MS or nano-
particle-polymer sensor arrays. Using GC-MS, Amal et al. (2015) found a total of 
133 different VOCs from 182 breath samples from OC patients, healthy women and 
women with benign gynecological neoplasia. Two VOCs which significantly 
distinguished cancer samples from benign samples were decanal and 2-butanone. 
Also, nonanal, styrene and hexadecane were found to be possible volatile markers 
for OC. They also used nanoarrays as sensors for analyzing the same breath samples, 
achieving a 71% accuracy, sensitivity and specificity, in distinguishing between 
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samples from OC patients and all other samples. Subsequently, another breath array 
for OC diagnostics was reported, based on modified gold nanoparticles as sensors. 
An array of ten sensors was exposed to the VOCs previously linked to OC. The 
researchers analyzed breath samples from 26 healthy controls and 17 women with 
epithelial OC. The analysis of all sensors separated the groups with an accuracy of 
83.7%, a sensitivity of 82.3% and a specificity of 84.6% (Kahn et al. 2015).  
The ability of various applications of the eNose to detect cancer has been 
investigated with various malignancies. Lung cancer has been studied most by 
eNose. The first examination of breath samples discriminated lung cancer patients 
from controls with an accuracy of 90.3% (Di Natale et al. 2003). Later, bladder 
(Bernabei et al. 2008; Weber et al. 2011) and prostate (Bernabei et al. 2008; Roine et 
al. 2014) cancers were detected from urinary headspace and breast, colorectal and 
prostatic cancers from breath samples (Peng et al. 2010), as well as colorectal cancer 
from fecal headspace (de Meij et al. 2014) with the eNose. 
Horvath et al. tested the capability of eNose to discriminate OC tissue odor from 
that of healthy gynecological tissue. A total of 23 tissue samples from grade 3 
seropapillary carcinomas were analyzed in a pilot and external validation study. The 
overall sensitivity of the results was 84% and the specificity 86.8% (G. Horvath, 
Chilo et al. 2010). 
There are only two studies published in which FAIMS was used as a detector of 
cancer. With the aid of FAIMS, colorectal cancer was detected in urine samples of 
83 cancer patients compared to 50 healthy controls, with a sensitivity of 88% and 
specificity of 60% (Arasaradnam et al. 2014). From urine headspace, FAIMS 
differentiated between pancreatic cancer patients (N=81) and healthy controls 
(N=81) with a sensitivity of 91% and specificity of 83%. Even the urine from early-
stage cancer patients was differentiated significantly from that from controls 
(Arasaradnam et al. 2018). 
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2.6 Lipidomics 
2.6.1 Overview of lipids  
Lipids are a large structurally and biologically diverse group of hydrophobic or 
amphipathic molecules (Sethi & Brietzke 2017). They accomplish three main roles 
in cells. First, they store energy, mainly as triacylglycerol and cholesterol esters in 
lipid droplets. Second, they make up cellular membranes, which is the most common 
location of cellular lipids. The main membrane lipids in eukaryotic cells are 
glycerophospholipids, of which phosphatidylcholines and phosphatidyletholamines 
are the most prominent. Third, they function as first and second messengers for 
molecular signaling and identification processes (S. E. Horvath & Daum 2013; van 
Meer et al. 2008). 
In 2005, Fahy et al. (2005) published a classification for lipids to standardize the 
information on lipid data. Lipids were divided into eight categories depending on 
their chemical structures and biochemical properties (see Table 14 below). Each lipid 
category is divided into subclasses using a variety of molecular differences in acyl 
carbon chain lengths and the number and positions of double bonds. With new 
analytical approaches, more than 40,000 lipid structures have already been listed in 
the LIPID MAPS database, and new lipids will certainly be found in the future (Lydic 
& Goo 2018). 
Table 14.  Lipid categories and examples of their classes (Lydic & Goo 2018; Y. Y. Zhao et al. 2015). 
Category Example classes 
Fatty Acyls Fatty acids and conjugates 
Glycerolipids Monoacylglycerols 
Triacylglycerols 
Glycerophospholipids Glycerophosphocholines 
Glycerophosphoinositols 
Sphingolipids Phosphosphingolipids 
Ceramides 
Sterol lipids Cholesterol and derivates 
Prenol lipids Isoprenoids 
Saccharolipids Acylaminosugars 
Polyketides Flavonoids 
Cytochalasins 
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Daily nutrition, genetic background and diseases have an influence on lipid 
contents and concentrations in plasma. Plasma lipids are transported by lipoproteins 
into the circulation and tissues. Lipoproteins, which consist of lipids and 
apolipoproteins, are separated into different classes: chylomicron, very low-density 
lipoprotein (VLDL), low-density lipoprotein (LDL) and high-density lipoprotein 
(HDL). Each lipoprotein has its own function in plasma lipid delivery (Lydic & Goo 
2018).  
2.6.2 Analytical methods for lipidomics 
Lipidomics is a branch of metabolomics that characterizes, identifies and quantifies 
lipid species and their multiple biological roles (Y. Y. Zhao et al. 2015). It emerged 
in the literature in 2003 (Han & Gross 2003; Lagarde et al. 2003) and has progressed 
since then, especially with recent technological advancements. Lipid profiling from 
cells, biological fluids and tissues provides new insights into pathophysiology, 
diagnostics and treatment of different diseases (Lydic & Goo 2018). 
There are two ways to analyze lipids: targeted and non-targeted analysis. In 
targeted analysis, specific lipids are investigated using an accurate method for 
quantification. The principle behind non-targeted analysis is to analyze all possible 
lipid species simultaneously (Sethi & Brietzke 2017). A lipidomic analysis involves 
multiple processes in the workflow to identify and quantify many lipids at the same 
time (Figure 7).  
Figure 7.  The workflow for lipidomics (modified from Lydic & Goo 2018; Yang & Han 2016). 
 
LC: liquid chromatography; GC: gas chromatography; NMR: nuclear magnetic resonance. 
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Normally, a 5-100 μL of plasma or serum or 1-100 mg of tissue is required for 
lipid profiling. The first step in lipidomic analysis is the extraction of lipids from the 
sample to remove proteins, saccharides and other compounds (Sethi & Brietzke 
2017). Liquid-liquid extraction developed by Folch et al. (1957) is the most common 
method of isolating lipids, and the organic solvent used is a combination of 
chloroform and methanol. Other solvents have also been used for extraction, 
depending on the hydrophobicity and amount of lipids in the sample. Liquid-liquid 
extraction is well-suited for a diverse spectrum of lipids in non-targeted lipidomics. 
Other extraction methods have also been developed in recent years, e.g. solid-phase 
extraction, a rapid method that performs better in targeted lipidomics (Lydic & Goo 
2018; Y. Y. Zhao et al. 2015). 
MS- or non-MS-based methods such as nuclear magnetic resonance (NMR) 
spectroscopy are utilized in lipidomics to detect lipids. After lipid extraction, various 
chromatographic methods such as GC, LC, thin layer chromatography and HPLC 
are often used to separate a broad range of lipids from complex samples before 
detection. Another option is to infuse lipids after ionization directly into MS for 
detection without prior separation. This method, called shotgun lipidomics, is rapid 
but more suitable for untargeted lipid profiling than chromatography with MS. These 
two methods are considered to complement each other (Lydic & Goo 2018; Sethi & 
Brietzke 2017; Y. Y. Zhao et al. 2015).  
The profusion of lipid species is identified from the chromatographic (e.g. LC-
MS) and MS/MS spectral data and quantified by comparisons of peak areas and ion 
peak intensities against standards (Lydic & Goo 2018). The data processed by 
lipidomics is enormous because each sample can contain a large number of lipid 
species. Therefore, there are several data-processing software options, in addition to 
analytical lipid databases, that can be used to aid such efforts (Sethi & Brietzke 2017). 
Pathway analysis is one method used to understand lipidomics findings in a 
biological context; there are biotechnological software platforms available to 
facilitate lipid pathway analysis (Lydic & Goo 2018). 
2.6.3 Lipid metabolism in cancer 
Cancer cells share characteristic metabolic alterations as a response to increased 
cellular growth and proliferation. The Warburg effect is the well-known metabolic 
adaptation in cancer cells: cells produce energy by non-oxidative glycolysis, i.e. 
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fermentation of pyruvate to lactate in cytoplasm, in contrast to the oxidative 
phosphorylation in mitochondria in healthy cells (Warburg 1956). An increased 
glutamine metabolism is also a commonly detected disturbance in cancer cells. 
Glutamine can be converted to citrate, which is needed by acetyl groups for fatty 
acid synthesis (Currie et al. 2013). 
There are several reported changes in lipid metabolism in cancer in response to 
cellular proliferation and the increased need for lipids. Most human cells obtain lipids 
from blood circulation as free fatty acids or combined with proteins such as 
lipoproteins. These lipids are acquired from dietary sources or synthesized de novo 
mainly in the liver, adipose tissue and lactating breasts. As early as the 1950s, it was 
noted that human neoplastic tissues can produce lipids through de novo synthesis (C. 
R. Santos & Schulze 2012; Swinnen et al. 2006). Increased lipogenesis in cancer leads 
to the elevated expression and activity of lipogenic enzymes. The enzymes showing 
increased activity in malignancies, also in OC, include ATP citrate lyase, acetyl-CoA 
carboxylase and fatty acid synthase (FAS), which are regulated by several signaling 
pathways (Pyragius et al. 2013). The increased expression of FAS is shown to 
correlate with the aggressiveness of OC (Ueda et al. 2010). Lipid rafts in cellular 
membranes which are synthesized from cholesterol and phospholipids, are increased 
in number in cancer cells. They are specialized microdomains which act as platforms 
for signaling molecules and receptors (Beloribi-Djefaflia et al. 2016; A. L. Santos & 
Preta 2018). One of the most studied pro-oncogenic signaling pathway is 
phosphatidylinositol-3-kinase (PI3K)-AKT which can enhance the expression of 
FAS (Yellen & Foster 2014). Oncoproteins and tumor suppressors such as p53 
regulate fatty acid synthesis by influencing the fatty acid precursors created from 
glucose and glutamine metabolism (Pyragius et al. 2013). The mevalonate pathway, 
which facilitates cholesterol synthesis, belongs to important processes in cancer. 
Cholesterol is especially needed for membranes. Lipid droplets, which contain 
triacylglycerols and cholesteryl esters, are more abundant in malignant cells than in 
healthy ones (C. R. Santos & Schulze 2012; Swinnen et al. 2006; see Figure 8). 
Inhibitory molecules targeting lipogenic enzymes are being developed for inhibiting 
tumor growth and metastatic spread (Beloribi-Djefaflia et al. 2016; Cha & Lee 2016; 
Q. Liu et al. 2017).  
Obesity is a contributing factor in many cancers, mainly due to its insulin 
resistance. An excess of adipose tissue leads to increased insulin secretion from 
pancreatic beta cells and the enhanced availability of insulin-like growth factor 1, 
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both of which stimulate the proliferation of tumor cells and protect them from 
apoptosis. Inflammatory cytokines secreted by adipose tissue can enhance tumor cell 
proliferation (C. R. Santos & Schulze 2012). A recent meta-analysis showed that a 
high consumption of nutritional fats may increase the risk of OC, which could be 
partly due to a stimulated secretion of extra-ovarian estrogen, which may promote 
tumor activity (Qiu et al. 2016). On the other hand, the cachexia commonly seen in 
connection with advanced cancer is caused by the reduction of fat stores through an 
increased lipolysis in adipose tissue. The breakdown of lipids leads to an increased 
amount of circulating free fatty acids and production of glycerol for gluconeogenesis 
in the liver, which supplies energy to the tumor cells (C. R. Santos & Schulze 2012).  
An altered lipid metabolism and increased synthesis of long-chain fatty acids 
promotes cancer development in many ways. Cancer cells need more lipids for 
membrane building, which is also essential for tumor cell growth and proliferation. 
De novo lipid synthesis and the elevated levels of available lipid droplets support the 
survival of tumor cells under oxidative and energy stress. An increase in fatty acid 
and cholesterol synthesis may stimulate signaling in tumorigenesis. Cancer cells have 
a high glycolysis rate due to their energy demand and therefore an increased lactate 
production. Lipids may also play a stabilizing role in the oxidation-reduction balance 
(C. R. Santos & Schulze 2012). 
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Figure 8.  Lipid metabolism in cancer cells (modified from C. R. Santos & Schulze 2012; Swinnen et 
al. 2006). 
  
    LDH: lactate dehydrogenase; ACL: ATP citrate lyase; ACC: acetyl-CoA carboxylase; FAS: fatty acid synthase. 
 
2.6.3.1 Lipidomics in ovarian cancer 
Phospholipids, the major component of cellular membranes, are associated with 
malignancies. They are associated with OC in many forms, such as increased levels 
of lysophosphatidic acid (LPA) and altered activity of phospholipase A2 (PLA2), 
phospholipase D and autotoxin (ATX) (Tania et al. 2010). LPA acts as an 
extracellular signaling molecule that binds to cell surface G protein-coupled 
receptors and activates the proliferation, survival and migration of cancer cells 
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(Pyragius et al. 2013), and LPA levels are elevated in the ascites and plasma of OC 
patients (Ren et al. 2006). LPA is produced by the activity of PLA2 and ATX 
enzymes. Elevated levels of PLA2 have been found in ascites and tissue samples in 
patients with epithelial OC (Cai et al. 2012), and blocking the ATX enzyme seems to 
inhibit the production of LPA. Phospholipase D is an enzyme essential for the 
formation of phosphatidic acid, a precursor of LPA (Tania et al. 2010). 
Altered sphingolipids have also been connected to malignancies. Ceramides 
(Cers), short-chain sphingolipids, are most often studied in carcinogenesis due to 
their role in the induction of apoptosis. Another sphingolipid, sphingosine-1-
phosphate, plays an opposite role in promoting cancer cell survival (Furuya et al. 
2011). Cers are formed by the hydrolysis of sphingomyelin or by de novo synthesis, 
and they can be converted back to sphingomyelin or to glycosphingolipids, including 
e.g. sulphatides (Furuya et al. 2011; Hajj et al. 2015). Sulphatides are shown to be 
elevated in OC tissues, although their role in the development of OC is unclear (Y. 
Liu et al. 2010). 
Activation of lipid metabolism is involved in early carcinogenesis, but lipids also 
feature in cancer development and progression. Therefore, lipid profiling of the body 
fluids, tissues and cells of cancer patients has been researched in recent years to 
detect novel biomarkers for the early diagnosis (Yang & Han 2016) and prognosis 
of cancer, as well as to find therapeutic targets (Lydic & Goo 2018). Table 15 
summarizes the lipid studies in human samples as potential diagnostic or prognostic 
factors in OC, showing alteration (decrease or increase) of lipids in cancer patients 
compared with controls. 
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3 AIMS OF THE STUDY 
This study was undertaken to assess whether new methods could improve 
preoperative diagnostics of ovarian cancer. The specific aims of the study were: 
 
1. To evaluate the feasibility of the various ultrasound scoring systems and 
three-dimensional power Doppler sonography in the assessment of ovarian 
tumors (Study I). 
2. To explore whether urinary polyamines analyzed by liquid chromatography-
tandem mass spectrometry discriminate benign and malignant ovarian 
tumors (Study II). 
3. To test whether field asymmetric ion mobility spectrometry can distinguish 
between the urine of women with benign and malignant ovarian tumors 
(Study III). 
4. To examine if there are alterations in lipid metabolism that can be found in 
serum/plasma samples obtained from patients with early- and advanced-
stage ovarian cancer of various histological subtypes (Study IV). 
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4 PATIENTS, MATERIALS AND METHODS 
4.1 Patients and study design (Studies I-IV) 
A total of 119 women aged at least 50 years with an indefinite ovarian tumor 
scheduled for surgery were prospectively enrolled into Study I. Obviously benign or 
malignant-looking ovarian tumors were not included, such as simple cysts or tumors 
with abundant ascites (the diameter of the largest ascites pouch was >10 cm). In 
addition, the entire tumor had to be visible in the transvaginal US assessment which 
was performed during the period of two weeks immediately prior to surgery. 
However, the stored US data of 19 women was lost due to the breakdown of the 
hard disk of the US machine. In connection with the preoperative laboratory tests, 
which included a CA125 sample, an extra serum sample was obtained from 111 
women to be stored in a freezer.  
The study population was partly the same in the three studies: 22 women in 
Study I were also in Study II, and 13 women in Study I were in Study III. For Studies 
II and III, we recruited postmenopausal women 50 and older with an unspecified 
adnexal mass waiting for surgery along with women scheduled for genital prolapse 
or urinary incontinence operations as controls. A total of 107 women gave their 
informed consent to the study, but only 98 women gave a urine sample; of them, 93 
were eligible for the Study II polyamine analysis and, later, 78 were eligible for the 
Study III FAIMS analysis. Sixty-six women were included in both Studies II and III. 
All women provided a urine sample on the morning of their operation, and the 
samples were stored in two tubes at -70°C to be analyzed later. All the operations in 
Studies I-III were performed at the Tampere University Hospital.  
Study IV was conducted in cooperation with the Oulu University Hospital in 
Finland and the Charitè Medical University in Berlin, Germany. Serum samples from 
Study I were included in the Study IV population. Also included were 54 
preoperatively collected plasma samples from the Oulu University Hospital and 189 
serum samples from the Tumor Bank-Ovarian Cancer Network of the Charité 
Medical University from women with adnexal masses. These were the two study 
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cohorts (Finland and Charité in Germany). The blood samples from these two 
cohorts were compared with previously analyzed data from 250 serum samples from 
Charitè (Braicu et al. 2017).  
The characteristics of the study groups after exclusions are presented in Table 16. 
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Table 16.  Study population, main objectives and main outcome measures in Studies I-IV. 
 Study I Study II Study III Study IV 
Study design Prospective Prospective Prospective Retrospective 
 
Number of 
patients 
98a 81b 69c 354  
250 (Reference Study 
Cohort) 
 
Study population 32 malignant ovarian 
tumors and 66 benign 
ovarian tumors 
37 malignant ovarian 
tumors, 23 benign 
ovarian tumors and 21 
healthy controls  
33 malignant ovarian 
tumors, 18 benign 
ovarian tumors and 18 
healthy controls 
138 malignant ovarian 
tumors, 25 borderline 
tumors and 191 
controls with benign 
gynecologic 
pathologies  
152 malignant ovarian 
tumors (Reference 
Study Cohort) and 98 
controls with benign 
gynecologic 
pathologies (Reference 
Study Cohort) 
Age (years) 
Md (range) 
61 (50-84) 66 (51-86) 64 (51-83) 56 (18-85)  
54 (17-92; Reference 
Study Cohort) 
 
Study objectives To compare various US 
scoring systems, serum 
CA125 and 3D-PD in 
assessing the nature of 
ovarian tumors 
To examine whether 
urine polyamine levels 
differ in women with 
benign and malignant 
ovarian tumors and 
healthy controls 
To clarify whether urine 
from women with benign 
and malignant ovarian 
tumors and from 
controls can be 
differentiated using 
FAIMS  
To validate the former 
findings of lipidomic 
alterations in serum of 
women with advanced 
HGSOC and to 
investigate whether the 
lipid changes occur 
also in serum/plasma of 
women with early-stage 
cancer and in other 
histological subtypes 
 
Sample collection FEB 2011 – NOV 2014 MAY 2013 – MAR 2016 MAY 2013 – MAR 2016 JAN 2009 – DEC 2015 
 
Main outcome 
measures 
The sensitivities, 
specificities and 
accuracies of each 
predictive model in 
detecting ovarian 
malignancy 
Changes in urinary 
polyamine 
concentrations in the 
different study groups 
The sensitivities, 
specificities and 
accuracies of FAIMS in 
finding differences 
between the study 
groups 
Lipidomic changes in 
early- and late-stage 
ovarian cancer vs. 
controls, and serous 
and histological 
subtypes vs. controls 
a Two patients excluded (tumors were of appendiceal origin). 
b 12 patients excluded: six malignant tumors were of colorectal origin; one tumor was a metastasis of uterine leiomyosarcoma; four 
patients had concurrent other malignancies; and one was not postmenopausal. 
c Nine patients excluded: six malignant tumors were of colorectal origin and one was metastasis of uterine leiomyosarcoma, two patients 
had concurrent other malignancy).  
US: ultrasound; 3D-PD: three-dimensional power Doppler; FAIMS: field asymmetric waveform ion mobility spectrometry; HGSOC: high-
grade serous ovarian carcinoma. 
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4.2 Methods 
The results from the assessed diagnostic methods were correlated with the final 
histopathology of the tumors. The offline evaluation of stored sonography data and 
3D volumes (Study I), the analysis of polyamines by LC-MS/MS (Study II) and the 
FAIMS urinary analysis (Study III) were performed blinded to the histopathological 
results. In Study IV, blood samples were randomized within each cohort before LC-
MS/MS lipidomic analyses were performed.  
4.2.1 Two- and three-dimensional sonography with power Doppler (Study I) 
All US examinations were conducted using a Voluson 730 Expert unit (GE Medical 
Systems, Zipf, Austria) with a multifrequency endovaginal probe (5-9 MHz) by one 
examiner (R.N.) The routine B-mode examination was performed first and the 
dimensions of the ovarian tumor were measured. If bilateral ovarian tumors existed, 
the more complex tumor was included in the study. The adnexal tumor was first 
evaluated using 2D US, and the vascularization of tumor was scored from 1 to 4 
using the IOTA classification system: 1 was no Doppler signal detected, and 4 was 
a highly vascularized tumor with abundant Doppler signals detected (Timmerman et 
al. 2000). The following PD settings were used: a frequency of 6 MHz, a power 
Doppler gain of -0.6, the wall motion filter on low 1, and a pulse repetition frequency 
of 0.6 kHz. 
In the beginning of the 3D evaluation, the size of the volume box was adjusted 
to cover the contours of the ovarian mass. The acquisition angle was set to 85 
degrees. The women hyperventilated briefly and then held their breath during the 
3D sweep. Once a volume was obtained and accepted as fulfilling the requirements 
(no movement artifacts, and the entire tumor was within the volume box), it was 
stored on a hard disk with the previously stored 2D data to be analyzed later offline. 
4.2.1.1 Ultrasound-based scoring methods 
After each US examination, the investigator categorized the tumor as benign or 
malignant (expert opinion). The RMI was calculated using the original formula 
(Jacobs et al. 1990). Tumors were analyzed from stored 2D data using the IOTA 
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simple rules (Timmerman et al. 2008). In the case of non-classifiable tumors, i.e. 
tumors to which none of the rules or both M- and B-rules applied, the tumor was 
classified by expert opinion. In addition, the probability of tumor malignancy was 
calculated using IOTA LR2 (Timmerman et al. 2005) with various cutoff levels, with 
the aid of the Predictive IOTA models for ovarian cancer application software, 
version 2013 (an app for IOS operating systems).  
4.2.1.2 Three-dimensional power Doppler angiography 
Offline analyses of stored 3D volumes were performed using the VOCAL imaging 
utility and 4DView software version 9.1 (GE Medical Systems, Zipf, Austria). With 
the aid of these programs, the visual and quantitative evaluation of 3D data was 
feasible on a Windows-based computer. Volumes of all tumors were constructed by 
manually outlining the contours of tumors inside the volume box in a mid-sagittal 
plane (Plane A) with 15-degree rotations. With the help of the histogram feature of 
the VOCAL utility, the vascular indices VI, FI and VFI were obtained from the 
selected tumor volume.  
Figure 9.  Volume analysis of an ovarian tumor using the VOCAL utility. 
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Figure 10.  Histogram feature with the respective vascular indices for the same volume. 
 
4.2.1.3 Interobserver agreement 
To estimate the agreement between two examiners, the stored 2D data from the 
ovarian tumors was re-evaluated offline and classified as either benign or malignant 
by another independent US examiner (S.S.) The volumes and vascular indices were 
also re-analyzed using 3D US data as previously described. The analyses were 
performed blinded to each other`s interpretations.  
4.2.2 Polyamine analysis by liquid chromatography-tandem mass 
spectrometry (Study II) 
The creatinine concentration was quantified enzymatically in Fimlab laboratory 
(Tampere, Finland) from a portion of each urine sample. The stored urine samples 
were thawed at room temperature and centrifuged. The LC-MS/MS analyses were 
performed at the University of Eastern Finland.  
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Urine specimens were first mixed with water and an internal standard (IS) 
working solution, which contained isotope-labeled molecules for each analyzed 
polyamine mimicking the target molecules in the LC but still distinguishable from 
them. The urine samples were filtered through the solid-phase extraction cartridge 
before LC-MS/MS analysis. 
The chromatographic separations of polyamines were performed using a reversed 
phase column with 0.1% heptafluorobutyric acid as an evaporative ion-pairing agent. 
The samples were ionized using a positive electrospray ionization source and then 
detected with an Agilent 6410 Triple Quadrupole MS. Deuterated ISs of each 
polyamine were used in the quantification, and the polyamine concentrations were 
normalized using creatinine concentrations. The obtained data was processed and 
quantified using Agilent Masshunter Workstation software (Agilent Technologies, 
Palo Alto, CA, USA). 
A detailed description of this LC-MS/MS technique has been reported by 
Häkkinen et al. (2013). This technique was validated and calibrated for quantitation 
limits for each polyamine. The amounts of polyamines remained stable in urine 
matrix and in water dilutions and did not change even after longer storages or several 
freezing-thawing procedures. Water dilution is needed in case polyamine 
concentrations are very high. Some urine compounds may have effect on sensitivity 
of the analyte (matrix effect) which was compensated using deuterated ISs. Also, the 
accuracy and precision of this technique were tested in intra- and inter-day analysis 
according to the FDA validation guideline using <15% as an acceptable variation 
value. 
4.2.3 The FAIMS analytical technique (Study III) 
For the FAIMS analysis, we used a commercial Lonestar (Owlstone, Cambridge, 
United Kingdom) device with an ATLAS sampling unit to standardize the analytical 
circumstances. The stored urine specimens were thawed to room temperature. The 
urine samples were mixed using a vortex and 5 mL of urine sample was pipetted into 
a 30 mL glass vial, which was heated to 40°C. Clean air was streamed over the 
sample, transferring VOCs into the device at a total flow rate of 2500 mL/min. 
Inside the Lonestar, the sample stream was ionized with nickel-63 isotope. 
Subsequently, the sample was passed into the electric field where it was analyzed by 
alternating the compensation voltage range between -6V and +6V in 512 steps for 
  
82 
 
field strengths of 0-90% in 51 steps. Each sample was scanned three times; 
afterwards, five scans with sterilized water were made to clean the device and reduce 
carryover. 
The FAIMS technique used has not been standardized due to its experimental 
nature but the other published studies have also utilized the same technique 
(Arasaradnam et al. 2014; Arasaradnam et al. 2018). I am not aware of previous 
studies of repeatability of FAIMS analysis. However, the urine samples were 
randomized before analysis in order to prevent any systematic bias.  
4.2.4 Lipidomic analysis by liquid chromatography-tandem mass 
spectrometry (Study IV) 
The blood samples stored at -70°C were thawed to a temperature of +4°C. Two 
lipidomic platforms, a global screening method and a phosphosphingolipid platform 
were used to perform the lipidomic profiling at the laboratory of Zora Biosciences 
Oy (Espoo, Finland). The isolation of lipids for the global screening method was 
performed by modified Folch extraction (Folch et al. 1957). A 10 μL sample was 
aliquoted into 96 wells of the plate, and a solvent containing chloroform, methanol 
and a mixture of synthetic ISs was added to the plate to extract lipids. In turn, a 25 
μL sample was aliquoted into a 96-well plate to which methanol and 0.1% butylated 
hydroxytoluene with a mixture of synthetic ISs was added for phosphosphingolipid 
extraction.  
A hybrid triple quadrupole/linear ion trap mass spectrometer with ultra-high-
performance liquid chromatography was used. Lipid detection was performed by MS 
analysis in the positive ion mode for both platforms. The data from the lipidomics 
screening platform was collected using a scheduled multiple reaction monitoring 
algorithm and from the phosphosphingolipid platform using multiple reaction 
monitoring. The lipidomics data was analyzed using Analyst and MultiQuant 3.0 
software (AB Sciex, Concors, Canada), and normalization with IS amount and 
sample volume was done in relation to the area or height ratios of each analyte and 
its respective IS peak. The analyzed lipid species and the mean coefficient of 
variation of each analyzed lipid, which varied between the analyses, are shown in 
Table 17.  
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Table 17.  Analyzed lipids 
Lipid class Number of lipids  Coefficient of variation 
Acylcarnitine (AC) 8 15% 
Cholesteryl ester (CE) 21 24% 
Ceramide (d16:1-d20:1) 37 22-36%* 
Diacylglycerol (DAG) 18 29% 
Globotriasoylceramide (Gb3) 4 41% 
Glucosyl/galactosylceramide (Glc/GalCer) 22 29% 
Lactosylceramide (LacCer) 10 28% 
Lysophosphatidylcholine (LPC) 53 11% 
Lysophosphatidylethanolamine (LPE) 13 12-13%* 
Phosphatidylcholine (PC) 116 20-23%* 
Phosphatidylethanolamine (PE) 38 27-30%* 
Phosphatidylglycerol (PG) 4 23% 
Phosphatidylinositol (PI) 19 19% 
Phosphosphingolipids (S1P/SA1P) 4 9% 
Sphingomyelin (SM) 41 16% 
Triacylglycerol (TAG) 42 11% 
Total 450  
*depending on the specific lipid class 
Braicu et al. (2017) gave a detailed description of this lipidomic analysis which 
was modified from the previously described method (Weir et al. 2013). The analysis 
technique used is a so-called high throughput screening method which has to be 
validated to specific targeted lipid molecules before using as a clinical test. The effect 
of thawing and freezing on the lipid concentrations should also be studied as part of 
the validation. 
4.3 Statistical analysis 
Sample sizes were not calculated due to the preliminary nature of all studies.  
In Study I, statistical analyses were performed using IBM SPSS Statistics version 22 
(IBM Corp., Armonk, NY, USA). The Kolmogorov-Smirnov test was used to assess 
the normal distribution of continuous variables. The groups were compared using 
the Mann-Whitney U-test, and correlations were assessed using Spearman’s 
correlation tests. Receiver operating characteristic (ROC) analyses were carried out 
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for each continuous variable to evaluate its performance as a predictive test. 
Appropriate cutoff levels for variables were calculated based on sensitivity, 
specificity, negative and positive predictive values. Categorical variables were tested 
using Pearson’s chi-square test or Fisher’s exact test. The concordance of US features 
as noted by two observers was calculated using Cohen’s kappa index, and the 
concordance of 3D-PD vascular indices using the related-samples Wilcoxon signed 
rank test. 
In Study II, MATLAB Version R2016b (Mathworks Inc., Natick, MA, USA) was 
used for statistical analysis. The distributions of continuous variables were evaluated 
using the Kolmogorov-Smirnov test. The comparisons in polyamine concentrations 
were assessed between all groups (controls, benign tumors and malignant tumors) 
using the Wilcoxon rank sum test; p <0.05 between the groups was considered 
statistically significant. The ROC curves for predictive biomarkers, urinary DiAcSpm 
and serum CA125 were computed and used to identify the optimal cutoff level for 
DiAcSpm. For CA125, the cutoff level selected was the commonly used 35 kU/L. 
Sensitivities and specificities for these threshold levels were measured. 
In Study III, data from the third scan of each urine sample, including both 
positive and negative ion channels, were discovered to be comparable with the 
average of all three scans. The data were processed using LDA and quadratic 
discriminant analysis (QDA) to create classification parameters. Subsequently, the 
data were cross-validated by 10-fold cross-validation to avoid overfitting. The 
statistical analyses were conducted using MATLAB Version R2017b (Mathworks 
Inc, Natick, MA, USA). 
In Study IV, we used R version 3.4.2, which is non-commercial software, for 
statistical analyses. Two groups (women with tumors vs. women controls) were 
compared by calculating the mean relative differences between the groups, and p-
values were calculated by unpaired t-tests on log-transformed concentrations. 
Heatmaps were visualized by Tableau software version 10.1. Logistic regression 
models obtained from the Charité cohort were tested in the Finnish cohort, and the 
AUC values were calculated using a pROC package.  
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4.4 Ethical considerations 
In conducting our studies, we complied with the Declaration of Helsinki. The sample 
collection and protocols for Studies I-IV were approved by the Pirkanmaa Hospital 
District Ethics Committee. Each patient gave written informed consent for the 
study. The local ethics committees of the Oulu University Hospital (Finland) and the 
Charitè Medical University (Berlin, Germany) also approved Study IV. 
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5 RESULTS 
A few recruited patients were excluded from the final analysis after the final 
histopathological diagnosis of a non-ovarian neoplasm. The detailed exclusions from 
each study are presented in the explanatory legends of Table 16 above. The 
histological diagnoses from Studies I-III are presented below in Table 18 and from 
Study IV in Table 19. 
Table 18.  Histopathological diagnoses from Studies I-III. 
Histology Study I Study II Study III 
Benign 66 23 18 
  Serous cystadenoma / adenofibroma 39 11 9 
Mucinous cystadenoma 3 2 1 
Fibroma / thecoma 5 2 2 
Teratoma 7   
Serous / hemorrhagic / simple/ necrotized cyst 7 6 4 
Endometriotic cyst 3 2 2 
Brenner tumor 1   
Bizarre leiomyoma 
 
1   
Borderline 7 9 9 
Serous 5 4 4 
Mucinous 2 5 5 
FIGO Stage    
I & II 7 8 9 
III & IV  1  
Malignant 25 28 24 
  Serous    
Low-grade  3   
High-grade  9 18 17 
  Mucinous    
Adenocarcinoma 3 3 2 
  Endometrioid    
Adenocarcinoma  1 1 
  Other    
Clear cell carcinoma 1   
Granulosa cell tumor 4 4 2 
Sertoli-Leydig cell tumor 1 1 1 
Carcinosarcoma 2 1 1 
Metastatic 2   
FIGO Stage    
I & II 14 10 7 
III & IV 9 18 17 
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Table 19.  Histopathological diagnoses in various study cohorts from Study IV. 
Histology Charitè Finland Charité Reference 
Study Cohort 
Benign  109 82 98 
Uterine fibroid 7 1 25 
Cyst / functional cyst / 
inclusion cyst 
29 9 1 
Cystic teratoma 12 8 5 
Endometrioid cyst / 
endometriosis 
14 1 2 
Non-ovarian cyst  4  
Cystadenoma / 
cystadenofibroma 
39 12 6 
Mucinous cystadenoma  3 2 
Serous cystadenoma  34 3 
Brenner tumor 1 2 1 
Fibroma / thecoma / 
fibroadenoma 
 6  
Incomplete abortion   5 
Adnexitis   5 
Other 7 2 43 
 
Borderline 18 7  
Serous 13 5  
Mucinous 2 2  
Other 3   
FIGO Stage    
I & II 12 7  
III & IV 3   
NA 3   
 
Malignant 62 76 152 
Serous 41 29 147 
Mucinous 6 18  
Endometrioid 9 14 5 
Other 6 15  
FIGO Stage     
I & II 26 52 8 
III & IV 33 22 133 
NA 3 2 11 
NA: not applicable. 
5.1  Ultrasound scoring methods (Study I) 
The calculated RMI values (and CA125 serum levels) of benign and malignant 
ovarian tumors differed to a statistically significant degree (p <0.001). The accuracies 
in detecting a malignancy were quite similar with CA125 (with the commonly used 
threshold value of 35 U/mL) and the RMI (with the most common used threshold 
value of 200), or 76.5% and 77.6% respectively. 
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Using the IOTA simple rules, 76 of 98 tumors could be classified, 68 of which 
were correct. The 22 remaining unclassifiable tumors were evaluated by an US 
examiner (R.N.), and 17 of 22 were correctly classified. The accuracy of the IOTA 
simple rules with the aid of expert opinion was 86.7%, compared with the accuracy 
of expert opinion alone, which was 90.8%. The sensitivity of the IOTA simple rules 
together with an expert opinion reached 90.6% but the specificity was poorer than 
expert opinion alone, i.e. 84.6% vs. 92.4% respectively. Attention must also be paid 
to the number of patients, which means that the difference between these two 
methods is not that great.  
Another IOTA method, LR2 (with a threshold value of 25%), achieved a 
sensitivity in detecting malignancies that was similar to that of the simple rules. 
However, LR2 failed – by comparison with the simple rules – in its specificity and 
accuracy. The vascularity of the tumors as analyzed by 2D PD was significantly 
higher in malignant than in benign tumors (p <0.001), and this method was as 
accurate and sensitive as LR2. 
The diagnostic performances of all the methods studied in Study I are presented 
in Table 20 below. 
Table 20.  Ultrasound-based scoring methods, including serum CA125, of differentiating between 
benign and malignant ovarian tumors. 
Method Sensitivity (%) 
(95% CI) 
Specificity (%) 
(95% CI) 
Accuracy (%) 
CA125a 59.4 
(40.6-76.3) 
84.9 
(73.9-92.5) 
76.5 
 
RMIb 71.9 
(53.3- 86.3) 
80.3 
(68.7-89.1) 
77.6 
Simple rulesc 90.6 
(75.0-98.0) 
84.6 
(73.9-92.5) 
86.7 
Expert opinion 87.5 
(71.0-96.5) 
92.4 
(83.2-97.5) 
90.8 
Tumor vascularityd 90.6 
(75.0-98.0) 
77.3 
(65.3-86.7) 
81.6 
LR2e 90.6 
(75.0-98.0) 
77.3 
(65.3-86.7) 
81.6 
    
CI: confidence interval.  
a Cutoff value 35 kU/L. 
b Cutoff value 200. 
c When the result was inconclusive, the expert evaluated the tumor. 
d Two-dimensional vascular score 1-2 vs. 3-4.  
e Cutoff value 25%. 
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5.1.1 Three-dimensional power Doppler angiography  
Three-dimensional vascular indices differed significantly between malignant and 
benign tumors (p <0.001). The VI and VFI were the most specific and accurate 
indices, comparable with the RMI, the simple rules and LR2. However, the 
combination of VFI value with the RMI/simple rules/LR2 did not improve their 
diagnostic performances. Table 21 below shows the diagnostic performances of 3D-
PD vascular indices and the combination of the VFI with other scoring methods.  
Table 21.  Diagnostic performances of 3D-PD vascular indices and combined methods. 
3D-PD indices 
Cutoff value 
Sensitivity (%) 
(95% CI) 
Specificity (%) 
(95% CI) 
PPV (%) 
(95% CI) 
NPV (%) 
(95% CI) 
Accuracy (%) 
VI (%) 
1.00 
67.7 
(48.6-83.3) 
90.9 
(81.3-96.6) 
77.8 
(57.7-91.4) 
85.7 
(75.3-92.9) 
83.5 
FI 
30 
83.9 
(66.3-94.6) 
51.5 
(38.9-64.0) 
44.8 
(31.7-58.5) 
87.2 
(72.6-95.7) 
61.9 
VFI 
0.31 
71.0 
(52.0-85.8) 
89.4 
(79.4- 95.6) 
75.9 
(56.5-89.7) 
86.8 
(76.4-93.8) 
83.5 
 
Combination methods     
RMI >200 and VFI 
>0.31 
51.6 
(33.1-69.9) 
95.5 
(87.3-99.1) 
84.2 
(60.4-96.6) 
80.8 
(70.3-88.8) 
81.4 
Simple rules with 
expert opinion and 
VFI >0.31 
71.0 
(52.0-85.8) 
95.5 
(87.3-99.1) 
88.0 
(68.8-97.5) 
87.5 
(77.6-94.1) 
86.7 
LR2 and VFI 
>0.31 
64.5 
(45.4-80.8) 
97.0 
(89.5-99.6) 
90.9 
(70.8-98.9) 
85.3 
(75.3-92.4) 
86.5 
PPV: positive predictive value. 
NPV: negative predictive value. 
The diagnostic performances of CA125, the RMI, LR2 and the 3D-PD vascular 
indices (VI, FI, VFI) are presented in ROC curves in Figure 11. The respective AUCs 
for these methods are 0.80, 0.81, 0.93, 0.86, 0.72 and 0.87. 
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Figure 11.  The ROC curves for CA125, the RMI, LR2 and the 3D-PD vascular indices. 
 
5.1.2 Interobserver agreement 
The expert opinions of two US examiners (R.N. and S.S.) were compared, and they 
disagreed in only five cases, all of which turned out to be histopathologically benign. 
Both of the experts missed four malignant tumors: a Stage IA endometrioid 
adenocarcinoma, a granulosa cell tumor and two serous BOTs. The agreement 
between the conclusions of the two observers was very good regarding tumor 
malignancy (Cohen’s к = 0.89; 95% CI 0.79-0.98). 
The 3D-PD vascular indices measured by both examiners did not differ from 
each other (p >0.1), which indicates a good level of interobserver agreement.  
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5.2 Urinary polyamines (Study II) 
A total of 12 polyamines (cadaverine, acetylated cadaverine, diacetylated cadaverine, 
acetylated putrescine, diacetylated putrescine, spermidine, N1-acetylated spermidine, 
N8-acetylated spermidine, DiAcSpd, spermine, acetylated spermine and DiAcSpm) 
were found in urine samples from the controls, the women with benign tumors and 
those with malignant tumors. However, only six of these polyamines were found in 
all samples (see Table 22 below). 
Table 22.  The polyamines found in all urine samples and their concentrations (μmol/g creatinine).  
Polyamine 
 
Controls  
(N = 21) 
Benign ovarian 
tumors  
(N = 23) 
Low-grade 
malignant 
tumors  
(N = 18) 
High-grade 
malignant 
ovarian tumors  
(N = 19) 
 
Range 
(μmol/g creatinine) 
AcCad 
 
0.04-5.64 
 
0.08-14.26 
 
0.11-13.08 
 
0.17-5.57 
 
AcPut 
 
6.57-19.28 
 
5.60-28.10 
 
9.15-41.45 
 
8.54-50.16 
 
N1AcSpd 
 
1.78-8.92 
 
1.04-8.17 
 
1.39-6.50 
 
2.52-18.50 
 
N8AcSpd 
 
1.84-4.75 
 
1.15-4.69 
 
1.65-5.03 
 
2.18-5.99 
 
DiAcSpd  
 
0.18-0.65 
 
0.14-1.32 
 
0.16-1.34 
 
0.23-1.20 
 
DiAcSpm 
 
0.06-0.20 
 
0.04-1.02 
 
0.06-0.37 
 
0.14-2.37 
 
AcCad: acetylated cadaverine; AcPut: acetylated putrescine; N1AcSpd: N1-acetylated spermidine;  
N8AcSpd: N8-acetylated spermidine; DiAcSpd: N1,N8-diacetylspermidine; DiAcSpm: N1,N12-
diacetylspermine. 
5.2.1 Diagnostic performance of urinary diacetylspermine  
Urinary DiAcSpm was the only polyamine which showed statistically significant 
differences between all studied groups, except between controls and women with 
benign ovarian tumors (see Table 23 ). The concentrations of DiAcSpm were highest 
in women with malignant ovarian tumors, especially high-grade and advanced 
cancers. The DiAcSpm concentrations in the different groups are presented in 
Figures 12 and 13. In addition, there were statistically significant differences between 
study groups in the urinary concentrations of DiAcSpd, N1AcSpd and N8AcSpd.  
  
92 
 
Table 23.  Comparisons between study groups in differences in urinary DiAcSpm concentrations.  
Comparisons p-value 
Benign ovarian tumors vs. all 
malignant ovarian tumors 
 
<0.001 
Benign ovarian tumors vs. low-
malignant potential ovarian tumors 
0.020 
Benign ovarian tumors vs. Stage I-II 
tumors 
 
0.017 
All malignant ovarian tumors vs. 
controls 
 
<0.001 
Low-malignant potential ovarian 
tumors vs. high-grade tumors  
 
<0.001 
Stage I-II vs. Stage III-IV tumors <0.001 
Figure 12.  Concentrations of urine DiAcSpm (μmol/g creatinine) by study group. Reprinted from the 
International Journal of Gynecological Cancer, Vol. 27, Niemi et al., “Urinary polyamines 
as biomarkers for ovarian cancer”, pp. 1360-1366, Copyright (2017), with permission from 
Wolters Kluwer.  
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Figure 13.  Concentrations of urine DiAcSpm (μmol/g creatinine) by study group. Reprinted from the 
International Journal of Gynecological Cancer, Vol. 27, Niemi et al., “Urinary polyamines 
as biomarkers for ovarian cancer”, pp. 1360-1366, Copyright (2017), with permission from 
Wolters Kluwer. 
 
 
Serum CA125 levels in all women with ovarian tumors had a sensitivity of 75.7% 
and specificity of 69.6% in distinguishing malignant tumors. Urinary DiAcSpm 
proved to be at least as good tumor marker as CA125, with a sensitivity of 86.5% 
and specificity of 65.2% (Figure 14). 
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Figure 14.  The ROC curves for urinary DiAcSpm and serum CA125. Reprinted from the International 
Journal of Gynecological Cancer, Vol. 27, Niemi et al., “Urinary polyamines as biomarkers 
for ovarian cancer”, pp. 1360-1366, Copyright (2017), with permission from Wolters 
Kluwer. 
 
5.3 FAIMS analysis of urine (Study III) 
The FAIMS analysis produces numerical data consisting of pixels with three values: 
compensating voltage, percentage of asymmetric radio frequency waveform and ion 
current. As many complex samples with various VOCs are impractical to be analyzed 
manually in order to find out non-linear peaks of each VOC, the data analysis is 
commonly performed by using multivariate analysis.  
The VOC analysis of urine using FAIMS technology was performed with QDA 
and LDA and validated using 10-fold cross-validation as described above. The main 
results from the data are shown in Table 24.  
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Table 24.  Results from the FAIMS signal data using both QDA and LDA classification. 
           QDA: quadratic data analysis. 
           LDA: linear data analysis.  
5.4 Lipidomic analysis (Study IV) 
 
A total of 450 lipids were analyzed, 155 of which were found to discriminate between 
OC patients and controls in the Charité and Finland study cohorts, as well as in the 
Charité Reference Study Group. The alteration between patients and controls was 
significant at least in two of those study cohort groups. This range of lipids was 
analyzed further.  
Classification pairs 
 QDA 
 
  LDA  
Sensitivity    
(%)  
(±2 Std) 
Specificity 
(%) 
(±2 Std) 
Accuracy 
(%) 
(±2 Std) 
Sensitivity 
(%) 
(±2 Std) 
Specificity 
(%)  
(±2 Std) 
Accuracy 
(%) 
(±2 Std) 
Benign ovarian 
tumors vs. controls 
 
Controls vs. 
malignant ovarian 
tumors   
 
Controls vs. high-
grade ovarian 
cancers 
93.4 
(±11.4) 
 
91.2 
(±7.2) 
 
 
89.1 
(±2.8) 
90.4 
(±14.4) 
 
63.1 
(±16.0) 
 
 
74.6 
(±9.6) 
91.9 
(±9.8) 
 
81.3 
(±8.2) 
 
 
81.9 
(±5.2) 
86.0 
(±11.2) 
 
90.4 
(±5.2) 
 
 
88.7 
(±3.2) 
86.1 
(±12.2) 
 
64.3 
(±12.8) 
 
 
75.6 
(±11.8) 
86.1 
(±9.6) 
 
81.2 
(±5.8) 
 
 
82.1 
(±6.0) 
 
Benign vs. malignant 
ovarian tumors 
 
91.5 
(±6.4) 
 
51.4 
(±32.0) 
 
77.3 
(±13.8) 
 
87.1 
(±9.0) 
 
27.1 
(±38.6) 
 
65.9 
(±13.8) 
 
Benign ovarian 
tumors vs. low-grade 
ovarian cancers 
 
Benign ovarian 
tumors vs. high-grade 
ovarian cancers 
 
73.1 
(±41.4) 
 
 
 
85.3 
(±15.0) 
 
92.9 
(±11.4) 
 
 
 
79.7 
(±12.0) 
 
83.9 
(±23.4) 
 
 
 
82.5 
(±10.0) 
 
35.9 
(±14.0) 
 
 
 
85.0 
(±15.0) 
 
78.8 
(±5.8) 
 
 
 
79.9 
(±11.2) 
 
59.3 
(±7.0) 
 
 
 
82.5  
(±9.6) 
 
Low-grade vs. high-
grade ovarian 
cancers 
 
87.8 
(±12.8) 
 
 
89.6 
(±16.6) 
 
88.7 
(±11.2) 
 
84.3 
(±16.0)    
 
79.7 
(±13.4) 
 
82.0 
(±10.8) 
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5.4.1 Lipidomic changes in early- and advanced-stage ovarian cancer and 
in various histological subtypes 
To examine whether lipidomic changes occur in earlier stages of OC (FIGO I-II), 
we selected lipids that showed a consistent increase or decrease in both FIGO Stage 
I-II vs. controls and FIGO Stage III-IV vs. controls, and were also significantly 
altered, at least in the Stage III-IV groups in the Finnish and Charité cohorts. With 
this approach, we found 39 lipids that were mainly decreased in OC patients. Only 
some ceramide and triacylglycerol species, depending on their fatty acid chains, 
showed increases in samples from OC patients. Typically, these lipid changes were 
more often statistically significant in samples from patients with advanced OC.  
In order to investigate whether these lipid alterations also exist in histological 
subtypes (endometrioid and mucinous) other than serous OC, we selected the lipids 
that showed same direction of change in both the Charité and Finnish cohorts in all 
histological subtypes. We found 23 lipids that were significant in either endometrioid 
or mucinous subtypes in both of the cohorts, and all of them were significant in 
serous OC. Levels of only two of these 23 lipids, Cer(d18:1/18:0) and 
TAG(18:1/18:1/20:4), were elevated in all subtypes of OC. Levels of all other lipids 
were decreased. 
Figure 15 shows all the lipids that were altered in early-stage OC, also in different 
histological subtypes. 
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Figure 15.  The most promising lipids showing alterations in all stages and various histologies. 
  
Cer: ceramide; LPC: lysophosphatidylcholine; PC: phosphatidylcholine; PC P: alkenyl-linked phosphatidylcholine; PI: 
phosphatidylinositol; SM: sphingomyelin; TAG: triacylglycerol. 
 
To investigate whether lipid changes in ovarian malignancies could improve the 
diagnostic value of serum CA125, we added lipids or lipid ratios to CA125. The 
increased serum/plasma levels of lipids in OC and CA125 were used as numerators 
in ratio calculations, and decreased lipids as denominators. Adding lipid data to 
CA125 improved the AUC values both in the Charité and Finnish study cohorts, 
and the increases were seen especially in Stage I-II ovarian tumors. Some of the 
models with the greatest improvements are presented in Table 25. 
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Table 25.  AUC values with 95% confidence intervals for the logistic regression models incorporating 
lipids and CA125, and also for CA125 alone and CA125 as a binary variable with its 
commonly used cutoff value. 
  Charitè                       Finland 
Variable 1 Variable 2 All Stages I-II 
Stages  
III-IV All 
Stages  
I-II 
Stages 
III-IV 
CA125 / 
Glc/GalCer(d18:1/26:0) 
Cer(d18:1/24:1) / 
LPC 14:0_sn2 
0.93 
(0.89-0.96) 
0.87 
(0.80-0.94) 
0.98 
(0.96-1.00) 
0.76 
(0.68-0.85) 
0.74 
(0.64-0.83) 
0.93 
(0.84-1.00) 
Cer(d18:1/24:1) / 
LPC 14:0_sn2 
CA125 / 
PC 37:2 
0.93 
(0.89-0.96) 
0.87 
(0.81-0.94) 
0.98 
(0.95-1.00) 
0.76 
(0.68-0.85) 
0.73 
(0.64-0.83) 
0.95 
(0.89-1.00) 
Cer(d20:1/24:1) / 
LPC 14:0_sn2 
CA125 / 
PC 37:2 
0.92 
(0.87-0.96) 
0.85 
(0.77-0.93) 
0.98 
(0.95-1.00) 
0.77 
(0.68-0.85) 
0.74 
(0.64-0.83) 
0.95 
(0.90-1.00) 
Cer(d18:1/24:1) / 
LPC 14:0_sn2 
CA125 / 
PI 38:2 
0.92 
(0.89-0.96) 
0.87 
(0.81-0.94) 
0.97 
(0.94-1.00) 
0.77 
(0.69-0.85) 
0.75 
(0.66-0.84) 
0.95 
(0.88-1.00) 
CA125 TAG(18:1/18:1/22:6) / LPC 14:0_sn2 
0.91 
(0.86-0.96) 
0.83 
(0.73-0.92) 
0.98 
(0.96-1.00) 
0.78 
(0.70-0.86) 
0.75 
(0.66-0.84) 
0.89 
(0.77-1.00) 
CA125  0.90 (0.84-0.95) 
0.81 
(0.71-0.90) 
0.97 
(0.94-1.00) 
0.72 
(0.62-0.81) 
0.67 
(0.57-0.78) 
0.95 
(0.91-1.00) 
CA125 
(35 U/mL cutoff)  
0.80 
(0.73-0.86) 
0.69 
(0.59-0.80) 
0.89 
(0.84-0.94) 
0.71 
(0.64-0.79) 
0.68 
(0.60-0.76) 
0.91 
(0.87-0.95) 
Glc/GalCer: glucosyl/galactosylceramide; Cer: ceramide; LPC: lysophosphatidylcholine; PC: phosphatidylcholine; PI: phosphatidylinositol; TAG: 
triacylglycerol. 
5.4.2 Lipidomic analysis in borderline ovarian tumors 
There were only eight lipids with significant changes in either Charité or Finnish 
cohorts, which showed an alteration in the same direction in both: the 
phosphatidylcholines, the phosphatidyletholamines and sphinganine-1-phosphate. 
Overall, the lipid changes in borderline tumors were minor compared with those in 
overtly malignant tumors. 
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6 DISCUSSION 
Further investigations are still necessary in preoperative OC diagnostics so that early 
diagnosis can improve and lead to better treatment results and survival rates for the 
patients. Serum biomarkers tend to increase as late as in the advanced stages, and the 
possibility of using imaging modalities is restricted in symptomless early-stage 
tumors. 
6.1 Three-dimensional sonography does not seem to offer 
significantly more benefit than two-dimensional sonographic 
scoring methods (Study I) 
Several 2D US-based prediction models and algorithms have been developed since 
the RMI was published in 1990 (Jacobs et al. 1990) in order to improve diagnostics 
of ovarian tumors. The IOTA study is the largest diagnostic study which has first 
standardized morphological and Doppler US features, and secondly collected a large 
database to test and compare former developed models and the subjective 
assessment of an experienced US examiner to novel IOTA US models and 
logarithms, which include simple rules, LR1 and 2 and ADNEX model. These IOTA 
models have been externally validated in various study groups after development and 
internal validation tests to discover the most optimal model for clinicians to triage 
suspected ovarian malignancies for appropriate surgery and on the other hand find 
out the tumors which may be treated conservatively or with minimal invasive surgery 
(Kaijser 2015). 
According to the literature, the benefit of 3D US for the evaluation of ovarian 
tumors is conflicting. The assessment of 3D-PD vascularity has shown some value 
in estimating adnexal masses (Alcazar & Jurado 2011). Our purpose was to collect 
many validated 2D US prediction models and examine if 3D-PD vascular indices 
have advantages alone or together with 2D US models in ovarian tumor 
discrimination. 
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In our series of 100 ovarian tumors, we found that expert opinion possessed the 
best accuracy (90.8%) and specificity (92.4%) in diagnosing ovarian malignancy. 
However, the sensitivities of the IOTA simple rules, LR2 and evaluation of tumor 
vascularity by 2D vascular scores were slightly better than that of expert opinion, 
although they could not achieve the accuracy and specificity of that method. The 
diagnostic performance of the RMI and serum CA125, with accuracies below 80%, 
was poorer than that of the IOTA models. 
Of the 3D-PD vascular indices, the VI and VFI were as accurate as and even 
more specific than LR2 and 2D US evaluation of vascularity, but they were distinctly 
less sensitive. The specificity of the test improved when the VFI was combined with 
the RMI, simple rules and LR2, with a coincidental decrease of sensitivity. 
Another US expert re-evaluated the stored data by giving his opinion of each 
tumor and re-measured the 3D-PD vascular indices. The interobserver agreement 
on the nature of the tumors (expert opinion) and on the 3D-PD measurements was 
very good/good. 
Our results indicating the superiority of subjective assessment by an expert are in 
concordance with a large-scale meta-analysis that proved expert opinion to be the 
best predictive US method in discriminating ovarian tumors preoperatively with a 
pooled sensitivity of 94% and specificity of 85% for postmenopausal women. LR2 
proved to be as good a diagnostic as expert opinion for postmenopausal women in 
this meta-analysis (Meys et al. 2016). When preoperative US examinations were 
performed by examiners with broad and varied experience, the RMI and simple rules 
were more reliable than subjective assessment (Sayasneh et al. 2013). The general 
recommendation is to use the RMI, simple rules and LR2 as a first-stage test and 
refer the unclear or inconclusive tumors for a second-opinion US examination by an 
expert (a two-step strategy). Another two-step strategy (simple rules and expert 
opinion) in a group of 1,049 postmenopausal women led to a sensitivity of 93% and 
specificity of 83% (Testa et al. 2014), which is comparable to our respective results 
of 91% and 85%.  
The 3D-PD vascular indices have been found to be elevated in ovarian 
malignancies (Alcazar et al. 2005), which our study also showed. Our results 
resembled those of a previous study which showed that 3D-PD vascular indices did 
not improve the results of 2D evaluation of vascularity (Silvestre et al. 2015). 
However, that study did not consider the menopausal status of patients. 
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Future studies should concentrate on combining different multimodal risk-
scoring models to test them as screening tests for ovarian malignancies in 
symptomatic and asymptomatic women in large populations. Future IOTA studies 
will include the validation tests for the ADNEX model and the use of MRI and 3D-
PD as a secondary test for inconclusive tumors. There is currently an ongoing large-
scale IOTA-based follow-up cohort study of conservatively treated ovarian cysts. 
The objective of the study is to add information to be used in decision-making 
regarding surgical intervention and on the risks of conservative treatment (Kaijser 
2015). Large-scale multicenter studies are needed to discover the most effective, 
reliable and safe method of making decisions regarding patient treatment and, in the 
future, hopefully also screening.  
6.2 Urinary DiAcSpm as a possible biomarker in ovarian cancer 
(Study II) 
Studies have found elevated levels of polyamines during highly proliferative 
processes such as those occurring in connection with cancer (Bae et al. 2018). They 
exist mainly in acetylated forms in urine (Hiramatsu et al. 1995), and especially 
diacetylated forms increase most in cancer, although their amounts in urine are very 
small (Kawakita et al. 2011; Sugimoto et al. 1995). However, the mechanism for 
elevated urinary polyamines such as DiAcSpm is unclear. It is assumed that the body 
can increase secretion of DiAcSpm as a response to the higher intracellular 
concentrations of DiAcSpm caused by tumor proliferation (Kawakita & Hiramatsu 
2006; Umemori et al. 2010).  
In our study, we used a previously described method, LC-MS/MS, for polyamine 
analysis (Häkkinen et al. 2013). We managed to measure all polyamines 
simultaneously, as opposed to previous studies, which have suffered from 
incomplete polyamine arrays and poor reproducibility. DiAcSpm from the urine of 
ovarian cancer patients was elevated compared with the levels found in women with 
benign ovarian tumors. Although the concentration of DiAcSpm intensifies as the 
cancer advances, even early-stage and low-malignant potential ovarian tumors 
showed higher concentrations than did benign tumors and controls. These novel 
OC results are concordant with previous results from other cancers (Enjoji et al. 
2004; Hiramatsu et al. 2005; Yamaguchi et al. 2005). Our study showed that urinary 
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DiAcSpm was even more sensitive than serum CA125 in distinguishing between 
benign and malignant ovarian tumors.  
In some cancers, DiAcSpm has proved to be not only a diagnostic biomarker, 
but also a prognostic biomarker for evaluating the efficacy of cancer treatment and 
the possibility of recurrence (Casero et al. 2018; Kato et al. 2014). Commercial kits 
for determining urinary DiAcSpm levels are available, which increases the potential 
of DiAcSpm as a non-invasive biomarker also in the early diagnosis of cancer 
(Kawakita et al. 2011). However, DiAcSpm is not a tumor-specific marker, as it may 
be elevated also in some benign proliferative processes (Kawakita & Hiramatsu 
2006).  
Polyamines seem to amplify the progression of cancer by increasing the 
metastatic capability of cancer cells and inhibiting the immune response against 
tumors (Soda 2011). Thus, one potential target of future anti-cancer treatment could 
be to diminish the polyamine uptake by cells, as an inhibition of polyamine synthesis 
by DFMO has had some preliminary efficacy in clinical trials (Alexiou et al. 2017; 
Murray-Stewart et al. 2016).  
6.3 Detection of volatile organic compounds from urine of 
ovarian cancer patients is possible with the aid of FAIMS 
(Study III) 
In canine studies, it has been discovered that cancers may have distinct odors that 
can be detected by dogs. The source of odors characteristic to cancer is released into 
the surrounding air in the form of VOCs (Lippi & Cervellin 2012). Tissue and blood 
samples from OC patients were also detected by trained dogs with a good sensitivity 
and specificity (G. Horvath et al. 2008; G. Horvath et al. 2010; G. Horvath et al. 
2013). These studies demonstrate that also OC may have its own distinct smell. 
Nevertheless, training of canines is time-consuming and the validation of studies also 
rather difficult. Therefore, more effortless and validated methods for the artificial 
recognition of VOCs have been developed for clinical use. 
Further studies generated technical counterparts such as the eNose to mimic the 
olfactory system and detect VOCs. Several studies have been published on various 
eNose applications aimed at detecting different cancers from exhaled breath, urine 
and blood (Bernabei et al. 2008; Turner & Magan 2004; Xue et al. 2008). Also OC 
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was identified from tissue and breath samples using the eNose (G. Horvath et al. 
2010) and nanoarray analysis (Amal et al. 2015).  
FAIMS is a special variant of ion mobility spectrometry based on measurements 
of the different movements of ionized molecules in samples in very high electric 
fields. It provides a qualitative spectrum derived from the complex chemical 
structures found in biological samples. Compared to the traditional eNose apparatus, 
FAIMS is more reproducible and sensitive. Also, FAIMS technology is better suited 
for portable equipment, which is beneficial for practical use (Arasaradnam et al. 
2014; Arasaradnam et al. 2018). 
Our third study demonstrated the potential of FAIMS in distinguishing urine 
from women with OC from controls and women with benign ovarian tumors. The 
sensitivity was good (91.2% and 91.5% respectively) but the specificity was weaker 
– improving, however, when only high-grade tumors were being distinguished from 
controls and benign tumors. FAIMS also seemed to differentiate urine from patients 
with low- and high-grade ovarian tumors. Our study reproduced the feasibility of 
using FAIMS for cancer detection in urine that was shown in previous positive 
results from patients with colorectal and pancreatic cancers (Arasaradnam et al. 2014; 
Arasaradnam et al. 2018).  
Future research should explore the potential of FAIMS in using urine samples to 
monitor the effect of therapy and recognize any recurrences of cancer after 
treatment. As a sensitive and non-invasive method, the FAIMS analysis of urine 
could even have potential as a screening method. First, however, a large collection 
of data from urine samples of OC patients should be analyzed to form a database.  
6.4 Lipidomic changes in blood occur even in early stages of 
ovarian cancer (Study IV) 
Many cancers cause the same metabolic changes in order to provide more energy for 
the abnormally rapid growth and proliferation of cancer cells (Currie et al. 2013). 
Metabolic profiling of blood and tissue samples from OC patients has been 
performed to identify the main metabolic pathways in OC: these investigations have 
shown alterations also in lipid metabolism (Buas et al. 2016; Denkert et al. 2006; 
Fong et al. 2011; Ke et al. 2015). A study by Braicu et al. (2017) showed specific lipid 
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changes in blood from HGSOC patients. Study IV was conducted to validate those 
results at an early-stage and in non-HGSOC, or in endometrioid and mucinous OC. 
Our results are in line with earlier studies showing that levels of most of the 
analyzed lipids were decreased in OC (Bachmayr-Heyda et al. 2017; Buas et al. 2016). 
Only some Cers and TAGs showed higher levels in the blood samples from OC 
patients. Study IV confirms that levels of Cer(d18:1/18:0), Cer(d18:0/18:0) and 
TAG(18:1/18:1/20:4) are higher even in the early stages (Stages I-II) of OC, but 
their concentrations intensify further in the advanced stages (Stages III-IV). Levels 
of Cer(d18:1/18:0) and TAG(18:1/18:1/20:4) were elevated not only in serous but 
also in mucinous and endometrioid OCs. 
Earlier results from other studies of lipids in OC vary, but phospho- and 
sphingolipids have been studied most. Phospholipids form the cellular membrane 
and take part in cellular signaling (Pyragius et al. 2013). Sphingolipids, especially Cers, 
induce apoptosis and may thus affect cancer development (Hajj et al. 2015). In 
pathway analysis, glycerophospholipid metabolism proved to be the main 
dysregulated pathway in OC, but also glycerolipid (including TAGs) and 
sphingolipid metabolism was altered (Y. Zhang et al. 2016). There is evidence that 
levels of some glycerophospholipids are elevated in localized cancer but decreased 
in advanced cancer (Jones et al. 2015). This could be explained by the excess 
consumption of lipids by rapidly growing tumors or the decrease of HDL in the 
blood of OC patients (Sun et al. 2016), while glycerophospholipids occur abundantly 
precisely in HDL particles (Hilvo et al. 2018). However, this phenomenon does not 
elucidate why there is an increase of some lipid species in OC and indicates that there 
must be some indeterminate mechanisms. 
We are not aware of other such extensive lipid analyses from OC patients. As a 
validation study, this study shows that lipid alterations exist at all stages of OC, and 
also in endometrioid and mucinous carcinomas other than HGSOC both in pre- and 
postmenopausal subjects. Lipid combinations combined with CA125 improved 
especially the detection of Stage I or II OCs, and could provide possible diagnostic 
and prognostic biomarkers for OC in the future. 
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6.5 Strengths and weaknesses  
The population in Study I consisted of one hundred women with adnexal tumors 
which were evaluated preoperatively by various US methods. The study group was 
small when one takes into account the fact that many validation studies of US 
methods include hundreds or thousands of patients with ovarian tumors. In addition, 
some of the US methods were originally not intended for use as preoperative 
differential diagnostics tools for expert US examiners but, rather, for the triage of 
adnexal tumors by non-expert examiners. However, in Study I, all of the patients 
were examined by the same US examiner. To our knowledge, there are no previous 
publications that include so many different US methods used on the same patients. 
In addition, another expert evaluated the same data blindly afterwards, and the 
agreement on results by these two examiners was good. However, one US examiner 
made a subjective evaluation of the tumor from real-time US and the other from 
saved static US images. It has been shown that real-time diagnosis is more accurate 
than a diagnosis based on static images (Van Holsbeke et al. 2008). We estimated 
tumor vascularity by calculating 3D-PD vascularity indices from the entire tumor. 
Other possible methods could have been to assess vascularity only from solid 
vascularized areas (Alcazar et al. 2005) or to use automatic spherical sampling from 
the most vascularized areas (Jokubkiene et al. 2007). Our method may have 
influenced the results in the case of large cystic tumors which are not entirely 
vascularized. However, it has been shown that the size of the calculated spherical 
area does not affect the 3D-PD indices (Kudla & Alcazar 2010). 
In Study II, we were the first to publish a standardized analysis of 12 polyamines 
in a single run with urine samples of women with ovarian tumors. The results should 
be regarded as interesting even though they are preliminary, but also the availability 
of this non-invasive method should increase interest in future validation studies in 
larger study populations.  
The strength of Study III lies in its proof-of-concept nature, which makes the 
results more interesting and may even offset the quite-small size of its study 
population. Another advantage of Study III is its non-invasive nature and good 
sensitivity, which is as yet the first known study to use FAIMS technology in the 
differential diagnostics of ovarian tumors. We have only found two earlier published 
studies that utilized FAIMS technology in cancer detection (Arasaradnam et al. 2014; 
Arasaradnam et al. 2018). The disadvantage of Study III is the long storage time of 
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the urine samples before analysis: this may have had an influence on VOC emissions 
and thus on the final results, according to a British study (Esfahani et al. 2016). The 
black box-approach of FAIMS analysis makes the interpretation of the result 
challenging for the clinician. In order to validate the method for clinical use, 
considerable emphasis should be given on evaluation of the repeatability of the 
method. This underlines the need of a rigorous study on the analytical performance 
of the technology that could be conducted with a reference sample that is created by 
spiking pooled urine with known concentrations of target molecules or creating a 
completely artificial sample that could be used as reference for the method. 
It would have been ideal to use the same study population in Studies I, II and III 
(and partly in Study IV as well). However, Study I included only tumors with a 
maximum diameter of 10 cm because the entire tumor had to fit into the transvaginal 
scan. Studies II-IV had no limitations as to the size of the tumor, and they also 
included women with advanced OC with ascites. 
Studies I-III featured relatively many non-epithelial OCs and low malignant 
potential ovarian tumors as well, making the study group heterogenous, and this may 
have influenced the results. However, in Studies II and III, the differences in results 
were seen between women with low malignant potential and benign ovarian tumors 
and not only in women with advanced OC. 
Studies I-III included women who were at least 50 years old, but their menopausal 
status was not confirmed by laboratory measurements. However, women whose last 
menstrual periods had occurred more than six months previously were classified as 
postmenopausal. Study IV included also women of fertile age. Consequently, the 
different preoperative evaluation methods or potential biomarkers used in our 
studies cannot be directly compared with each other. As mentioned above, the best 
option in comparing the accuracy of the methods would have been to have the same 
large study group in Studies I-III. As it is, only a few women were in all of these 
three studies. 
In Study IV, we were able to validate previously published lipid changes in the 
serum of patients with HGSOC (Braicu et al. 2017) in a larger and more 
heterogenous study population, which showed that the lipidomic alterations in OC 
are seen also beyond HGSOC. Study data sets consisted not only of serum samples, 
but also plasma ones, but the lipid changes we discovered did not differ in the plasma 
dataset compared with the serum cohorts. Neither serum lipoprotein levels nor body 
mass index scores in the study population were available, and they may have had 
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some effect on lipid results in blood. Also, the blood samples were not collected 
from patients in a fasting condition, but we assumed that the differences in lipid 
alterations between patients with OC and with a benign tumor would have been even 
greater in fasting samples. However, we had study cohorts from Finland and 
Germany, and the lipid alterations were apparent in all cohorts, which means that 
the results may be generalizable. 
6.6 Future prospects 
Future areas of investigation could include a combination of urinary DiAcSpm 
analysis and FAIMS technology to discover whether elevated DiAcSpm levels 
correlate with the FAIMS results. On the other hand, it would be relevant to 
compare urine polyamines, especially DiAcSpm, with serum lipidomic analysis to see 
whether the main lipidomic changes in serum correlate with the increase in 
DiAcSpm levels in urine, and whether these two together, combined with serum 
CA125, would improve the diagnostic value of CA125. 
Currently, US findings with serum CA125 are the main diagnostic tools used to 
estimate ovarian tumor malignancy. In future, it should be studied whether urinary 
DiAcSpm alone or serum lipidomic changes alone or whether they together 
combined with US findings would be more sensitive and specific than CA125. 
To organize these studies, a large population of women with ovarian tumors 
should be recruited and systematically examined by US, with serum and urine 
samples collected from them as well.  
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7 SUMMARY AND CONCLUSIONS  
The goal of this study was to evaluate the performance of traditional US methods in 
the preoperative diagnostics of adnexal masses, and to search for novel biochemical 
and biophysical methods to be used in addition to or instead of traditional US. To 
accomplish this, we evaluated the benefit of 3D-PD examination added to 
conventional 2D US, serum CA125 and various 2D US scoring methods in the 
preoperative discrimination between benign and malignant ovarian masses (Study I). 
In addition, preoperative urine samples from controls and from women with benign 
and malignant ovarian tumors were analyzed using LC-MS/MS to detect polyamines 
and compare their concentrations across study groups (Study II). A novel method 
using FAIMS technology was assessed to detect ovarian malignancies from 
preoperatively collected urine samples (Study III). Finally, the lipidomic alterations 
in early- and advanced-stage OC and in various histological subtypes were examined 
from preoperative blood samples (Study IV). 
The main findings and conclusions of this Thesis are as follows: 
1. Clinical expert opinion based on 2D US examination discriminates best 
between malignant and benign ovarian tumors, with an accuracy of 90.8%, a 
sensitivity of 87.5% and a specificity of 92.4%. The diagnostic value of 3D-
PD vascular indices is not significantly better than the RMI. Adding 3D-PD 
indices to the RMI and other 2D US scoring methods does not provide any 
noticeable improvement. 
2. Six mono- and diacetylated polyamines were found in all urine samples, but 
only urinary concentrations of DiAcSpm showed significant elevation (p 
<0.001) in women with malignant ovarian tumors compared with benign 
ovarian tumors and controls. 
3. VOC analysis of urine with FAIMS technology is able to discriminate women 
with ovarian malignancy from controls and women with benign ovarian 
tumors with accuracies of 81.3% and 77.3%, respectively. 
4. There were parallel alterations in 39 lipids which exist both at early- and late-
stage OC. Mostly, these lipid changes are significant as early as in Stages I and 
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II, but intensify as the cancer advances. Twenty-three of those lipids were 
altered, not only in serous but also in mucinous and endometrioid OC. The 
addition of lipids or lipid ratios to serum CA125 increased the AUC values, 
especially in the case of early-stage OCs.  
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Reliability of preoperative evaluation of
postmenopausal ovarian tumors
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Abstract
Background: Preoperative evaluation of ovarian tumors is challenging. This study was undertaken to evaluate the
performance of conventional two-dimensional (2D) ultrasound and CA125 in predicting malignant or benign nature
of pelvic masses, and to investigate if three-dimensional power Doppler (3DPD) ultrasound provides any added
value. Ninety-six postmenopausal and four perimenopausal women with supposed ovarian tumors were examined
by standardized 2D and 3DPD ultrasounds preoperatively. The tumors were evaluated using the risk of malignancy
index (RMI), International Ovarian Tumors Analysis (IOTA) group simple rules, expert opinion, IOTA logistic regression
model 2 (LR2) and 3D vascular indices, and were postoperatively compared to histopathological results.
Results: Ninety-eight tumors turned out to be ovarian in origin. Of these, 66 were benign and 32 malignant. RMI
(cut-off value 200), simple rules, expert opinion and LR2 (cut-off value 25) were used to predict malignant nature of
the tumors and had sensitivities of 71.9, 90.6, 87.5 and 90.6%, and specificities of 80.3, 84.6, 92.4 and 77.3%, respectively.
When the 3D vascularization flow index (VFI) was added to RMI and LR2, the accuracy of the test improved from 77.6
to 81.4% and from 81.6 to 86.5%, respectively, at the expense of sensitivity, while VFI gave no added benefit for simple
rules and expert opinion. Agreement between two examiners using expert opinion was good (Cohen’s kappa = 0.89).
Conclusions: The subjective opinion of an expert seems to be the most reliable method in assessing ovarian tumors,
and the 3DPD indices seem to provide no significant added value.
Keywords: Expert opinion, IOTA LR2, IOTA simple rules, Ovarian cancer, Ovarian tumor, Power doppler, Three-
dimensional ultrasound
Background
Ovarian cancer has the leading mortality rate of all
gynecological cancers, and the incidence of ovarian can-
cer is at its peak among postmenopausal women. The
optimal treatment of ovarian neoplasms requires correct
preoperative characterization of tumors. The surgical
treatment of ovarian cancer should be reserved for
gynecological oncologists, while benign tumors can be
operated on less radically by general gynecologists, or
even managed conservatively.
Preoperatively ultrasound features combined with the
measurements of CA125 has been used to predict the
malignancy of a pelvis mass (Risk of Malignancy Index,
RMI) since early 1990’s [1]. However, subjective assess-
ment by an experienced ultrasound examiner has been
considered to be the best diagnostic method for ovarian
tumors [2, 3]. While not all gynecologists are so well ac-
customed to ultrasound examinations, in 2008 the Inter-
national Ovarian Tumors Analysis (IOTA) group
presented simple ultrasound-based rules that include
five rules for predicting malignant tumors (M-rules) and
five for predicting benign tumors (B-rules). If one or
more M-rules with absence of B-rules or B-rules with
absence of M-rules are present, the tumor is supposed
to be malignant or benign, respectively. In a multicenter
study, these rules were applicable for 76% of all tumors
and showed a sensitivity of 95% and specificity of 91%
[4]. If none of the rules is valid or if both M- and B-rules
are present, a tumor is considered to be inconclusive
[4, 5]. In that case the opinion of an expert ultra-
sound examiner is needed, which is called a two-step
strategy [6]. In addition, the IOTA group developed
two logistic regression models (LR1 and LR2) [7].
LR1 is based on 12 different variables, and LR2 is
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based on 6, including patient history, clinical signs
and ultrasound features. These models have shown
sensitivities of 92–95% and 89–95% with specificities
of 74–87% and 73–86% in detecting ovarian malig-
nancies, respectively [8]. Nevertheless, in several stud-
ies, the impression of an expert ultrasound examiner
has still been considered to be the best method, or at
least equivalent to LR1 and LR2, for diagnosing ovar-
ian pathology [8, 9].
An increased density of microvessels and abnormal
vascular tree of the tumor are characteristic of malignant
ovarian processes [10, 11]. These phenomena have given
new insight for the use of three-dimensional (3D) ultra-
sound and 3D power Doppler (3DPD) in evaluating the
vascularization of ovarian tumors to discriminate be-
tween benign and malignant tumors. Unfortunately,
there are no clear cut-off rules for 3D ultrasound fea-
tures, limiting their clinical utility [12].
The purpose of this study was to examine if 3DPD
ultrasound can offer additional benefits over conven-
tional two-dimensional ultrasound and other diagnostic
methods as a useful tool for predicting malignancy of an
adnexal mass. The aim was to find the most applicable
and reliable preoperative diagnostic approach for post-
menopausal women.
Methods
Between February 2011 and November 2014, one hun-
dred women over 50 years of age presenting with an ab-
normal adnexal mass(es) at the Department of
Obstetrics and Gynecology of Tampere University Hos-
pital, were recruited to the study. All patients were des-
tined for surgery. Overtly benign or malignant looking
tumors like unilocular simple ovarian cysts and tumors
associated with marked ascites (depth of the greatest
pool over 10 cm) were excluded. In principle, the max-
imum allowed diameter of the tumors was 10 cm, allow-
ing the entire tumor to be assessible transvaginally.
However, there were five tumors, the maximum diam-
eter of which exceeded 10 cm at the final examination,
but it never exceeded 12 cm.
According to preoperative findings, the patients were
operated on by either a gynecological oncologist or a
general gynecologist, using either laparoscopic or open
technique.
The patients were assessed within 2 weeks prior to
surgery by vaginal two-dimensional (2D) and 3D ultra-
sound examination with power Doppler. In the case of
bilateral ovarian tumors, both masses were examined,
and the more complex tumor was assessed for the study.
All ultrasound examinations were performed by an
experienced gynecologist or the author R.J.N., using a
Voluson 730 Expert unit (GE Medical Systems, Zipf,
Austria) with a multifrequency transvaginal transducer
(5–9 MHz). A normal B-mode ultrasound assessment
included the calculation of the size of the adnexal mass.
The power Doppler settings were standardized: fre-
quency, 6 MHz; power Doppler gain, -0.6; wall motion
filter (WMF), low 1; pulse repetition filter (PRF),
0.6 kHz. The extent of vascularization of the tumor was
described by a score from 1 to 4 (1 = no blood flow de-
tected, 4 = high blood flow detected) [13]. 3DPD was
used to examine the ovarian tumor after the 2D evalu-
ation. The acquisition sweep angle was set to 85°.
A serum sample was obtained preoperatively, and RMI
was calculated by using the original formula of Jacobs et
al. in which the serum CA125 level, ultrasound scan re-
sult and patient’s menopausal status are taken into ac-
count [1]. The ultrasound data were stored on a hard
disk for later evaluation. Based on the ultrasound exam-
ination, the examiner classified the adnexal tumor as be-
nign or malignant (expert opinion), immediately
following the actual examination. From the 2D data, the
tumors were classified by using the IOTA simple rules.
If none of these rules applied or if both M- and B-rules
were applicable, the tumor could not be classified. In
such case, the tumor was evaluated subjectively by the
examiner as benign or malignant.
The IOTA LR2 was implemented by using the Predict-
ive IOTA models for ovarian cancer application soft-
ware, version 2013 (App for IOS operating systems). In
the LR2 model, the six variables used are age of the pa-
tient, presence/absence of ascites, presence/absence of
papillations/papillary projections with blood flow, max-
imum diameter of the largest solid component, irregular
cyst walls and presence/absence of acoustic shadows.
This calculated model yields the probability of malig-
nancy of an ovarian tumor.
The analyses of the stored 3D volumes were per-
formed by the same investigator (R.J.N.) using a virtual
organ computer-aided analysis (VOCAL™) imaging pro-
gram and 4D-View software (GE Healthcare, v 9.1). The
volume of each adnexal tumor was measured by manual
delineation of the contour of the mass with a 15°-rota-
tion step. Using the VOCAL software’s histogram fea-
ture, three vascular indices were calculated from the
adnexal tumors: vascularization index (VI), flow index
(FI) and vascularization flow index (VFI). VI represents
the number of vessels in the studied volume and is
expressed as a percentage. FI reflects the intensity of
blood flow at the time of the 3D sweep. VFI is inter-
preted to be a combination of VI and FI representing
both vascularization and blood flow. FI and VFI are
expressed as values ranging from 0 to 100 [12, 14, 15].
To estimate the interobserver agreement, another ex-
perienced ultrasound examiner (S.K.S.) re-evaluated the
stored ultrasound data and classified the malignancy of
tumors (expert opinion), and analysed 3D volumes.
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The ultrasound examinations and off-line assessments
were performed blinded for each other’s results and the
histopathological diagnoses while analyzing the tumors.
The preoperative findings were finally compared to post-
operative histopathological diagnoses. For the purpose of
this analysis, the borderline and low grade ovarian tu-
mors were classified as malignant because normally also
they are staged surgically. All participants gave their in-
formed consent to the study, which was approved by the
Ethics Committee of Tampere University Hospital (ETL
R10080, 6 August 2010).
Statistical analysis
No sample size calculation was performed due to the
preliminary descriptive nature of this study. All data
were analyzed using IBM SPSS Statistics for Windows,
version 22 (Armonk, NY, IBM Corp.). The normality of
the distributions of continuous variables was evaluated
by Kolmogorov-Smirnov tests. Due to the skewness of
the distributions, the comparisons of groups were per-
formed using Mann-Whitney U-tests, and correlations
were evaluated using Spearman’s correlation tests. Re-
ceiver operating characteristics curves (ROC) were used
for evaluating the performance of serum CA125, RMI,
LR2 and 3D vascular indices as predictive tests for
malignancy. The best cut-off values of the models were
calculated in consideration of sensitivity, specificity,
positive predictive value and negative predictive value.
Binomial variables were evaluated by Fischer’s exact tests
or Pearson Chi-Square tests when appropriate.
The agreement of ultrasound features by both ultra-
sound examiners (R.J.N. and S.K.S.) was estimated by cal-
culating the Cohen’s kappa index. A kappa value of less
than 0.20 indicates poor agreement, 0.21–0.40 moderate
agreement, 0.61–0.80 good agreement and 0.81–1.00 very
good agreement [16]. Interobserver agreement of 3DPD
indices were analyzed by related-samples Wilcoxon signed
rank test.
Results
In 100 patients with supposed adnexal masses, the
tumors of 98 patients turned out to be true ovarian
tumors, while the remaining two were appendiceal in
origin. Of the 98 ovarian tumors, sixty-six (67.3%) were
benign, of which 19 were bilateral. Respectively, 32
(32.7%) of the tumors were malignant, of which six were
bilateral. Of the malignant tumors, 17 were epithelial
serous, five epithelial mucinous, and eight of other path-
ology. Two of the malignant tumors were metastases of
intestinal cancer. The histologic diagnoses of adnexal
masses are presented in Table 1.
The median age of the patients was 61 (range, 50–84)
years. Tumor pathology did not depend on the age of
the women or the bilaterality of the tumors. Three of
the women in the benign ovarian tumor group and one
in the malignant group were in fact perimenopausal, be-
cause they had experienced menstrual bleeding during
the previous 6 months. Systemic hormone replacement
therapy was used before surgery by 17 women with be-
nign tumors and by five with malignant tumors. The
median body mass index was 26 (range, 20–44) for
women with benign tumors and respectively 27 (range,
19–39) for women with malignant tumors. The median
diameters of the tumors in the groups were 6 (range,
3–11) and 7 (range, 3–12) cm, respectively. The me-
dian serum CA125 levels were 15 (range, 6–127) and
50 (range, 9–3195) kU/L, respectively, and the differ-
ence between the groups was significant (p < 0.001).
The calculated median values of RMI for benign and
malignant cases were 99 (range, 10–1143) and 360
(range, 27–7488), respectively (p < 0.001). The age of
the patients, body mass indexes and CA125 levels did
not correlate with each other.
The performances of the assessed methods are given
in Table 2. Seventy-six (77.6%) of the tumors were
Table 1 Histology of the tumors
Histologic type Number Percent
Benign 66 (67.3)
Serous cystadenoma/adenofibroma 39
Fibroma/thecoma 5
Teratoma 7
Brenner tumor 1
Endometrioma 3
Mucinous cystadenoma 3
Serous/hemorrhagic cyst 7
Bizarre leiomyoma 1
Malignant 32 (32.7)
Epithelial tumors
Serous
High grade 9
Low grade 3
Borderline 5
Mucinous
Adenocarcinoma 3
Borderline 2
Clear cell carcinoma 1
Carcinosarcoma 2
Non-epithelial tumors
Granulosa cell tumor 4
Sertoli-Leydig cell tumor 1
Metastatica 2
Total 98 (100.0)
aPrimary tumors: sigmoid carcinoma and carcinoma of the appendix
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classifiable using the simple rules, and 68 of these
(89.5%) were correctly classified. Incorrectly classified
tumors were all false-positive malignant tumors, and
their histopathological diagnoses were serous cystade-
noma/-fibroma (n = 4), thecoma (n = 2), one serous cyst
and one Brenner tumor each. The unclassifiable tumors
(n = 22) were evaluated by expert opinion (R.J.N.), and
77.3% (17 of 22) were classified correctly.
The opinions of the experts (R.J.N. and S.K.S.) differed
in five cases, including two serous and one mucinous
cystadenoma, one teratoma, and one benign Brenner
tumor. In addition, both experts failed in the case of two
malignant tumors: one endometrioid adenocarcinoma
FIGO Stage IA and one granulosa cell tumor. Two ser-
ous borderline cystadenomas were erroneously classified
as benign. The interobserver agreement of the malig-
nancy of tumors between both examiners was very good
(Cohen’s kappa = 0.89, 95% CI 0.79–0.98; percentage of
agreement of correct classification = 87.8%).
The tumor vascularity as examined by 2D ultrasound
was higher in malignant tumors compared to benign tu-
mors (p < 0.001). Predictions of tumor malignancy by
scoring the vascularity yielded the same sensitivity
(90.6%) as the simple rules with the expert opinion and
LR2 with a cut-off value of 25. In comparison, 81.6% (80
of 98) of the tumors were classified correctly by vascu-
larity assessment and LR2 (with a cut-off value 25),
whereas the expert opinion correctly diagnosed 90.8%
(89 of 98) of the cases. LR2 values and 3D vascular indi-
ces (VI, FI and VFI) were significantly different between
benign and malignant tumors (p < 0.001). VI and VFI
were the most sensitive and specific 3DPD indices
(Table 3), being at least as specific as RMI, simple rules
and LR2 in detecting malignant tumors. The subjective
evaluation of tumor vascularity by 2DPD was more sen-
sitive and almost as specific and accurate as 3DPD vas-
cular indices. When 2D vascularity scoring or LR2 was
combined to simple rules with the expert opinion, the
Table 2 Diagnostic performances of different methods at various cut-off values in detecting ovarian malignancy
Diagnostic method
Cut-off value
Sensitivity
%
95% CI Specificity
%
95% CI PPV
%
95% CI NPV
%
95% CI Accuracy
%
Serum CA125 (kU/L)→ Area under the ROC curve = 0.80
24 71.9 53.3–86.3 78.8 67.0–87.9 62.2 44.8–77.5 85.3 73.8–93.0 76.5
35 59.4 40.6–76.3 84.9 73.9–92.5 65.5 45.7–82.1 81.2 69.9–89.6 76.5
RMI→ Area under the ROC curve = 0.81
200 71.9 53.3–86.3 80.3 68.7–89.1 63.9 46.2–79.2 85.5 74.2–93.1 77.6
220 71.9 53.3–86.3 83.3 72.1–91.4 67.7 49.5–82.6 85.9 75.0–93.4 79.6
Simple rules with expert opiniona 90.6 75.0–98.0 84.6 73.9–92.5 74.4 57.9–87.0 94.9 85.9–98.9 86.7
Expert opinion 87.5 71.0–96.5 92.4 83.2–97.5 84.6 68.1–94.9 93.9 85.0–98.3 90.8
Tumor vascularityb 90.6 75.0–98.0 77.3 65.3–86.7 65.9 50.1–79.5 94.4 84.6–98.8 81.6
LR2 (%)→ Area under the ROC curve = 0.93
10 100.0 89.1–100.0 36.4 24.9–49.1 43.2 31.8–55.3 100.0 85.8–100.0 57.1
25 90.6 75.0–98.0 77.3 65.3–86.7 65.9 50.1–79.5 94.4 84.6–98.8 81.6
43 81.3 63.6–92.8 90.9 81.3–96.6 81.3 63.6–92.8 90.9 81.3–96.6 87.8
IOTA International Ovarian Tumor Analysis; CI Confidential interval; PPV Positive predictive value; NPV Negative predictive value; ROC Receiver operating
characteristics; RMI Risk of malignancy index; LR2 Logistic regression model 2
aTwo-step strategy: as a result of inconclusive findings by simple rules, the expert evaluates the tumor
bTwo-dimensional ultrasound vascular score 1-2 vs 3-4
Table 3 Diagnostic performances of three-dimensional power Doppler indices at different cut-off values in detecting ovarian malignancy
3DPD indices
Cut-off value
Sensitivity
%
95%
CI
Specificity
%
95%
CI
PPV
%
95%
CI
NPV
%
95%
CI
Accuracy
%
VI (%)→ Area under the ROC curve = 0.86
1.00 67.7 48.6–83.3 90.9 81.3–96.6 77.8 57.7–91.4 85.7 75.3–92.9 83.5
FI→ Area under the ROC curve = 0.72
30 83.9 66.3–94.6 51.5 38.9–64.0 44.8 31.7–58.5 87.2 72.6–95.7 61.9
VFI→ Area under the ROC curve = 0.87
0.31 71.0 52.0–85.8 89.4 79.4–95.6 75.9 56.5–89.7 86.8 76.4–93.8 83.5
3DPD Three-dimensional power Doppler; CI Confidential interval; PPV Positive predictive value; NPV Negative predictive value; ROC Receiver operating characteristics; VI
Vascularization index; FI Flow index; VFI Vascularization flow index
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specificity slightly increased, albeit at the expense of
sensitivity (data not shown).
The interobserver agreement between the two experts
was good also in the case of calculated 3DPD indices, as
shown in Table 4.
By combining RMI and LR2 with VFI and using suit-
able cut-off values, the accuracies and specificities of
RMI and LR2 improved, while their sensitivities de-
creased. On the other hand, combining these 3DPD
indices with simple rules or the expert opinion did not
improve either method’s accuracy. Newly created com-
bination models are given in Table 5.
Discussion
To the best of our knowledge, this is the first study to
compare such a large spectrum of various preoperative
methods (serum CA125, RMI, simple ultrasound rules,
expert opinion, 2DPD and IOTA LR2) along with 3DPD
indices for discrimination between benign and malignant
ovarian tumors. The results of the present study imply
that clinical expert opinion still provides the best
method for diagnosing malignant ovarian tumors, with
no additional benefit provided by use of 3DPD indices.
Regarding the specificity of 3DPD indices, VI and VFI
are only as specific as the traditional methods CA125
and RMI, but the combination of them with LR2 and
RMI provides a clear improvement of specificity, but
unfortunately at the expense of sensitivity.
The present results regarding the superiority of ex-
pert opinion are in accordance with previous studies.
Timmerman et al. [5] found in their prospective study
comparing IOTA-based simple rules, LR1 and LR2,
and subjective assessment of the sonologist that ex-
pert’s opinion is either better or equivalent to the
scoring systems.
A weakness of this study is the rather small number of
patients, but on the other hand, all the patients were ex-
amined by the same investigator, which in turn can be
considered to be an advantage. Moreover, the data was
assessed by another examiner yielding a very good agree-
ment between both examiners. Another advantage is a
quite homogenous patient population, with only four
perimenopausal women among 96 postmenopausal pa-
tients. A potential bias of the study is that although RMI
was originally developed as a triage test for use by a less
experienced ultrasound examiner to predict the malig-
nancy of a tumor, in this study it was rather used by an
ultrasound expert in parallel with simple rules and LR2
designed to triage patients who should be operated on
by a gynecologic oncologist [5, 8]. The main rationale
for including also RMI was to provide a reader less expe-
rienced in ultrasound, with a familiar comparator for the
more specific triage methods.
CA125 is widely used as a tumor marker for epithelial
ovarian cancer. It is quite accurate among postmeno-
pausal women, while the relatively great number of
false-positive results limits its utility in premenopausal
setting. Our cut-off value was 35 kU/L, whereas some
reports have used lower cut-offs, which might explain
the lower sensitivity of CA125 (59.4%) in our study. In a
review article on seven studies, the pooled sensitivity
and specificity of CA125 in postmenopausal women
were 85.9 and 85.2%, respectively [17]. We also tested a
lower cut-off value of 24 kU/L, which clearly improved
sensitivity, while somewhat weakening specificity.
In their original study, Jacobs et al. described a sensi-
tivity of 85% and a specificity of 97% for a RMI cut-off
level of 200 [1]. A review of RMI on 13 studies showed
that for a cut-off level of 200, the pooled estimate for
sensitivity was 78% (95% CI 71–85%) and for specificity
was 87% (95% CI 83–91%), which is still better than in
our study [18]. The reason for this may be our rather
limited sample size, or the fact that the majority of the
malignant tumors were of low malignant potential i.e.
borderline epithelial, granulosa and Sertoli-Leydig cell
tumors, which may have contributed to the less-than-
optimal performance of RMI.
An IOTA-based protocol classified a woman as being
at high risk for ovarian malignancy if the estimated LR2
risk was at least 25%, at intermediate risk if LR2 was be-
tween 5 and 25% and at low risk if LR2 was below 5%
[19]. It has been presumed that the LR2-based protocol
is more accurate than the RMI-based protocol, and is
recommended to be used instead of RMI in discriminat-
ing ovarian tumors and concluding treatment protocols
[19]. In the multicenter study of Testa et al., LR2 and
RMI achieved AUC values of 0.90 and 0.85, respectively
in 1,049 postmenopausal patients [6]. The corresponding
AUC values in the present study were quite similar, 0.93
and 0.81. We argue that LR2 ≥ 25% risk is the most prac-
tical value in clinical work because in our study it
achieved a negative predictive value of 94.4%.
Different preoperative scoring systems of ovarian tu-
mors were evaluated in the meta-analysis of Kaijser et al.
The pooled sensitivity and specificity of simple rules in
five validated studies were found to be 93 and 81%,
Table 4 Interobserver agreement between two experts using
three-dimensional power Doppler (3DPD) indices
3DPD
indices
Expert opinion 1 Expert opinion 2 p-valuea
Median
(25–75% quartiles)
Median
(25–75% quartiles)
VI 0.337 (0.069–1.098) 0.259 (0.066–0.894) 0.151
FI 31.796 (25.308–35.821) 31.693 (26.351–36.638) 0.839
VFI 0.112 (0.019–0.397) 0.079 (0.019–0.292) 0.257
3DPD Three-dimensional power Doppler; VI Vascularization index; FI Flow
index; VFI Vascularization flow index
aCalculated by related-samples Wilcoxon signed rank test
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respectively [20]. However, the inconclusive cases were
assessed to be malignant, which differs from our study
where in the inconclusive results obtained by the simple
rules protocol, the tumors were subjectively classified as
being either benign or malignant by the same examiner.
This is described as a two-step strategy [6]. In our data
85/98 of tumors were classified correctly by using this
two-step strategy. Only three of 13 incorrectly classified
tumors were false negative, or they were malignant al-
though they were classified as benign. We reached
equivalent results as the meta-analysis by Testa et al.,
which yielded a sensitivity of 93% and specificity of 83%
for the two-step strategy in postmenopausal women [6].
Our results are also in line with a large database of
IOTA studies which has shown that the pattern recogni-
tion by an experienced clinician is the best method in
assessing ovarian tumors [8]. Recently, Piovano et al.
showed that when serum CA125 was added to simple
rules with subjective assessment for diagnosing ovarian
tumors, the diagnostic accuracy increased, with an ac-
ceptable cost/benefit ratio [21].
In recent years, several studies have been published,
where 3D ultrasound assessment has been used in
gynecological cancers, including ovarian cancer. It has
been shown that 3DPD vascular indices are elevated in
malignant ovarian tumors [22]. Jokubkiene et al. also
found this difference, but quantitative 3DPD indices of
an ovarian tumor measured by another expert did not
add any significant information to subjective quantita-
tion by the original examiner of 2DPD findings [23].
Similarly, Guerriero et al. reported that 3DPD indices
failed to improve accuracy as a secondary test for ovar-
ian tumors alongside the evaluation of central
vascularization by 2DPD [24]. On the contrary, Geomini
et al. found that 3D ultrasonography significantly im-
proved the discrimination of ovarian pathology, when
they compared 2D to 3D ultrasound models [25]. Two
methods of vascular sampling, manual [22] and spherical
[23], have been purported to be alternatives to measur-
ing the vascularity of the whole tumor, but based on our
experience, the entire tumor should be taken account. In
support of this, Kudla and Alcazar have shown that the
size of the sphere volume does not affect power Doppler
indices [26].
Our results do not differ from those of the only previ-
ous study that compared simple rules and 3DPD. The
study of Silvestre et al. assessed 3DPD examination and
simple rules in the identification of ovarian tumors [27].
They did not use other preoperative diagnostic methods,
and the menopausal status of the patients was ignored.
Similar to our study, the ovarian tumors were classified
by conventional 2DPD according to IOTA vascular
scores. They found that VI and VFI differentiated malig-
nant tumors from benign ones, but they were not more
accurate than 2D vascular scores. The use of 3D vascular
indices did not decrease the number of false positive
results obtained by simple rules.
Conclusions
Combining the 3DPD vascular index VFI with RMI or
LR2 may increase the specificity of the diagnostic test, but
an ultrasound examination by an experienced clinician still
seems to be the most reliable method in the preoperative
work-up of ovarian tumors.
Abbreviations
2D: Two-dimensional; 2DPD: Two-dimensional power Doppler;
3D: Three-dimensional; 3DPD: Three-dimensional power Doppler;
FI: Flow index; IOTA: International Ovarian Tumors Analysis; LR: Logistic
regression model; RMI: Risk of malignancy index; VFI: Vascularization
flow index; VI: Vascularization index
Acknowledgements
Not applicable.
Funding
The study was supported by Finnish Cancer Society and Competitive
Research Funding of the Tampere University Hospital (Grant 9S040).
Availability of data and materials
The datasets used and analysed during the current study are available and
can be provided by the corresponding author upon request.
Authors’ contributions
RN did all the ultrasound examinations and wrote the first draft of the
manuscript. SS evaluated the stored data as the second investigator and
reviewed the manuscript. TL did the statistical analysis. JM presented the
original idea, supervised the study, and revised the manuscript. All authors
read and approved the final manuscript.
Authors’ information
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Table 5 Diagnostic performances of combined methods to detect malignancy at specific cut-off values
Developed method Sensitivity
%
95% CI Specificity
%
95% CI PPV
%
95% CI NPV
%
95% CI Accuracy
%
RMI > 200 and VFI > 0.31 51.6 33.1–69.9 95.5 87.3–99.1 84.2 60.4–96.6 80.8 70.3–88.8 81.4
Simple rules with expert opiniona and VFI > 0.31 71.0 52.0–85.8 95.5 87.3–99.1 88.0 68.8–97.5 87.5 77.6–94.1 86.7
LR2 > 25 and VFI > 0.31 64.5 45.4–80.8 97.0 89.5–99.6 90.9 70.8–98.9 85.3 75.3–92.4 86.5
IOTA International Ovarian Tumor Analysis; CI Confidential interval; PPV Positive predictive value; NPV Negative predictive value; RMI Risk of malignancy index; VFI
Vascularization flow index; LR2 Logistic regression model 2
aTwo step-strategy: As a result of inconclusive by simple rules, the expert evaluates the tumor
Niemi et al. Journal of Ovarian Research  (2017) 10:15 Page 6 of 7
Consent for publication
Not applicable.
Ethics approval and consent to participate
All participants gave their informed consent to the study, which was
approved by the Ethics Committee of Tampere University Hospital (ETL
R10080, 6 August 2010).
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Obstetrics and Gynecology, Tampere University Hospital, P.O.
Box 2000FI-33521 Tampere, Finland. 2Research and Innovation Center,
Tampere University Hospital and Faculty of Social Sciences, University of
Tampere, FI-33014 Tampere, Finland. 3Faculty of Medicine and Life Sciences,
University of Tampere, FI-33014 Tampere, Finland.
Received: 22 December 2016 Accepted: 2 March 2017
References
1. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of
malignancy index incorporating CA 125, ultrasound and menopausal status
for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet
Gynaecol. 1990;97(10):922–9.
2. Valentin L, Hagen B, Tingulstad S, Eik-Nes S. Comparison of ‘pattern
recognition’ and logistic regression models for discrimination between
benign and malignant pelvic masses: a prospective cross validation.
Ultrasound Obstet Gynecol. 2001;18(4):357–65.
3. Timmerman D. The use of mathematical models to evaluate pelvic masses;
can they beat an expert operator? Best Pract Res Clin Obstet Gynaecol.
2004;18(1):91–104.
4. Timmerman D, Testa AC, Bourne T, Ameye L, Jurkovic D, Van Holsbeke C,
et al. Simple ultrasound-based rules for the diagnosis of ovarian cancer.
Ultrasound Obstet Gynecol. 2008;31(6):681–90.
5. Timmerman D, Ameye L, Fischerova D, Epstein E, Melis GB, Guerriero S,
et al. Simple ultrasound rules to distinguish between benign and malignant
adnexal masses before surgery: prospective validation by IOTA group. BMJ.
2010;341:c6839.
6. Testa A, Kaijser J, Wynants L, Fischerova D, Van Holsbeke C, Franchi D, et al.
Strategies to diagnose ovarian cancer: new evidence from phase 3 of the
multicentre international IOTA study. Br J Cancer. 2014;111(4):680–8.
7. Timmerman D, Testa AC, Bourne T, Ferrazzi E, Ameye L, Konstantinovic ML,
et al. Logistic regression model to distinguish between the benign and
malignant adnexal mass before surgery: a multicenter study by the
International Ovarian Tumor Analysis Group. J Clin Oncol. 2005;23(34):8794–801.
8. Kaijser J, Bourne T, Valentin L, Sayasneh A, Van Holsbeke C, Vergote I, et al.
Improving strategies for diagnosing ovarian cancer: a summary of the
International Ovarian Tumor Analysis (IOTA) studies. Ultrasound Obstet
Gynecol. 2013;41(1):9–20.
9. Meys EM, Kaijser J, Kruitwagen RF, Slangen BF, Van Calster B, Aertgeerts B, et
al. Subjective assessment versus ultrasound models to diagnose ovarian
cancer: A systematic review and meta-analysis. Eur J Cancer. 2016;58:17–29.
10. Orre M, Lotfi-Miri M, Mamers P, Rogers PA. Increased microvessel density in
mucinous compared with malignant serous and benign tumours of the
ovary. Br J Cancer. 1998;77(12):2204–9.
11. Konerding MA, Malkusch W, Klapthor B, van Ackern C, Fait E, Hill SA, et al.
Evidence for characteristic vascular patterns in solid tumours: quantitative
studies using corrosion casts. Br J Cancer. 1999;80(5-6):724–32.
12. Alcazar JL, Rodriguez D. Three-dimensional power Doppler vascular
sonographic sampling for predicting ovarian cancer in cystic-solid and solid
vascularized masses. J Ultrasound Med. 2009;28(3):275–81.
13. Timmerman D, Valentin L, Bourne TH, Collins WP, Verrelst H, Vergote I.
Terms, definitions and measurements to describe the sonographic features
of adnexal tumors: a consensus opinion from the International Ovarian
Tumor Analysis (IOTA) Group. Ultrasound Obstet Gynecol. 2000;16(5):500–5.
14. Alcazar JL, Jurado M. Three-dimensional ultrasound for assessing
women with gynecological cancer: a systematic review. Gynecol Oncol.
2011;120(3):340–6.
15. Pairleitner H, Steiner H, Hasenoehrl G, Staudach A. Three-dimensional power
Doppler sonography: imaging and quantifying blood flow and vascularization.
Ultrasound Obstet Gynecol. 1999;14(2):139–43.
16. Brennan P, Silman A. Statistical methods for assessing observer variability in
clinical measures. BMJ. 1992;304(6840):1491–4.
17. Wang J, Gao J, Yao H, Wu Z, Wang M, Qi J. Diagnostic accuracy of serum
HE4, CA125 and ROMA in patients with ovarian cancer: a meta-analysis.
Tumour Biol. 2014;35(6):6127–38.
18. Geomini P, Kruitwagen R, Bremer GL, Cnossen J, Mol BW. The accuracy of
risk scores in predicting ovarian malignancy: a systematic review. Obstet
Gynecol. 2009;113(2 Pt 1):384–94.
19. Van Calster B, Timmerman D, Valentin L, McIndoe A, Ghaem-Maghami S,
Testa AC, et al. Triaging women with ovarian masses for surgery:
observational diagnostic study to compare RCOG guidelines with an
International Ovarian Tumour Analysis (IOTA) group protocol. BJOG. 2012;
119(6):662–71.
20. Kaijser J, Sayasneh A, Van Hoorde K, Ghaem-Maghami S, Bourne T,
Timmerman D, et al. Presurgical diagnosis of adnexal tumours using
mathematical models and scoring systems: a systematic review and
meta-analysis. Hum Reprod Update. 2014;20(3):449–62.
21. Piovano E, Cavallero C, Fuso L, Viora E, Ferrero A, Gregori G, et al. diagnostic
accuracy and cost-effectiveness of different strategies to triage adnexal
masses: a prospective study. Ultrasound Obstet Gynecol. 2016; doi: 10.
1002/uog.17320.
22. Alcazar JL, Merce LT, Garcia MM. Three-dimensional power Doppler vascular
sampling: a new method for predicting ovarian cancer in vascularized
complex adnexal masses. J Ultrasound Med. 2005;24(5):689–96.
23. Jokubkiene L, Sladkevicius P, Valentin L. Does three-dimensional power
Doppler ultrasound help in discrimination between benign and malignant
ovarian masses? Ultrasound Obstet Gynecol. 2007;29(2):215–25.
24. Guerriero S, Ajossa S, Piras S, Gerada M, Floris S, Garau N, et al. Three-
dimensional quantification of tumor vascularity as a tertiary test after B-mode
and power Doppler evaluation for detection of ovarian cancer. J Ultrasound
Med. 2007;26(10):1271–8.
25. Geomini PM, Coppus SF, Kluivers KB, Bremer GL, Kruitwagen RF, Mol BW. Is
three-dimensional ultrasonography of additional value in the assessment of
adnexal masses? Gynecol Oncol. 2007;106(1):153–9.
26. Kudla MJ, Alcazar JL. Does sphere volume affect the performance of three-
dimensional power Doppler virtual vascular sampling for predicting
malignancy in vascularized solid or cystic-solid adnexal masses? Ultrasound
Obstet Gynecol. 2010;35(5):602–8.
27. Silvestre L, Martins WP, Candido-Dos-Reis FJ. Limitations of three-
dimensional power Doppler angiography in preoperative evaluation of
ovarian tumors. J Ovarian Res. 2015;8:47. 015-0174-y.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to ﬁnd the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Niemi et al. Journal of Ovarian Research  (2017) 10:15 Page 7 of 7

Urinary Polyamines as Biomarkers for Ovarian Cancer
Riikka Johanna Niemi, MD,* Antti N. Roine, MD, PhD,Þ Merja R. Ha¨kkinen, PhD,þ
Pekka S. Kumpulainen, DSc,§ Tuomo A. Keina¨nen, PhD,þ Jouko J. Vepsa¨la¨inen, PhD,þ
Terho Lehtima¨ki, MD, PhD,|| Niku K. Oksala, MD, PhD, DSc,¶#
and Johanna U. Ma¨enpa¨a¨, MD, PhD***
Objectives: Elevated concentrations of polyamines have been found in urine of patients
with malignant tumors, including ovarian cancer. Previous research has suffered from poorly
standardized detection methods. Our liquid chromatographyYtandem mass spectrometry
(LC-MS/MS) method is capable of simultaneous standardized analysis of most known
polyamines. Liquid chromatographyYtandem mass spectrometry has not previously been
used in the differential diagnostics of ovarian tumors in postmenopausal women.
Materials and Methods: In this prospective study, postmenopausal women (n = 71)
presenting with an adnexal mass and, as controls, women with genital prolapse or urinary
incontinence scheduled for surgery (n = 22) were recruited in the study. For analysis of the
polyamines, a morning urine sample was obtained before surgery. Preoperative serum
CA125 concentrations were determined in the study group.
Results: Twenty-three women with benign and 37 with malignant ovarian tumors were
eligible. Of all analyzed polyamines, only urinary N1,N12-diacetylspermine showed sta-
tistically significant differences between all groups except controls versus benign tumors.
N1,N12-diacetylspermine was elevated in malignant versus benign tumors (P G 0.001), in
high-grade versus low malignant potential tumors (P G 0.001), in stage III to IV versus stage
I to II cancers (P G 0.001), and even in early-stage cancer (stage IYII) versus benign tumors
(P = 0.017). N1,N12-diacetylspermine had better sensitivity (86.5%) but lower specificity
(65.2%) for distinguishing benign and malignant ovarian tumors than CA125 with a cut-off
value of 35 kU/L (sensitivity, 75.7%; specificity, 69.6%).
Conclusions: Urinary N1,N12-diacetylspermine seems to be able to distinguish benign and
malignant ovarian tumors as well as early and advanced stage, and low malignant potential
and high-grade ovarian cancers from each other, respectively.
Key Words: LC-MS/MS, Ovarian tumor, Ovarian cancer, DiAcSpm, Polyamine
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Ovarian cancer is the leading cause of deaths due to gy-necological cancer in the United States and Europe. The
lack of specific symptoms makes the diagnosis of ovarian
cancer difficult, with ultrasound being typically the first
imaging test used to distinguish benign and malignant tumors
from each other. Ultrasound features combined with CA125
and menopausal status have been used to calculate the risk
of malignancy index.1 A major problem in ultrasound
imaging is the relatively large number of false-positive
results. Unfortunately, CA125 antigen lacks sensitivity
even in the postmenopausal setting, as it is not expressed by
approximately 20% of early-stage ovarian cancers.2
Polyamines are molecules essential for nearly all living
organisms with critical roles in cell signaling and growth in
vertebrates. Putrescine, spermidine, and spermine are the
most common polyamines detected in mammals. Polyamines
exist in urine mainly in acetylated forms.3 Increased polyamine
concentrations are found during active cellular proliferation,
like in patientswith cancer.4 Ovarian cancer was one of the first
cancers linked to polyamines.5 These early studies were
hampered by methodological problems, but subsequently, the
development of gas chromatographyYmass spectrometry en-
abled quantitation of both free and acetylated polyamines in
human urine without hydrolysis of polyamines.6 Recently, an
optimized LC-MS/MS method has been developed, which
allows for a simultaneous analysis of up to 14 polyamines in
different forms in urine.7
The present study was undertaken as a proof of concept
study to explore the usefulness of LC-MS/MS in differential
diagnostics of ovarian tumors.
MATERIALS AND METHODS
Patients
From May 2013 to March 2016, 71 patients presenting
with an abnormal adnexal mass and scheduled for surgery at
the Department of Obstetrics and Gynecology of Tampere
University Hospital were prospectively recruited to the study.
They had to be at least 50 years old, and the only exclusion
criterion was an ongoing treatment for cancer. Besides pelvic
examination, a vaginal ultrasound scan was performed, and a
serum sample for CA125 was obtained from each patient. The
final sample size was 60 patients, after exclusion of ineligible
patients (Fig. 1).
Twenty-two postmenopausal women scheduled for sur-
gery because of genital prolapse or urinary incontinence from
May 2013 to April 2014 were recruited as controls. One patient
of the control group had to be excluded because of an incidental
endometrial adenocarcinoma. All subjects provided a morning
urine sample at the day of operation. The sampleswere stored at
j70-C until analysis for polyamines.
All participants gave their informed consent to the
study, which was approved by the ethics committee of Tampere
University Hospital (ETL R10066).
Liquid ChromatographyYTandem Mass
Spectrometry Analysis
TheLC-MS/MSanalysiswas conducted at theUniversity
of Eastern Finland (Kuopio, Finland) and was performed using
the previously described method.7 In short, the chromatographic
FIGURE 1. Study population.
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separations were carried out using a reversed phase column
(Phenomenex Kinetex C18 150  2.1 mm, 2.6 Km) and 0.1%
heptafluorobutyric acid as the evaporative ion-pairing reagent.
Detection was performed with Agilent 6410 triple quadrupole
mass spectrometry equipped with an electrospray ionization
source and using selected reaction monitoring method. Deu-
terated polyamines were used as stable internal standards in
quantification. Polyamine concentrations were normalized using
creatinine concentration. The concentrations are expressed as
micromole of polyamine per gram of creatinine.
The creatinine concentrations of the urine samples were
determined enzymatically using Cobas 6000, C 501-module
(Roche diagnostics GmbH, Mannheim, Germany) at Fimlab
Laboratories.
Statistical Analysis
No formal sample size calculations were made because
of the preliminary nature of the study. The statistical analysis
was performed by using MATLAB Version R2016b. The
normality of the distributions of continuous variables was
evaluated by Kolmogorov-Smirnov tests. Due to the skewness
of the distributions, the differences in polyamine concentra-
tions between the distinct groups were analyzed by Wilcoxon
rank sum test. The differences in the concentrations of poly-
amines are visualized by box plots. A probability value of less
than 0.05 was considered as statistically significant. All tests
were two-sided. To compare the predictive performance of
diacetylspermine (DiAcSpm) and CA125, a receiver operating
characteristics analysis was accomplished.
RESULTS
Patients and Tumors
All 81 women in the final study population were older
than 50 years and postmenopausal. The median age (75 years;
range, 55Y83 years) in the control group was significantly
higher than in the groups with benign (65 years; range, 51Y73
years) and malignant tumors (64 years; range, 51Y86 years),
respectively (P = 0.02). Three of the controls and 4 of the
cases had used systemic hormonal therapy before surgery. Five
patients (1 in the control group, 1 with a benign, and 3 with a
malignant ovarian tumor) had previously been treated for breast
cancer and 1 patient (with a malignant ovarian tumor) for thyroid
cancer, but all of them were disease free at the time of sampling.
Of the ovarian tumors, 23 were benign and 37 were ma-
lignant (Fig. 1). The benign group consisted of 11 serous and
2 mucinous cystadenomas, 2 fibromas, 5 simple and 2
endometriotic cysts, and 1 necrotized cyst. Eighteen of the
malignant tumors were of low malignant potential (4 serous
and 5 mucinous borderline tumors, 3 mucinous adenocar-
cinomas, 4 granulosa cell tumors, 1 Sertoli-Leydig cell
tumor, and 1 endometrioid adenocarcinoma). Eighteen of
the high-grade tumors were serous carcinomas (HGSC) and
one was a carcinosarcoma. One of the patients with HGSC
had 2 primary tumors, or the stage IIIC ovarian cancer and an
invasive ductal grade 3 breast cancer, whichwere operated on at
the same session.
The median serum concentrations of CA125 were 18.0
kU/L (range, 5Y1984), 53.5 kU/L (range, 7Y841), and 546.0
kU/L (range, 22Y8152) in the patients with benign tumors,
with low malignant potential tumors, and with high-grade
tumors, respectively. The difference of the tumor marker
concentration between the groups was statistically significant
(P G 0.001).
Urinary Polyamines and Their Metabolites
The polyamines and their metabolites detected by the
LC-MS/MS are given in Table 1. Six polyamines or acetylated
putrescine, acetylated cadaverine, N1-acetylated spermidine
(N1AcSpd), N8-acetylated spermidine (N8AcSpd), N1,N8-
diacetylspermidine (DiAcSpd), and DiAcSpm were con-
stantly found in all urine samples, but only DiAcSpm showed
statistically significant differences between all groups except
between controls and benign ovarian tumors (Figs. 2, 3). The
polyamine concentrations were independent of body mass
index (data not shown).
A detailed description of the urinary concentrations of
DiAcSpm in different settings is given in Table 2. There were
no differences between the women with genital prolapse or
urinary incontinence and the women with benign tumors. Of
the women with malignant tumors, the ones with high-grade
and advanced stage tumors had the highest urinary concen-
trations of DiAcSpm. However, the concentrations were
significantly higher also in women with low malignant po-
tential and early-stage tumors than in the controls.
Besides DiAcSpm, there was also a significant differ-
ence in concentrations of DiAcSpd, N1AcSpd, and N8AcSpd
between low malignant potential and high-grade malignant
ovarian tumors (P = 0.02, 0.004 and 0.013, respectively) and
between benign and malignant ovarian tumors in concentra-
tions of DiAcSpd and N8AcSpd (P = 0.015 and 0.042).
Performance of CA125 and Urinary
DiAcSpm
In distinguishing benign tumors from the malignant
ones, the specificity and sensitivity of CA125 (using the
standard used cut-off value 35 kU/L) were 69.6% and 75.7%,
respectively. Correspondingly, the specificity of DiAcSpm
(cut-off value of 0.097 Kmol/g creatinine) was 65.2% and
sensitivity 86.5% (Fig. 4).
DISCUSSION
The main finding of this preliminary study was that
urinary concentrations of DiAcSpm are elevated among
postmenopausal women with malignant ovarian tumors as
compared with women with benign ovarian tumors or genital
prolapse. Although DiAcSpm concentrations were higher in
the case of high-grade and advanced stage cancers than
among low malignant potential and early-stage cancers, re-
spectively, there was still a statistically significant difference
in DiAcSpm levels between early-stage (and low malignant
potential) and benign tumors.
Previous studies used methodology with limited poly-
amine array and were unable to measure all polyamines in a
single run, which deteriorated repeatability and increased
variability of different studies. Another limitation was that
acetylated polyamines, which are highly specific for malig-
nant disease, could not be measured. Consequently, the earlier
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research focused on less specific unacetylated polyamines.8
Many methods rely on derivatization techniques where
polyamines are conjugated with other molecules to allow
extraction and analysis.9 This technique is not suitable for the
analysis of diacetylated polyamines due to acetylation of
active amino groups. Our LC-MS/MS method optimized for
TABLE 1. The polyamines studied and their urinary concentrations (micromole per gram creatinine) in patients with
ovarian tumors and in controls
Polyamine
Controls (n = 21)
Benign Ovarian
Tumors (n = 23)
Low-Grade Malignant
Tumors (n = 18)
High-Grade Malignant
Ovarian Tumors
(n = 19)
Creatinine,
Range,
Kmol/g
Detection
Rate
Creatinine,
Range,
Kmol/g
Detection
Rate
Creatinine,
Range,
Kmol/g
Detection
Rate
Creatinine,
Range,
Kmol/g
Detection
Rate
Cad NAY2.65 13/21 NAY3.94 19/23 NAY20.19 15/18 NAY48.7 9/19
AcCad 0.04Y5.64 21/21 0.08Y14.26 23/23 0.11Y13.08 18/18 0.17Y5.57 19/19
DiAcCad NAY0.48 13/21 NAY0.28 18/23 NAY1.79 12/18 NAY0.63 8/19
AcPut 6.57Y19.28 21/21 5.60Y28.1 23/23 9.15Y41.45 18/18 8.54Y50.16 19/19
DiAcPut NAY0.24 17/21 NAY0.62 18/23 NAY0.75 16/18 NAY0.25 17/19
Spd NAY0.30 20/21 0.08Y0.27 23/23 0.10Y0.28 18/18 0.09Y0.56 19/19
N1AcSpd 1.78Y8.92 21/21 1.04Y8.17 23/23 1.39Y6.50 18/18 2.52Y18.50 19/19
N8AcSpd 1.84Y4.75 21/21 1.15Y4.69 23/23 1.65Y5.03 18/18 2.18Y5.99 19/19
DiAcSpd 0.18Y0.65 21/21 0.14Y1.32 23/23 0.16Y1.34 18/18 0.23Y1.20 19/19
Spm NAY0.55 8/21 NAY0.45 12/23 NAY0.25 12/18 NAY0.32 14/19
AcSpm NAY0.01 3/21 NAY0.01 4/23 NAY0.004 1/18 NAY0.04 7/19
DiAcSpm 0.06Y0.20 21/21 0.04Y1.02 23/23 0.06Y0.37 18/18 0.14Y2.37 19/19
NA indicates that analyzed concentration was below the lowest calibration point.
AcSpm, acetylated spermine; Cad, cadaverine; AcCad, acetylated cadaverine; DiAcCad, diacetylated cadaverine; AcPut, acetylated pu-
trescine; DiAcPut, diacetylated putrescine; DiAcSpm, N1,N12-diacetylspermine.
FIGURE 2. The urinary concentrations of N1,
N12-diacetylspermine (DiAcSpm) (micromole per gram
creatinine) in controls and in patients with ovarian tumors.
FIGURE 3. The urinary concentrations of N1,
N12-diacetylspermine (DiAcSpm) (micromole per gram
creatinine) in the womenwith stage I to II and stage III to
IV ovarian tumors.
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noninvasive and standardized single-run analysis of urine can
be used for simultaneous analysis of up to 14 polyamines in
free, mono- and diacetylated forms in human urine,without any
derivatization.7 In the present study, however, 1,3-diaminopropane
and putrescine were not detectable. In addition, results con-
cerning diacetylated cadaverine and diacetylated putrescine
should be interpreted with caution, because their analysis is
only semiquantitative.7
Although we are not aware of any subsequent studies
since the report by Suh et al,10 on the urinary polyamine
profile in ovarian cancer, our results are in accordance with
previous experience with other tumors. Patients with non-
Hodgkin lymphoma or urogenital cancer (testicular, prostatic,
renal, and bladder carcinoma) have been found to have elevated
urinary concentrations of DiAcSpm and those with urogenital
cancer also of DiAcSpd.6,11Y13 In breast cancer, even early-
stage disease seems to be associated with elevated levels of
DiAcSpm in the urine.13 In colon cancer, urinary DiAcSpm
may be a better tumor marker than carcinoembryonic antigen
or cancer antigen 19-9.13,14 Besides being predictive
markers, there is a possibility that DiAcSpm and DiAcSpd
could be used also as prognostic markers, at least in testicular
or prostatic cancer.11 Urinary DiAcSpm has been shown to be
both diagnostic and prognostic marker also for nonsmall cell
lung cancer.15,16
In the present study, the performance of CA125 used in
the preoperative diagnostic work-up of pelvic tumors was
poorer than in published large screening studies.1,17Y20 The
reason may be by chance only due to the rather limited sample
size, but the fact that a large portion of the malignant tumors
were of low malignant potential or borderline epithelial,
granulosa, and Sertoli-Leydig cell tumorsmay have contributed
to the less than optimal performance. In any case, urinary
DiAcSpm was a more sensitive marker of malignant ovarian
tumors than CA125 with a cut-off value 35 kU/L, while being
less specific.
FIGURE 4. Receiver operating characteristic curves for urinary N1,N12-diacetylspermine (DiAcSpm) and CA125 in
benign and malignant ovarian tumors with optimal (DiAcSpm 0.097 Kmol/g creatinine) and typically used
(CA125 35 kU/L) thresholds.
TABLE 2. The urinary concentrations of N1,N12-diacetylspermine (DiAcSpm) (micromole per gram creatinine) in
patients with ovarian tumors and in controls and comparisons between the groups
N1,N12-diacetylspermine, Kmol/g creatinine
Mean (SD) Median Minimum Maximum Comparison P
Controls 0.10 (0.04) 0.09 0.06 0.20 Versus benign tumors NS
Benign tumors 0.15 (0.21) 0.08 0.04 1.02
All malignant tumors 0.54 (0.62) 0.26 0.06 2.37 Versus benign tumors
Versus controls
G0.001
G0.001
Low malignant potential
tumors
0.17 (0.09) 0.16 0.06 0.37 Versus benign tumors 0.020
High-grade tumors 0.89 (0.72) 0.67 0.14 2.37 Versus low malignant potential tumors G0.001
Stage IYII tumors 0.19 (0.15) 0.16 0.06 0.69 Versus benign tumors 0.017
Stage IIIYIV tumors 0.87 (0.72) 0.64 0.14 2.37 Versus Stage IYII tumors G0.001
NS, not significant.
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Although the mechanism underlying elevated concen-
trations of DiAcSpm in the urine of patients with cancer is not
completely understood, an increased synthesis of polyamines
in proliferating cells, including malignant cells, is well doc-
umented. It has been suggested that the increased secretion of
DiAcSpm may reflect a defense mechanism by the organism
to lower intracellular polyamine concentrations by acetylating
and excreting polyamines and hence decreasing the growth
rate of the tumor.8,13,21 It has also been purported that the
production of DiAcSpm in tumorigenesis may be a result of
host macrophage activation.22
The results of the present study are to be considered
as preliminary, to be confirmed in larger patient cohorts.
Chronic inflammatory diseases may influence DiAcSpm
concentrations. However, in the study of pancreatico-biliary
diseases, the levels of DiAcSpm in urine were lower in be-
nign inflammatory conditions than in cancers.23 Presence of
urinary tract infection may also have a confounding influence
on urinary polyamines, increasing especially the level of
putrescine.24 The impact of infection cannot totally be ruled
out in the present study, because a routine urine sample for
diagnosing urinary infection was taken only from the patients
of the control group. Moreover, cadaverine in human urine
is suggested to be derived from the gut microbial flora.24 A
limitation of the study is that there were no patients with a
benign teratoma, because among benign tumors, teratomas
have been associated with elevated levels of urinary poly-
amines.5 On the other hand, teratomas are typically tumors
of adolescents and young adults and not of postmenopausal
women, the risk population for ovarian cancer.
Ornithine decarboxylase is one of the key enzymes in
polyamine synthesis and is stimulated by estrogens in estrogen-
responsive tissues.25 A previous study found that urinary
DiAcSpm values are higher in women than in men, whereas
postmenopausal women had lower concentrations than pre-
menopausal ones.26 Accordingly, Byun et al27 showed that
patients with premenopausal breast cancer had higher (free and
monoacetylated) polyamine levels in serum than postmeno-
pausal ones, whose polyamine levels were similar to healthy
controls. In our study, allwomenwere postmenopausal, but 7 of
them used hormone replacement therapy, creating a potential
bias. However, excluding these patients did not alter the results.
The controlwomenwere older than the oneswith tumors,which
may have had impact on the results. However, there was no
significant difference between DiAcSpm levels of control
group and women with benign ovarian tumors. One patient in
the malignant tumor group had been treated for breast cancer
for 5 years, but she had no signs of recurrence. Another patient
had a grade 3 breast cancer concurrently with the stage IIIC
HGSC, whichmay have affected her DiAcSpm level. However,
her urinary level of DiAcSpm was of similar magnitude as in
the patients with advanced high-grade tumors in general.
We used a morning urine sample in our study, which,
however, may not have been necessary. According to a study
on healthy people, a spot urine sample at any time of the day
represents the true excretion rate of DiAcSpm after creatinine
normalization.26 Although the LC-MS/MS method is very
accurate, it is as such not suitable for routine clinical use, at
least not for time being.7 However, if only 1 (DiAcSpm) or a
few polyamines need to be analyzed, the analysis could
probably be made faster and less expensive to perform. Alter-
native methods to measure only urinary DiAcSpm in routine
clinical practice include an enzyme-linked immunosorbent
assay13,28 or a colloidal gold aggregation procedure.29
In conclusion, urinary levels of DiAcSpmwere elevated
in patients with malignant ovarian tumors, even in patients
with tumors of low malignant potential and early-stage tumors.
These preliminary findings suggest that urinary DiAcSpmmay
in the future become a useful diagnostic marker for malignant
ovarian tumors in the postmenopausal setting.
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• Analysis of volatile organic compounds (VOCs) offers a new diagnostic method.
• VOCs from urine can be analyzed by FAIMS (ﬁeld asymmetric ion mobility spectrometry).
• FAIMS distinguished urine from ovarian cancer patients compared to controls.
• Patients with high vs. low grade ovarian cancer have also different VOC signatures.
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Aim.We hypothesized that ﬁeld asymmetric waveform ion mobility spectrometry (FAIMS) as a novel artiﬁ-
cial olfactory technology could differentiate urine of women with malignant ovarian tumors from controls and
women with benign tumors, based on previous ﬁndings on the ability of canine olfactory system to “smell” can-
cer.
Patients andmethods. Preoperative urine samples from 51womenwith ovarian tumors, both benign andma-
lignant, and from 18 women with genital prolapse, as controls, were collected. The samples were analyzed by
FAIMS device. Data analysis was processed by quadratic data analysis (QDA) and linear discriminant analysis
(LDA), and cross-validated using 10-fold cross-validation.
Results. Thirty-threewomen hadmalignant ovarian tumors, ofwhich 18were high-grade cancers. FAIMS dis-
tinguished controls from malignancies with the accuracy of 81.3% (sensitivity 91.2% and speciﬁcity 63.1%), and
benign tumors frommalignancies with the accuracy of 77.3% (sensitivity 91.5% and speciﬁcity 51.4%). Moreover,
low grade tumors were also separated from high grade cancers and benign ovarian tumors with accuracies of
88.7% (sensitivity 87.8% and speciﬁcity 89.6%) and 83.9% (sensitivity 73.1% and speciﬁcity 92.9%), respectively.
Conclusions. This proof of concept-study indicates that the FAIMS fromurinehas potential to discriminatema-
lignant ovarian tumors from no tumor-bearing controls and benign tumors.
© 2018 Elsevier Inc. All rights reserved.
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1. Introduction
Annually 22,000 new ovarian cancer (OC) cases are diagnosed in the
United States, and the survival rates are poor due to the majority of OCs
being detected at advanced stages [1]. While early diagnosis and ade-
quate cytoreductive surgery improve prognosis, there is a need for bet-
ter preoperative diagnostic methods for ovarian tumors.
Various ultrasound-basedmodels have been developed for preoper-
ative evaluation of ovarianmasses. These include e.g. Risk ofMalignancy
Index (RMI) [2] and logistic regression analyses and ultrasound-based
rules from the International Ovarian Tumor Analysis (IOTA)-study. Al-
though they have relatively high sensitivity and speciﬁcity, they are
non-applicable for about 20% of tumors [3].
Studies on urinary biomarkers for OC are relatively sparse. Urinary
protein biomarkers, human epididymis protein 4 (HE4) andmesothelin,
have shown to improve the early detection of serous OC compared to
serum biomarkers [4]. Metabolite changes related to OC have been dis-
covered as potential biomarkers [5,6], like N1,N12-diacetylspermine in
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polyamine analyses [7]. In addition, circulating microRNAs have been
shown to be abundant in urine of OC patients [8].
Many diseases are linked to distinct odors caused by volatile organic
compounds (VOCs) released into exhaled air, urine, blood and stool [9].
Horvath et al. trained dogs to discriminate OC patients and healthy con-
trols from tissue samples [10] and blood samples from cancer patients
[11] with high accuracy. The costly training, limited working capacity
and cultural factors have prevented the use of “sniffer dogs” in the clinic.
Artiﬁcial olfactionwith electronic devices could be easier to validate and
adopt into clinical practice [9].
Gas chromatography-mass spectrometry (GC–MS) has been used
extensively in analysis of VOCs but it involves complex technology
and has high costs. Electronic nose (eNose) technology provides a
more economical and simpler way to qualitatively analyze VOCs. The
technology mimics the working principle of mammalian olfactory sys-
tem (Fig. 1). Ion mobility spectrometry (IMS) works according to the
same principles, providing a qualitative VOC spectrum from the sample.
Field asymmetric waveform IMS (FAIMS) is amodern and sensitive var-
iant of IMS providing a high sensitivity and stability [12]. The working
principle of FAIMS is illustrated in Fig. 2.
There is mounting evidence of the potential of eNose devices in de-
tection of cancer from various samplemedia [12]. FAIMS speciﬁcally has
previously been shown to detect colorectal and pancreatic cancers from
urine [13,14]. Detection of OC has been only attempted from cancer tis-
sue [15]. Urine is a promising samplingmethod since it can be obtained
non-invasively.
We hypothesized that FAIMSwould be capable of differentiating the
urine of women with OC from benign ovarian tumors and controls.
2. Materials and methods
2.1. Subjects and study design
Between May 2013 and March 2016, 60 women with an adnexal
tumor scheduled for surgery gave a morning urine sample in the oper-
ation day at the Department of Obstetrics and Gynecology of Tampere
University Hospital. They were all postmenopausal, and none of them
had an ongoing treatment for cancer. After operation nine tumors
were excluded due to their non-ovarian origin or a concurrent malig-
nant tumor. The ﬁnal sample size after exclusions was 51. Eighteen
women scheduled for urinary incontinence or genital prolapse surgery
were recruited as controls. The samples were stored at −70 °C until
analysis. Because of the proof-of-concept nature of the study, no
power calculations could be done. The size of the study population
was based on the experience from previous studies with similar tech-
nology [16].
The samples were defrosted and analyzed using Owlstone Lonestar
(Owlstone Inc., Cambridge, United Kingdom) device which uses FAIMS
technique. The sensor was coupled with ATLAS sampling unit
(Owlstone Inc., Cambridge, United Kingdom) that standardizes the ana-
lytical conditions by controlling the temperature and dilution of the
VOCs evaporated from the sample.
2.2. Protocol of FAIMS
For FAIMS analysis, we used settings previously described by
Arasaradnam et al. [13]. The step-by-step analysis protocol was as
follows:
1) Urine samples were ﬁrst thawed at room temperature and analyzed
in random order.
2) A 5 ml urine sample was aliquoted to a 30 ml glass vial and warmed
to 40 °C.
3) Once the sample achieved the target temperature, three consecutive
scans were conducted to minimize the effect of scan-to-scan
variation.
4) After the analysis, the sample vial was removed from the sampling
unit and a vial of 5ml of puriﬁedwaterwasplaced in to the chamber.
5) The vapour released from the puriﬁedwater acts as a cleaning agent
that removes the carry-over effect of trace VOCs from the urine sam-
ple that are retained in the sensor. Five consecutive scans with puri-
ﬁed water were conducted.
The next urine sample was placed to the sampling chamber and the
process was repeated. To ensure stable and clean carrier gas for the sys-
tem, we utilized standard pressurized clean air that was cleaned from
residual humidity with a silica gel ﬁlter and from residual VOCswith ac-
tivated charcoal ﬁlter before entering the system.We used the ﬂow set-
tings recommended by the manufacturer for urine samples: The ﬂow
rate over the sample was 500 ml/min, which was mixed to
2000 ml/min stream of clean air for a total ﬂow of 2500 ml/min for
the sensor. The FAIMS scanning settings used were also ones provided
by the manufacturer: Dispersion ﬁeld from 0 to 90% was scanned in
51 steps and compensation voltage from−6 to +6 V was scanned in
512 steps. Each scan contains two ion windows, one for negative and
one for positive ions. One window is produced by the negative ions
Fig. 1. Theworking principle ofmammary and eNose compared A) VOCs enter a sampling unitwhere the humidity, the temperature and the concentration of the sample are optimized. B)
Optimized sample enters the sensor unit where different VOCs attach to different areas of the sensor and produce electrical currents. C) Electrical currents are referred to a computing
system for analysis where they are associated with previously gathered information. D) A result of the analysis is produced.
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that collide the positive detector and the other is produced by the pos-
itive ions that collide the negative detector, respectively. The detectors
are illustrated in Fig. 2.
The ionwindow is a spectrum that has compensation voltage on the
X axis and dispersion ﬁeld on the Y axis as seen in Fig. 3. The compensa-
tion voltage is the base voltage between the electric plates in the sepa-
ration part of the FAIMS sensor. This biases the ion ﬂow either towards
negative or positive plate. The dispersion ﬁeld strength represents the
strength of the electrical ﬁeld between the plates as a percentage of
the maximum ﬁeld that can be created by the system. The ion window
is compiled by adjusting the dispersion ﬁeld strength stepwise and on
each step scanning the selected compensation voltage range at each
step. The scans were saved on the hard drive of the Lonestar system
fromwhich theywere transferred to anUSBdrive for statistical analysis.
2.3. Statistical methods
The last of the three scans from the urine sample was found to be
equal in performance when compared to the average of three scans,
andwas taken for analysis. One scan consists of a matrix of 52,200mea-
surement values, including both positive and negative ion window. The
areas with no response were removed and the remaining signal was
downsampled, selecting every other line and column of the scan, leav-
ing 1536 points for each measurement.
Forward feature selection with linear discriminant analysis (LDA)
and quadratic discriminant analysis (QDA) were utilized to ﬁnd dis-
criminating features from each group. Both LDA and QDA seek a classi-
ﬁer that is optimal for discrimination of the groups. LDA is a special case
of QDA where the covariance of each group is assumed to be equal
which results in a linear discriminator whereas QDA allows the covari-
ances to differwhich also enables quadratic, parable-shaped discrimina-
tors. Because LDA is a simpler method, it is preferred as the ﬁrst option
to test. The results were cross-validated by 10-fold cross-validation to
avoid overﬁtting. In this method, the dataset is divided into 10 groups.
One group is then excluded from the dataset and the remaining nine
groups are used to create the classiﬁcation parameters as the training
set. The excluded group is then classiﬁed using these parameters.
Since, due to random division for the cross validation, the classiﬁcation
Fig. 2. Illustration on the working principle of FAIMS A) Sample vial is placed in to the sampling chamber where VOCs are released from the sample. VOCs are then transferred to the
analyzer by clean air ﬂow. B) In the analyzer, VOCs are ﬁrst ionized by a radioactive isotope and gain electrical charge. C) Ionized VOCs enter separation area where they are
alternately exposed to high and low electric ﬁelds between the electric plates. The plates also have a baseline compensation voltage that is periodically adjusted. The different
properties of VOCs cause them to travel at different speed in the separation chamber and behave differently in high and low electric ﬁelds. This results in separation of the VOCs
according to their charge, shape and mass. D) At the last stage of the analysis, VOCs collide with detectors, creating electric currents that create a unique spectrum for each molecular
mixture.
Fig. 3. Average FAIMS spectrum from a patient with ovarian cancer and from a control Stars indicate the areas of the spectrum that yielded optimum discrimination of the two groups.
Compensation voltage is on X-axis and dispersion ﬁeld strength is on Y-axis.
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parameters change to a certain extend in every run, the process was re-
peated 100 times to reduce the effect of variation and to calculate aver-
ages and standard deviations for classiﬁcation results. The analysis was
conducted with MATLAB R2017b (MathWorks Inc., Natick, MA, USA).
3. Results
Characteristics of the ﬁnal study population are presented in Table 1.
The averages and standard deviations of the 100 runs of QDA and LDA
analysis are given in Table 2. The performances of QDA and LDA seem
to bemostly equal yet there is a notable difference in comparisons of be-
nign tumors with low grade vs. high grade malignant tumors, respec-
tively. The data produced by FAIMS is nonlinear by nature [17], and it
is likely that nonlinear methods such as QDA yield better results in
most cases, especiallywhen the differences between groups are less dis-
tinct. By QDA analysis, benign ovarian tumors were distinguished from
malignant tumorswith sensitivity and speciﬁcity of 91.5% and 51.4%, re-
spectively. However, the speciﬁcity improved to 79.7% when they were
compared only to high-grade ovarian cancers. Even low grade ovarian
malignancies were discriminated from high grade ovarian cancers
with sensitivity of 87.8% and speciﬁcity of 89.6%, and from benign ovar-
ian tumors with sensitivity of 73.1% and speciﬁcity of 92.9%,
respectively.
Fig. 3 shows average FAIMS outputs from urine sample of a control
and of a woman with ovarian cancer.
4. Discussion
This study provides preliminary evidence that FAIMS analysis of
VOCs can discriminate urine samples from OC patients, patients with
non-malignant tumors and healthy controls. High grade ovarian cancers
seem to be separated from low grade ovarian cancers, benign ovarian
tumors and controls.
The study further demonstrates that OC is associated with distinct
odor [18–20]. The fact that this phenomenon is apparent in urine sug-
gests that a systemic process is involved. It is apparent that metastatic,
systemic cancer may elicit profound changes in urine composition
that may be an indication of decreasing renal function. However, in
the case of colorectal cancer, even early stage cancers could be detected
[13]. There is in fact mounting body of evidence that cancer releases
VOCs to systemic circulation that consequently are released through al-
veoli to breath and via glomerular ﬁltration to urine [21]. This suggests
that breath and urine can be considered alternative sampling methods
for same VOCs. The feasibility of FAIMS/IMS has been demonstrated in
both sampling sources [13,22]. Reliable sampling from exhaled breath
is challenging [23] and the performance of breath VOC analysis in OC
seems to be inferior to our results obtained from urine [18,24]. Since
urine can be obtained non-invasively, we consider it as a more promis-
ing sampling source for VOC analysis in OC.
VOCs in different sample mediums and cancers seem to have com-
mon features, which are related to oxidation such as benzene deriva-
tives [13,18,21]. The metabolic origin and function of most of these
VOCs are unclear. They can originate from endogenous and exogenous
sources and may thus be a result also from environmental exposure in-
stead of the cancer [21]. In this studywe achieved a good discrimination
of high grade and low grade cancers. It has been suggested that KRAS
and TP3 mutations play a role as a watershed in development of high
or low grade serous OC, i.e. type I and II OCs [25]. These singlemutations
have resulted in VOC changes in cellular model [26] that reﬂect those
found in urine in other cancers [13]. We speculate that the VOC alter-
ations concerning various mutations should be studied in future also
in ovarian cancer.
This studymust be considered as preliminary, and the results should
be veriﬁed in larger patient cohorts with this repeatable method. How-
ever, there is urgent need for early detection of especially aggressive
type II OCs, with an ultimate goal to improve the prognosis of this dev-
astating disease [25]. An important topic in future FAIMS research is to
examine if cytoreductive surgery and immunosuppressive therapy
have inﬂuences on VOC emissions of urine samples. FAIMS technology
itself has advantages compared to GC–MS- and eNose implications;
the technology by nature is sensitive to trace concentrations of mole-
cules, is considerably more economical than MS-based methods, and
does not suffer stability problems of other eNose technologies [27]. In
contrast to canine studies, FAIMS is standardized and repeatable,
whereas it is almost impossible to replicate research settings of canine
studies because of variation in dogs.
Our study has also limitations. First, the present results cannot as
such be generalized to unselected populations, but rather should be
considered valid in the setting of tertiary hospitals, as part of the diag-
nostic work-up of adnexal tumors. Second, the number of analyzed
urine samples was quite small. However, the proportions of three pa-
tient groups (controls, benign and malignant tumors) were balanced.
Third, the considerable number of lowmalignant potential and border-
line ovarian tumors in our study certainly has an inﬂuence on our re-
sults comparing benign and malignant ovarian tumors, and may have
contributed to the rather great deviation seen between comparisons
of benign tumors and all or low-grade malignant tumors. However,
the comparisons between benign ovarian tumors or controls and high
grade ovarian tumors aremore accurate and speciﬁc. Fourth, the storage
time of our samples was several years, which may have reduced the
VOC emissions and thus differences between groups, as has been
shown in a recent study examining the effect of storage on VOC proﬁles
of urine [28]. In addition, the effects of the diet and possiblemedications
may have had inﬂuence on the concentration and composition of urine
although the samples were collected in the morning after at least 4 h
Table 1
Demographic data of study population.
Malignant tumors Benign tumors Controls
n 33 18 18
Age (years)
Median (range)
64
(51–82)
64
(51–73)
71
(55–83)
Diagnosis (n) Low grade cancers (15)
- mucinous adenocarcinoma Stage IA and IC (1 + 1)
- endometrioid adenocarcinoma Stage IA (1)
- mucinous borderline Stage IA (5)
- serous borderline Stage IA (4)
- Sertoli-Leydig cell tumor Stage IIIC (1)
- Granulosa cell tumor Stage IA (2)
High grade cancers (18)
- carcinosarcoma
Stage IIIC (1)
- high grade serous adenocarcinoma
• Stage IC (1)
• Stage IIC (1)
• Stage III/IV (15)
Serous cystadenoma (9)
Mucinous cystadenoma (1)
Fibroma (2)
Simple cyst (3)
Endometriotic cyst (2)
Necrotized cyst (1)
Genital prolapse or urinary
incontinence (18)
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fasting. The fact that the highest discrimination rate was achieved for
benign tumors and controls suggests that there is a degree of bias be-
tween patient groups. This may also result from the larger and more
heterogenous nature of cancer group.
5. Conclusion
According to our results,wepropose that theVOC signature of urine of
ovarian cancer patients can be recognized by FAIMS and that it has poten-
tial for being a non-invasive method in the detection of ovarian malig-
nancy. Our novel study encourages us to examine further possibilities of
FAIMS for diagnostics and follow-up of gynecological malignancies.
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Abstract 21 
 22 
Background: Previous results obtained from serum samples of late-stage, high-grade serous ovarian 23 
carcinoma patients showed large alterations in lipid metabolism. To validate and extend the results, 24 
we studied lipidomic changes in early-stage ovarian tumors. In addition to serous ovarian cancer, we 25 
investigated whether these changes occur in mucinous and endometrioid histological subtypes as 26 
well.  27 
Methods: Altogether, 354 serum or plasma samples were collected from three centers, one from 28 
Germany and two from Finland. We performed lipidomic analysis of samples from patients with 29 
malignant (N=138) or borderline (N=25) ovarian tumors, and 191 controls with benign pathology. 30 
These results were compared to previously published data.  31 
Results: We found 39 lipids that showed consistent alteration both in early- and late-stage ovarian 32 
cancer patients as well as in pre- and postmenopausal women. Most of these changes were already 33 
significant at an early stage and progressed with increasing stage. Furthermore, 23 lipids showed 34 
similar alterations in all investigated histological subtypes.  35 
Conclusion: Changes in lipid metabolism due to ovarian cancer occur in early-stage disease but 36 
intensify with increasing stage. These changes occur also in other histological subtypes besides high 37 
grade serous carcinoma. Understanding lipid metabolism in ovarian cancer may lead to new 38 
therapeutic and diagnostic alternatives. 39 
 40 
Key words: ovarian cancer; lipid; lipidomic; diagnostic; early-stage; histology; biomarker 41 
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Background 44 
Prognosis of ovarian cancer improves remarkably if the disease is diagnosed at an early-stage, as 45 
early detection affords better opportunities for curative treatment. Current diagnostic methods 46 
primarily include vaginal ultrasound combined with the blood test to measure cancer antigen 125 (CA 47 
125) levels. These methods lack specificity and sensitivity, especially in non-advanced ovarian 48 
cancer.1 Therefore, there is a demand for new detection methods and biomarkers for distinguishing 49 
benign and borderline ovarian tumors, as well as early-stage and advanced ovarian cancer. 50 
 51 
Malignant tumors, including ovarian cancer, adopt many metabolic abnormalities to meet the 52 
increased energy demand associated with increased cellular proliferation and tumor growth.2 In 53 
ovarian cancer, the metabolic alterations in tissues and body fluids have been investigated by 54 
metabolic profiling to identify biomarkers for early detection and reliable prognosis.3-5 Recently, 55 
using liquid chromatography-mass spectrometry (LC-MS), Gaul et al. found from serum 16 56 
diagnostic metabolites, including many lipids and fatty acids, that distinguish early-stage ovarian 57 
cancer samples from healthy control samples.6 In a lipidomic study, Buas et al. showed 34 58 
significantly altered metabolites between serous ovarian carcinoma and benign serous ovarian tumor 59 
patients, and the plasma levels of the lipids were reduced in patients with a malignant disease.7 60 
Recently, our metabolomic analyses of tumor and blood samples from high-grade serous ovarian 61 
carcinoma (HGSOC) patients showed elevated concentrations of hydroxybutyric acids, implicating 62 
that these molecules could act as diagnostic and prognostic biomarkers.8 Subsequently, lipidomic 63 
profiling of the same samples showed an overall reduction in the levels of most of the lipid species 64 
but elevations in specific ceramide (Cer) and triacylglycerol (TAG) lipids in metastatic ovarian cancer 65 
patients.9 66 
 67 
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Despite several studies showing lipidomic alterations in ovarian cancer, we are not aware of any 68 
studies that confirm which lipid species are the most consistently altered. To this end, as well as to 69 
validate our published lipidomic results and extend the analyses to low malignant potential 70 
(borderline) ovarian tumors and early-stage ovarian cancers, we applied the same previously used 71 
methodology9 to analyze blood samples from patients with early-stage ovarian cancers. These results 72 
were subsequently compared to the results obtained from patients with benign gynecological disease. 73 
Our further aim was to investigate whether the lipidomic alterations found in patients with HGSOC 74 
can be applied to other histological subtypes, i.e., to mucinous and endometrioid ovarian carcinoma.  75 
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Materials and methods 76 
Patients and samples 77 
We performed lipidomic profiling on two study cohorts, one from Charitè (N=189) and another from 78 
Finland (N=165, from Tampere (N=111) and Oulu (N=54) University Hospitals). In addition, we 79 
used data from an independent, previously published study9, referred herein as the Charité discovery 80 
(N=250). The Charité discovery study included 5 additional samples from patients with endometrioid 81 
tumors that were excluded from the original publication.9 Clinical characteristics of these three study 82 
cohorts are shown in Table 1. The samples from both Charité studies were serum samples, while the 83 
Finnish samples were a mixture of serum and plasma, as shown in Table 1. All samples were 84 
collected preoperatively. In total, in these three studies, 290 samples were collected from patients 85 
with malignant ovarian tumors, 25 samples from subjects with borderline ovarian tumors, and 289 86 
from women with benign gynecological tumors, endometriosis, infection, or other conditions. The 87 
diagnosis of invasive and borderline ovarian tumors was based on the WHO Classification.10 The 88 
gynae-pathologists at the respective hospitals (University Hospitals of Oulu and Tampere, Finland, 89 
and Charité, Berlin, Germany) did the histological analyses, and immunohistochemistry was used 90 
when needed. The Charité samples were collected at the Tumor Bank - Ovarian Cancer Network 91 
(www.toc-network.de) at the Charitè Medical University (Berlin, Germany) between 07/2013 and 92 
09/2016. The Finnish samples, from Tampere University Hospital and Oulu University Hospital, 93 
were collected between 2/2011-11/2014 and between 01/2009-12/2015, respectively.  94 
 95 
Lipidomic analysis of serum samples (LC-MS/MS) 96 
The samples were randomized within each cohort before lipidomic analysis. The lipidomic analysis 97 
has been previously described in detail.9 Briefly, lipidomic analyses were performed using two 98 
platforms, a global screening method and a phosphosphingolipid platform. For the screening method, 99 
10 µl of sample was needed for the extraction of the lipids using a modified Folch extraction.11 For 100 
6 
 
the phosphosphingolipid method, 25 µl of sample was needed for the extraction of lipids using protein 101 
precipitation in methanol.  102 
 103 
Lipidomic screening and phosphosphingolipid platforms were both analyzed on a hybrid triple 104 
quadrupole/linear ion trap mass spectrometer (QTRAP 5500, AB Sciex, Concords, Canada) equipped 105 
with ultra-high-performance liquid chromatography (UHPLC) (Nexera-X2, Shimadzu, Kyoto, 106 
Japan). Chromatographic separation of the lipidomic screening platform was performed on an 107 
Acquity BEH C18, 2.1 × 50 mm id. 1.7 µm column (Waters Corporation, Milford, MA, USA). 108 
Chromatographic separation of the phosphosphingolipid platform was performed on an AQUASIL 109 
C18, 2.1 × 50 mm, 5 µm (Thermo Fisher Scientific, Waltham, MA, USA) column set at 60 °C. For 110 
the MS analysis, a targeted approach in the positive ion mode was used for both platforms. The data 111 
were collected using a scheduled multiple reaction monitoring (sMRM™) algorithm for the 112 
lipidomics screening platform12 and multiple reaction monitoring (MRM) for phosphosphingolipids. 113 
The lipidomic data were processed using Analyst and MultiQuant 3.0 software (AB Sciex), and the 114 
area or height ratios of the analyte and its corresponding IS peak were normalized with the IS amount 115 
and the sample volume. The details of the chromatography and mass spectrometry conditions have 116 
been previously described.9 117 
 118 
The number of lipids and the mean coefficient of variation for each lipid class, determined from the 119 
quality control samples (6 in each 96-well plate), are shown in Supplementary Table S1. The list of 120 
all analyzed lipids has been published previously.9 121 
 122 
Statistical analyses 123 
Group comparisons (patients vs. controls) were performed by calculating the mean relative difference 124 
between the groups, and the p-values were determined by parametric t-tests on log-transformed 125 
concentrations. R version 3.4.2 was used for all statistical analyses. Tableau 10.1 was used for 126 
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heatmap visualizations. For diagnostic calculations, logistic regression models were developed using 127 
all samples in the Charité cohort and tested in the Finnish cohort. The AUC values were determined 128 
using the pROC package.13 The top models presented in the article were selected by calculating the 129 
sum of the AUC values in both cohorts, and selecting the models with the highest values. 130 
  131 
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Results 132 
Validation of altered lipidomic profile in ovarian cancer patients 133 
To validate the lipidomic alterations detected in ovarian cancer patients, we determined which lipids 134 
were similarly altered between the patients and the controls in the two study cohorts (Charité and 135 
Finland), in addition to the previously published Charité discovery cohort (Table 1), provided that 136 
the change between the patients and the controls was significant in at least two cohorts. The results 137 
confirmed that ovarian cancer causes wide lipidomic changes as 155 lipids showed the same direction 138 
of change in all cohorts, and most of these changes were also statistically significant in all three 139 
independent cohorts (Supplementary Table S2). All further analyses were limited to these 155 140 
lipids. 141 
 142 
Lipidomic changes emerge in early-stage ovarian cancer patients 143 
To identify which lipids have the best diagnostic potential, or those already altered in early-stage 144 
(I/II) cancer, we selected lipids that showed consistent increase or decrease both in stage I/II vs. 145 
controls and stage III/IV vs. controls, including all cohorts and histological subtypes. In addition, the 146 
lipids had to be significantly altered at least in stage III/IV patients in the Charité and Finnish cohorts. 147 
This approach resulted in 39 lipids which are shown in a heatmap in Figure 1. Samples from patients 148 
with ovarian cancer revealed a consistent decrease in the concentration of most of the analyzed lipid 149 
classes and included phospholipids (phosphatidylcholines (PCs), lysophosphatidylcholines (LPCs) 150 
and phosphatidylinositols (PIs)), cholesteryl esters (CEs), glucosyl/galactosyl ceramides 151 
(Glc/GalCers) and sphingomyelins (SMs). In turn, an increase was observed in many ceramides 152 
(Cers) with certain fatty acyl (FA) side chain compositions. Cers with 18:0, 20:0 and 24:1 FAs were 153 
increased, while 24:0 FA-containing Cers were decreased. The TAG lipid species also showed a 154 
variable trend depending on the FA side chains; TAGs with shorter FA side chains were decreased, 155 
whereas those with longer FA side chains were increased. In many lipid species, the alterations were 156 
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more significant in advanced stage (III/IV) patients but were already present in early-stage patients 157 
(I/II) (Figure 1). The lipidomic changes were consistent in both pre- and postmenopausal patient 158 
populations (Figure 1). 159 
 160 
Tumors of various histological subtypes induce similar lipid changes 161 
As the previous results were derived from HGSOC patients only9, we investigated whether some 162 
changes in lipid species are also significant in patients with other histological subtypes (mucinous 163 
and endometrioid). Thus, we selected lipids showing the same direction of alteration in all histological 164 
subtypes of the Charité and Finnish cohorts. In addition, the selected lipids had to be significant in 165 
either mucinous or endometrioid subtypes in either of the cohorts. Twenty-one of 23 lipids were 166 
decreased in all histological subtypes (Figure 2), and only Cer(d18:1/18:0) and TAG(18:1/18:1/20:4) 167 
were increased. The most significant alterations were observed in PCs and LPCs. All lipid changes 168 
were significant in the serous subtype, which was expected based on the large number of cases in 169 
both cohorts. Interestingly, CA 125 was not significantly altered in mucinous subtype samples, while 170 
most lipid changes were significant in the Charité cohort despite a low number of mucinous cases 171 
(N=6). For endometrioid histology, none of the lipids were significant in the Charité cohort (N=9), 172 
whereas the Finnish cohort, with a slightly greater number of cases (N=14), showed significant 173 
alterations. 174 
 175 
Fewer lipid changes are seen in borderline tumors than in malignant tumors 176 
We also analyzed whether the observed lipidome alterations are present in borderline ovarian tumors. 177 
When only those lipids that were altered in the same direction in both cohorts and significant in at 178 
least one of them were selected, there were only a few significant alterations (Figure 3). Thus, it 179 
appears that borderline tumors do not cause as much of a change to the lipidome as malignant tumors. 180 
 181 
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Lipids improve the diagnostic value of CA125 for the detection of early-stage cancer 182 
Finally, we investigated whether lipids can improve the diagnostic value of CA 125. As lipid ratios 183 
have shown diagnostic value in other diseases14, we investigated combinations of all lipids and lipid 184 
ratios together with CA125. The lipids used for this analysis are shown in Figure 1. For the ratio 185 
calculations, the increased lipids in ovarian cancer patients and CA 125 were used as numerators, and 186 
all other lipids were used as denominators. To find more robust biomarkers, those lipids and lipid 187 
ratios were excluded that were significantly different (t-test p<0.05 and mean relative change > 10%) 188 
between control samples of the Charité and Finland cohorts. The models were generated using all 189 
subjects in the Charité cohort, and tested in the stage I/II and III/IV ovarian cancer patients separately, 190 
in addition to the validation in the Finnish cohort. As an example, the models with the highest 191 
improvement in both the Charité and Finnish cohorts are shown in Table 2. In the Charité cohort, CA 192 
125 as a continuous variable instead of using the 35 U/mL cut-off improved the AUC values, and 193 
further improvement was seen for the detection of early-stage cases with incorporation of lipids, but 194 
not for late-stage cases where already CA 125 alone performed well. In the Finnish cohort, which had 195 
a higher proportion of other than serous malignant tumors, the AUC values for CA 125 and also the 196 
models with lipids were lower than in the Charité, but again the lipids improved the diagnostic value 197 
of CA 125 for the detection of stage I/II cancers. 198 
 199 
  200 
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Discussion 201 
The present global lipidomics study investigating early- and advanced-stage ovarian cancer of various 202 
histological subtypes was performed to validate and extend our previous results on lipid changes in 203 
HGSOC patients. Altered lipid metabolism seems to be linked to ovarian cancer, but specific findings 204 
are still strikingly variable. Our data are in line with those earlier studies showing an overall decrease 205 
in the serum/plasma concentration of lipid metabolites7 and glycerophospholipids15,16 in ovarian 206 
cancer patients. The intensification of lipid changes in the advanced stage ovarian cancer patients 207 
suggests that the tumors are exploiting circulating lipids and lipoproteins with proportion to their size. 208 
The overall decrease of PCs may be associated with reduction of HDL cholesterol and ApoA1 in the 209 
ovarian cancer patients17,18, as PCs are known to be abundant especially in the HDL particles.19 210 
However, this phenomenon cannot be used to explain the increase of lipid species in ovarian cancer 211 
patients. It has been suggested that changes in lipid metabolism during ovarian cancer pathogenesis 212 
reflect higher levels of cell division20, enhanced fatty acid β-oxidation5, and increased cellular 213 
proliferation or motility due to increased PI3-kinase activity21, yet there are likely to be additional 214 
mechanisms explaining the alterations of specific lipids. 215 
 216 
These results confirm our previous report describing an increase in the serum concentration of 217 
Cer(d18:1/18:0), Cer(d18:0/18:0) and TAG(18:1/18:1/20:4) in ovarian cancer patients.9 Moreover, 218 
the phenomenon is evident at the early stages of disease development, i.e. stage I/II, but was found 219 
to become more pronounced with disease progression. In addition to HGSOC, Cer(d18:1/18:0) and 220 
TAG(18:1/18:1/20:4) were also significantly increased in mucinous and endometrioid ovarian cancer 221 
samples from the Finnish cohort. However, the number of mucinous and endometrioid carcinoma 222 
samples was likely too low in the Charitè cohort to show any significant difference. Interestingly, 223 
Cer(d18:1/18:0) and its precursor Cer(d18:0/18:0) have been associated with the development of 224 
insulin resistance and type 2 diabetes.22-24 Taken together, these alterations to the lipid profile and 225 
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other metabolic changes, such as increase of ketone bodies8, suggest that the metabolic profile of 226 
ovarian cancer patients resemble a diabetic phenotype. 227 
 228 
Sphingolipids, especially Cers, have been linked to the development and progression of cancer25, but 229 
results appear vary depending on the type of tumor.26 Cers are considered to have anti-cancer 230 
properties, to act as second messengers for cell apoptosis25 and to modulate cell growth.27 Another 231 
sphingolipid, sphingosine-1-phosphate (S1P), has opposing cellular effects to Cers.26 The role of 232 
sphingolipid metabolism in ovarian cancer has been investigated in a recent study in which 74 women 233 
with HGSOC were found to have significantly elevated plasma and tissue concentrations of C16-Cer, 234 
C18:1-Cer and C18-Cer compared to those of healthy controls28, which is in line with our results. 235 
The researchers speculated that the increased amounts of Cers would be associated with particularly 236 
aggressive epithelial ovarian cancer cases and that the increased Cer concentrations would lead to 237 
increased conversion to S1P, as they found an elevated S1P concentration in tumor tissue. However, 238 
congruent with our data, elevation of S1P could not be observed in blood. 239 
 240 
Buas et al. have shown reduction of all measured TAGs in the plasma of ovarian cancer patients.7 241 
However, in a lipidomic analysis of low and highly aggressive ovarian cancer cell lines, TAGs 242 
increased dramatically along aggressiveness of the cells and were assumed to be the largest source of 243 
cellular energy.29 In a mouse model of HGSOC, compared to healthy mice, the serum levels of 244 
LPE(16:0) and PIs were decreased, while TAG(55:7) was significantly increased at early-stage cancer 245 
development.30 On the other hand, decreased levels of TAGs in epithelial ovarian cancer patients 246 
have been shown to predict early recurrence of cancer.31 In our study, only the concentrations of 247 
TAGs with longer fatty acid chains were increased or not altered, while those TAGs with short fatty 248 
acid chains were decreased. Our former study proposed that this result could be explained by genetics 249 
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via low expression of the ABCD1 gene9 which is associated with transport of long-chain fatty acids 250 
into the peroxisome for β-oxidation.32 251 
 252 
Phospho- and sphingolipids are the most studied lipids in regard to the pathogenesis of ovarian 253 
cancer.33 In 2004, it was shown that plasma levels of lysophospholipids varied between healthy 254 
controls and ovarian cancer patients, as well as pre- and postoperatively.34 Moreover, in a pathway 255 
analysis, glycerophospholipid (LPCs and PCs) metabolism was a main dysregulated pathway in the 256 
pathogenesis of ovarian carcinoma.35 Alteration of LPC levels may be caused by the binding and 257 
activation of specific cell surface G protein-coupled receptors (GPCRs), which can activate cell 258 
growth and proliferation.36 Altered LPCs and lysophosphatidylethanolamines (LPEs) contribute to 259 
genetic instability and cancer initiation via enhanced phospholipase A2 (PLA2) activity37 and 260 
inflammation.3 Phospholipids are needed in cancer cells to generate the cellular membrane and 261 
maintain membrane integrity.3 A large metabolic profiling study3 of 448 plasma samples from 262 
epithelial ovarian cancer patients identified 53 specific metabolites that distinguished early- and late-263 
stage ovarian cancer with an AUC of 0.88. These metabolites included LPCs and LPEs which were 264 
elevated in localized ovarian cancer but reduced in metastasized ovarian cancer. A potential 265 
explanation for the reduced levels of LPCs and LPEs in advanced cancer could be that rapidly 266 
proliferating tumors consume more phospholipids in their attempt to maintain membrane integrity, 267 
leading to an exhaustion of substrates.30 Also lysophosphatidic acid (LPA) has been purported to be 268 
a possible biomarker because some studies have shown LPA to be elevated in plasma samples of 269 
ovarian cancer patients.34,38, but we could not confirm this as we did not monitor LPAs in our 270 
lipidomic method. 271 
 272 
Borderline ovarian tumors have low malignant potential and elevated mitotic activity without stromal 273 
invasion. They commonly occur in younger women compared to ovarian cancer patients and have 274 
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lower recurrence rates.39 Denkert et al. found significantly different metabolite levels (including 275 
metabolites from glycerolipid metabolism and free fatty acids) in borderline ovarian tumor tissues 276 
compared to invasive ovarian carcinomas using gas chromatography/time-of-flight mass 277 
spectrometry.20 However, they had only nine borderline tumors in their study. Based on the present 278 
study, lipid metabolism in borderline ovarian tumors differs from that in invasive cancers. The Charité 279 
cohort had more borderline ovarian tumors (N=18) than the Finnish cohort. These samples were 280 
mainly serous epithelial tumors. Significant differences were observed only for occasional 281 
plasmalogens as compared to benign controls. 282 
 283 
In the Charitè cohort, the results were evaluated by menopausal status. Greater alterations in Cer 284 
d16:1, d18:0 and d18:1 were observed in postmenopausal women. However, in some PC lipids, 285 
premenopausal changes were stronger. A serum lipidomics study of ovariectomized healthy rats 286 
showed that Cers and phospholipids increased in response to estrogen deficiency while TAGs 287 
decreased, which was contrary to earlier studies.40 Our study lacks data on possible hormone 288 
replacement or hormone therapy in the Charitè premenopausal group. The samples from the Finnish 289 
cohort were postmenopausal with no current hormone therapy. 290 
 291 
Our study had some limitations. First, changes in lipoprotein levels can at least partly explain the 292 
overall decrease of lipids among cancer patients, but unfortunately, we did not have lipoprotein levels 293 
available from the patients. Neither did we have the information on BMI, which may also affect lipid 294 
levels. Second, in the Finnish cohort, the sample sets contained both serum and plasma samples, 295 
which may affect the lipid levels. However, it is worth noting that the lipid changes were consistent 296 
with the two other data sets, and thus, it can be assumed that the difference does not significantly 297 
affect the results. Moreover, the logistic regression models developed in the Charité cohort showed 298 
high AUC values in the Finnish cohort, which also supports the validity of the results. Third, there 299 
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was an age imbalance in the cohorts, as the Charité cohort patients were older than the controls. 300 
However, the results were consistent with the Finnish cohort, where the controls were older than the 301 
patients. This finding and our previous age-adjusted lipidomic analyses9 suggest that age does not 302 
explain the differences in lipid metabolism observed in ovarian cancer patients. Fourth, the blood 303 
samples were not collected during a fasting condition, which may affect the results. However, it is 304 
worth noting that there were no differences between groups and that it is expected that fasting samples 305 
might have given a better separation between the ovarian cancer patients and the subjects with benign 306 
disease. 307 
 308 
We have shown that blood lipidomic changes occur in several patient cohorts and already at the early-309 
stage ovarian cancer, but intensify with the progression of the disease. Many of the lipid changes are 310 
similar in patients with serous, mucinous and endometrioid ovarian carcinoma, suggesting that 311 
rewiring of lipid metabolism is an integral part of ovarian carcinogenesis. The results provide an 312 
excellent basis for further development of diagnostics and the future investigations should also 313 
explore the potential of exploiting the altered ovarian cancer lipid metabolism for therapeutic 314 
purposes. 315 
  316 
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Figure 1. Heatmap showing lipidomic changes in early- (I/II) and late-stage (III/IV) ovarian cancer 437 
patients. In addition, the results are shown in pre- and postmenopausal patients of all stages. The 438 
difference is calculated relative to controls. The color scale (from -70% to 100%) is adjusted 439 
according to the lipids, in cancer patients CA 125 showed mean elevation higher than 100%. ***, 440 
p<0.001; **, p<0.01; *, p<0.05. Charité study had 60 premenopausal controls and 17 cancer cases as 441 
well as 48 postmenopausal controls and 42 cancer cases. 442 
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Figure 2. Heatmap showing lipidomic changes in ovarian cancer patients with different histological 444 
subtypes as compared to control subjects. The color scale (from -70% to 100%) is adjusted according 445 
to the lipids, in some of the analyses CA 125 showed elevation higher than 100%. ***, p<0.001; **, 446 
p<0.01; *, p<0.05. 447 
 448 
 449 
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Figure 3. Heatmap showing lipidomic changes in patients with borderline tumors as compared to 450 
control subjects. The color scale is adjusted according to the lipids (from -70% to 100%), CA 125 451 
showed elevation higher than 100% in the Charité cohort. ***, p<0.001; **, p<0.01; *, p<0.05. 452 
 453 
 454 
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Table 1. Clinical characteristics of the study cohorts. For age, the values represent median and interquartile 456 
range and p-values in the comparison against the control group are denoted as follows: ***, p<0.001; **, 457 
p<0.01; *, p<0.05; N.S., not significant. 458 
    Charité Finland 
Charité 
discovery 
Malignant   62 76 152 
Age  57 (50-72)*** 58 (51-64)* 59 (50-67)*** 
Histology serous 41 29 147 
  mucinous 6 18   
  endometrioid 9 14 5 
  other 6 15   
Stage I&II 26 52 8 
  III&IV 33 22 133 
  NA 3 2 11 
Sample serum 62 22 152 
  plasma  54   
Borderline   18 7   
Age  51 (44-57) 
N.S. 63 (56-67) N.S.   
Histology serous 13 5   
  mucinous 2 2   
  other 3    
Stage I&II 12 7   
  III&IV 3    
  NA 3    
Sample serum 18 7   
Benign   109 82 98 
Age  49 (40-58) 62 (56-69) 41 (31-55) 
Diagnosis other 7 2 43 
  uterine fibroid 7 1 25 
  cyst 4 9 1 
  cystic teratoma 12 8 5 
  functional cyst 22    
  inclusion cyst 3    
  endometrioid cyst 5    
  non-ovarian cyst  4   
  cystadenoma 32 2 4 
  mucinous cystadenoma  3 2 
  cystadenofibroma 7 10 2 
  serous cystadenoma  34 3 
  Brenner tumor 1 2 1 
  fibroma/thecoma  5   
  fibroadenoma  1   
  incomplete abortion   5 
  adnexitis   5 
  endometriosis 9 1 2 
Sample serum 109 82 98 
 459 
  460 
Table 2. AUC values with 95% confidence intervals for the logistic regression models. As comparison, the models are shown also for CA 125 alone or CA 461 
125 as binary variable dichotomized by the clinically used 35 U/mL cut off value. 462 
    Charité Finland 
Variable1 Variable 2 All Stage I/II Stage III/IV All Stage I/II Stage III/IV 
CA125 / Glc/GalCer(d18:1/26:0) Cer(d18:1/24:1) / LPC 14:0_sn2 0.93 (0.89-0.96) 0.87 (0.80-0.94) 0.98 (0.96-1.00) 0.76 (0.68-0.85) 0.74 (0.64-0.83) 0.93 (0.84-1.00) 
Cer(d18:1/24:1) / LPC 14:0_sn2 CA125 / PC 37:2 0.93 (0.89-0.96) 0.87 (0.81-0.94) 0.98 (0.95-1.00) 0.76 (0.68-0.85) 0.73 (0.64-0.83) 0.95 (0.89-1.00) 
Cer(d20:1/24:1) / LPC 14:0_sn2 CA125 / PC 37:2 0.92 (0.87-0.96) 0.85 (0.77-0.93) 0.98 (0.95-1.00) 0.77 (0.68-0.85) 0.74 (0.64-0.83) 0.95 (0.90-1.00) 
Cer(d18:1/24:1) / LPC 14:0_sn2 CA125 / PI 38:2 0.92 (0.89-0.96) 0.87 (0.81-0.94) 0.97 (0.94-1.00) 0.77 (0.69-0.85) 0.75 (0.66-0.84) 0.95 (0.88-1.00) 
CA125 TAG(18:1/18:1/22:6) / LPC 14:0_sn2 0.91 (0.86-0.96) 0.83 (0.73-0.92) 0.98 (0.96-1.00) 0.78 (0.70-0.86) 0.75 (0.66-0.84) 0.89 (0.77-1.00) 
TAG(18:1/18:1/22:6) / LPC 14:0_sn2 CA125 / PC 37:2 0.91 (0.86-0.96) 0.83 (0.74-0.91) 0.98 (0.96-1.00) 0.78 (0.70-0.86) 0.75 (0.66-0.84) 0.88 (0.73-1.00) 
TAG(18:1/18:1/22:6) / LPC 14:0_sn2 CA125 / PC P-34:2 +1 0.91 (0.86-0.96) 0.83 (0.75-0.92) 0.98 (0.96-1.00) 0.78 (0.70-0.86) 0.75 (0.66-0.84) 0.89 (0.75-1.00) 
TAG(18:1/18:1/22:6) / LPC 14:0_sn2 CA125 / SM 37:2 0.91 (0.86-0.95) 0.83 (0.73-0.92) 0.98 (0.96-1.00) 0.78 (0.70-0.86) 0.75 (0.66-0.84) 0.91 (0.80-1.00) 
Cer(d20:1/24:1) / LPC 14:0_sn2 CA125 / PI 38:2 0.91 (0.87-0.96) 0.85 (0.76-0.93) 0.97 (0.94-1.00) 0.78 (0.70-0.86) 0.76 (0.67-0.85) 0.95 (0.88-1.00) 
TAG(18:1/18:1/22:6) / PC 30:0 CA125 / PC 30:0 0.90 (0.85-0.95) 0.82 (0.73-0.91) 0.98 (0.95-1.00) 0.79 (0.72-0.87) 0.77 (0.68-0.85) 0.91 (0.78-1.00) 
CA125   0.90 (0.84-0.95) 0.81 (0.71-0.90) 0.97 (0.94-1.00) 0.72 (0.62-0.81) 0.67 (0.57-0.78) 0.95 (0.91-1.00) 
CA125 (35 U/mL cut-off)   0.80 (0.73-0.86) 0.69 (0.59-0.80) 0.89 (0.84-0.94) 0.71 (0.64-0.79) 0.68 (0.60-0.76) 0.91 (0.87-0.95) 
 463 
Lipid class Number of lipids CV
AC 8 15 %
CE 21 24 %
Cer d16:1 8 26 %
Cer d18:0 7 36 %
Cer d18:1 9 25 %
Cer d18:2 9 27 %
Cer d20:1 4 22 %
DAG 18 29 %
Gb3 4 41 %
Glc/GalCer 22 29 %
LacCer 10 28 %
LPC 40 11 %
LPC P/LPC O 13 11 %
LPE 11 12 %
LPE P/LPE O 2 13 %
PC 70 20 %
PC P/PC O 46 23 %
PE 23 27 %
PE P/PE O 15 30 %
PG 4 23 %
PI 19 19 %
S1P/SA1P 4 9 %
SM 41 16 %
TAG 42 11 %
Supplementary Table S1. Number of lipids and the mean coefficient 
of variation (CV) for all the analyzed lipid classes.
Supplementary Table S2. Lipids that showed consistent alteration in all three and were significant in at least two study cohorts.
Lipid class Lipid name Change (%) p-value Change (%) p-value Change (%) p-value
CE 14:0 -10,5 0,113 -22,3 1,2E-05 -22,3 4,1E-06
CE 14:1 -13,0 0,247 -28,2 1,5E-04 -22,0 4,7E-05
CE 16:2 -11,8 0,060 -20,7 3,3E-04 -21,1 2,0E-07
CE 18:0 -9,8 0,113 -10,8 0,020 -26,7 4,9E-10
CE 18:2 -9,9 0,028 -2,1 0,568 -21,9 7,2E-10
Cer(d16:1/23:0) -7,0 0,300 -28,5 2,6E-06 -24,9 5,7E-04
Cer(d16:1/24:0) -17,7 0,027 -30,2 6,0E-07 -29,3 6,1E-08
Cer(d16:1/26:0) -15,7 0,055 -18,7 0,003 -17,1 0,004
Cer(d18:0/18:0) 36,1 0,001 45,0 0,044 49,7 5,7E-05
Cer(d18:0/20:0) 28,2 0,023 58,2 4,1E-04 22,0 0,018
Cer(d18:0/23:0) -8,8 0,158 -20,4 0,001 -17,4 0,004
Cer(d18:1/18:0) 56,2 2,9E-06 52,5 1,9E-04 71,4 7,2E-12
Cer(d18:1/20:0) 15,9 0,027 24,4 0,027 39,7 9,9E-08
Cer(d18:1/24:0) -4,4 0,570 -13,6 0,002 -11,9 0,009
Cer(d18:1/24:1) 18,8 0,003 6,9 0,477 30,5 1,1E-06
Cer(d18:2/18:0) 28,0 0,005 20,7 0,063 26,2 5,2E-04
Cer(d18:2/23:0) -10,9 0,190 -17,9 7,8E-04 -18,5 5,6E-04
Cer(d18:2/24:0) -13,4 0,105 -20,8 9,9E-05 -22,4 1,1E-05
Cer(d18:2/26:0) -10,7 0,298 -9,8 0,037 -14,2 0,040
Cer d20:1 Cer(d20:1/24:1) 29,1 6,8E-04 13,5 0,126 43,9 2,1E-07
DAG DAG(14:0/18:1) -24,0 0,203 -23,5 9,6E-04 -39,1 6,9E-04
Gb3 Gb3(d18:1/24:0) -16,8 0,011 -7,7 0,788 -23,1 8,6E-05
Glc/GalCer(d16:1/20:0) -21,6 0,011 -25,1 0,001 -16,8 9,7E-04
Glc/GalCer(d16:1/22:0) -19,0 0,015 -29,5 4,2E-05 -23,4 1,5E-05
Glc/GalCer(d16:1/23:0) -22,8 0,003 -22,5 0,008 -19,3 3,8E-04
Glc/GalCer(d16:1/24:0) -26,9 4,5E-04 -25,8 0,013 -23,1 5,0E-06
Glc/GalCer(d18:1/20:0) -15,4 0,019 -6,7 0,845 -19,7 9,2E-05
Glc/GalCer(d18:1/22:0) -18,8 0,001 -11,2 0,752 -25,9 2,6E-07
Glc/GalCer(d18:1/23:0) -19,4 0,003 -15,9 0,081 -23,8 7,8E-07
Glc/GalCer(d18:1/24:0) -17,2 0,002 -19,7 0,047 -24,2 4,7E-07
Glc/GalCer(d18:1/26:0) -16,3 0,016 -23,7 0,002 -21,0 9,4E-05
Glc/GalCer(d18:2/20:0) -19,9 0,003 -11,7 0,587 -23,3 1,7E-04
Glc/GalCer(d18:2/22:0) -19,2 0,002 -19,6 0,022 -17,9 5,0E-04
Glc/GalCer(d18:2/23:0) -22,2 0,003 -20,5 0,012 -21,6 5,2E-05
Glc/GalCer(d18:2/24:0) -17,1 0,002 -17,5 0,088 -23,9 4,8E-08
LacCer LacCer(d16:1/16:0) -3,9 0,495 -12,8 0,016 -21,1 5,3E-05
LPC 14:0_sn1 -31,2 1,9E-05 -13,7 0,001 -19,1 0,002
LPC 14:0_sn2 -34,0 3,1E-05 -21,0 3,4E-05 -30,3 2,3E-05
LPC 18:2_sn1 -32,0 1,1E-05 -5,0 0,147 -29,7 1,9E-07
LPC 18:2_sn2 -33,4 2,9E-06 -12,8 0,004 -34,7 2,3E-12
LPC 20:0_sn1 -24,5 6,2E-05 -2,7 0,308 -16,6 0,003
LPC 20:0_sn2 -25,2 9,9E-06 -6,9 0,085 -14,6 0,011
LPC 20:2_sn2 -25,4 6,7E-06 -7,0 0,067 -16,4 3,2E-05
LPC 20:3_sn2 -19,0 0,003 -2,6 0,226 -24,4 1,4E-06
LPC 22:0_sn1 -27,2 1,6E-07 -13,3 0,004 -28,7 6,3E-10
LPC 24:0_sn1 -21,0 3,4E-06 -10,0 0,015 -28,7 1,5E-12
LPC 24:0_sn2 -19,0 2,0E-05 -11,6 0,007 -28,9 2,3E-13
LPC O-20:0 -19,6 0,001 -6,0 0,095 -15,5 7,1E-04
LPC O-22:0 -15,6 0,007 -6,6 0,074 -25,3 4,8E-11
LPC O-22:1 -22,3 3,7E-04 -5,3 0,113 -17,5 0,002
LPC O-24:1 -15,3 0,019 -6,1 0,093 -17,8 8,2E-05
LPC O-24:2 -25,3 5,5E-05 -8,5 0,203 -33,0 1,2E-08
LPE 18:2_sn1 -37,7 5,8E-06 -1,3 0,288 -40,1 1,5E-11
LPE 18:2_sn2 -37,2 1,8E-06 -4,0 0,191 -35,4 4,6E-10
LPE P-16:0 -9,9 0,013 -23,3 1,5E-07 -12,4 0,197
LPE P-18:0 -13,2 0,005 -12,8 9,4E-05 -7,8 0,382
PC 28:0 -47,2 5,5E-06 -47,8 2,7E-07 -59,0 1,5E-15
PC 30:0 -26,4 0,001 -25,1 2,1E-05 -43,4 4,0E-15
PC 30:1 -39,4 2,1E-04 -34,6 1,2E-06 -52,1 2,4E-13
PC 30:2 -57,6 4,2E-08 -48,2 4,5E-07 -61,4 2,1E-14
PC 31:1 -14,8 0,311 -23,8 0,002 -36,9 1,9E-08
PC 32:1 -12,2 0,795 -15,0 0,016 -29,0 1,9E-06
PC 32:2 -38,0 8,7E-07 -26,7 1,9E-06 -52,5 4,0E-19
PC 32:3 -42,9 1,1E-05 -34,3 2,9E-07 -58,5 4,2E-17
PC 33:2 -18,0 0,010 -7,8 0,098 -35,6 6,9E-13
PC 33:3 -23,3 0,021 -23,4 1,9E-04 -42,0 4,2E-11
PC 34:2 -15,9 0,001 -5,8 0,198 -28,6 4,5E-10
PC 34:3a -22,1 5,0E-04 -14,2 0,010 -37,9 9,7E-14
PC 34:3b -19,2 0,025 -17,5 0,001 -35,8 3,9E-12
PC 34:3c -25,4 0,002 -21,8 0,010 -44,1 1,2E-13
PC 34:4 -35,4 1,3E-05 -22,1 4,5E-05 -52,1 5,6E-16
PC 34:5 -28,0 0,006 -39,4 2,9E-08 -41,3 1,4E-05
PC 35:2a -16,5 0,036 -0,4 0,931 -26,3 2,6E-06
PC 35:2b -16,1 0,006 -2,9 0,413 -28,1 1,1E-09
PC 35:3a -26,7 1,3E-05 -5,9 0,151 -39,8 3,1E-15
PC 35:3b -17,1 0,019 -4,5 0,206 -35,9 2,0E-09
PC 36:1 -16,3 0,033 -9,5 0,038 -12,5 0,053
PC 36:2 -22,6 7,2E-05 -7,7 0,103 -35,1 2,0E-13
PC 36:3a -30,8 3,2E-07 -3,8 0,280 -36,0 2,2E-14
PC 36:3b -14,6 0,040 -4,9 0,186 -29,2 1,9E-08
PC 36:5a -16,9 0,030 -10,6 0,097 -32,1 1,4E-07
PC 36:6 -28,8 7,7E-04 -20,3 7,5E-04 -46,4 2,0E-09
PC 36:7 -32,8 9,3E-04 -52,7 1,6E-13 -27,4 2,1E-05
PC 37:1 -16,8 0,004 -5,1 0,300 -20,5 4,6E-06
PC 37:2 -26,5 2,6E-05 -11,7 0,022 -36,3 6,0E-13
PC 37:3 -13,5 0,031 -2,2 0,432 -30,4 7,4E-09
PC 38:0 -10,9 0,049 -5,9 0,106 -29,1 5,0E-11
PC 38:3 -19,4 0,007 -3,0 0,262 -30,6 1,5E-09
PC 38:5b -4,4 0,564 -19,6 0,002 -16,1 0,003
PC 38:6a -28,1 9,3E-05 -9,9 0,051 -35,0 2,6E-10
PC 38:6b -33,2 1,3E-06 -5,8 0,446 -38,0 7,1E-13
PC 40:8 -22,0 0,004 -7,7 0,051 -33,4 6,8E-10
PC P PC P-34:2 -29,8 2,3E-06 -12,7 0,035 -33,3 2,7E-13
PC O-32:1 -17,6 0,011 -3,4 0,490 -31,3 7,1E-10
PC O-34:1 -13,4 0,012 -0,2 0,968 -22,2 1,2E-08
PC O-34:2 -29,9 1,0E-05 -12,6 0,031 -39,7 6,7E-17
PC O-36:1 -10,2 0,075 -9,8 0,026 -27,6 1,5E-07
Charité DiscoveryCharité Finland
LPC
LPC O
LPE
LPE P
PC O
PC
Glc/GalCer
CE
Cer d16:1
Cer d18:0
Cer d18:1
Cer d18:2
PC O-36:2b -27,1 4,4E-06 -2,1 0,924 -36,3 4,2E-14
PC O-36:3a -28,9 4,8E-07 -4,6 0,424 -38,7 4,8E-16
PC O-36:3b -22,1 1,5E-04 -0,2 0,644 -33,2 4,7E-13
PC P 36:2a -25,8 1,0E-04 -9,0 0,235 -26,8 6,2E-08
PC P-32:0 -17,6 0,001 -6,8 0,214 -20,2 8,1E-07
PC P-32:1 -16,2 0,018 -11,7 0,159 -21,4 1,6E-05
PC P-34:1 -13,8 0,039 -3,2 0,815 -13,9 3,6E-04
PE 34:3 -19,1 0,328 -19,5 0,009 -49,7 8,1E-07
PE 36:2 -10,7 0,326 -17,1 0,010 -37,9 1,5E-06
PE 36:3a -31,0 0,005 -3,9 0,359 -53,8 2,0E-07
PE 36:3b -44,6 0,003 -5,4 0,674 -54,7 3,9E-08
PE 36:5 -6,4 0,700 -25,9 4,1E-05 -26,5 0,023
PE 38:3 -9,7 0,583 -10,6 0,042 -40,4 6,8E-07
PE 38:5b -7,2 0,995 -23,5 1,0E-04 -36,9 1,6E-04
PE O-34:1 -25,6 3,8E-05 -11,7 0,030 -12,4 0,047
PE O-36:4 -35,9 1,3E-05 -2,6 0,148 -49,1 4,9E-11
PE O-38:5 -35,4 3,0E-06 -0,2 0,419 -38,5 1,3E-09
PE O-38:6 -22,7 0,001 -4,2 0,259 -16,2 0,044
PG 34:1 -2,6 0,870 -13,6 0,024 -22,9 0,011
PG 36:2 -5,5 0,740 -16,6 0,007 -25,6 3,5E-04
PI 32:0 -22,0 0,181 -19,6 0,005 -49,6 3,0E-04
PI 34:1 -18,7 0,050 -7,2 0,163 -31,3 4,7E-04
PI 34:2 -17,6 0,016 -4,1 0,371 -31,3 6,4E-06
PI 36:1 -30,7 4,1E-05 -16,7 0,001 -40,1 3,8E-07
PI 36:3a -42,8 1,4E-08 -1,9 0,195 -51,5 9,9E-10
PI 36:3b -27,7 2,1E-04 -3,8 0,223 -39,6 3,0E-09
PI 38:2 -25,1 2,7E-04 -16,1 0,002 -40,5 3,5E-07
PI 38:3a -23,5 4,9E-04 -4,8 0,104 -33,8 1,6E-09
PI 38:3b -23,7 0,007 -3,9 0,458 -13,3 0,050
S1P d16:1 -10,2 0,045 -14,2 1,6E-04 -20,0 1,4E-08
S1P d18:1 -3,7 0,333 -9,3 0,001 -19,3 1,3E-07
S1P d18:2 -11,3 0,007 -2,0 0,396 -29,3 1,2E-13
SA1P SA1P d18:0 -6,4 0,126 -11,0 5,6E-04 -24,8 5,3E-13
SM 30:2 -29,3 1,2E-04 -24,5 2,5E-04 -35,8 2,2E-11
SM 31:1 -9,3 0,158 -11,3 0,033 -24,7 1,2E-07
SM 32:1 -3,4 0,615 -9,8 0,004 -17,3 7,4E-06
SM 32:2 -14,4 0,006 -13,7 9,7E-04 -28,0 3,3E-11
SM 36:0 27,8 0,012 40,0 0,008 6,9 0,288
SM 37:2 -24,7 4,2E-05 -9,5 0,069 -34,8 1,4E-13
SM 39:1 -8,9 0,203 -16,5 1,7E-04 -27,5 1,3E-10
SM 40:2b -10,0 0,044 -7,9 0,021 -27,3 4,5E-12
SM 44:2 12,6 0,035 13,1 0,041 5,0 0,304
TAG(14:0/16:0/18:1) -21,2 0,112 -31,0 6,4E-06 -37,3 1,0E-04
TAG(14:0/16:0/18:2) -16,3 0,318 -31,2 1,7E-05 -36,5 2,3E-04
TAG(14:0/16:1/18:1) -23,5 0,085 -30,4 1,1E-05 -44,3 1,5E-04
TAG(14:0/16:1/18:2) -28,1 0,009 -35,5 1,7E-05 -50,9 2,4E-06
TAG(14:0/17:0/18:1) -1,9 0,555 -20,4 0,004 -22,6 0,045
TAG(14:0/18:0/18:1) -17,5 0,166 -29,4 4,4E-05 -44,4 1,7E-04
TAG(14:0/18:2/18:2) -26,4 0,010 -23,0 0,013 -47,7 3,3E-06
TAG(14:1/16:0/18:1) -18,9 0,528 -30,3 1,9E-05 -35,4 0,005
TAG(14:1/16:1/18:0) -11,6 0,860 -23,7 0,001 -28,7 0,016
TAG(14:1/18:0/18:2) -12,7 0,391 -14,0 0,008 -25,3 0,014
TAG(14:1/18:1/18:1) -9,6 0,408 -15,7 0,009 -33,0 1,2E-04
TAG(16:0/18:1/18:1) 18,4 0,002 3,0 0,780 9,2 0,037
TAG(16:1/16:1/16:1) -19,3 0,207 -26,7 5,2E-04 -43,7 5,2E-05
TAG(16:1/16:1/18:0) -19,2 0,108 -27,6 2,5E-05 -40,5 6,6E-05
TAG(18:1/18:1/20:4) 30,3 0,003 40,5 9,7E-07 28,4 6,7E-06
TAG(18:1/18:1/22:6) 52,8 6,0E-04 28,6 0,004 54,9 5,4E-08
TAG
PE
PE O
PG
PI
S1P
SM
PC O

